[{"id": 145001, "ingredient1": "Indinavir", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145164/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145002, "ingredient1": "Indomethacin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145165/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 145003, "ingredient1": "Isoniazid", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145166/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 145004, "ingredient1": "Nitisinone", "ingredient2": "Lomitapide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145167/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 145005, "ingredient1": "Nitisinone", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1. Increased exposure to lonafarnib may increase the risk and/or severity of adverse effects such as nausea, vomiting, diarrhea, anorexia, electrolyte disturbances, liver enzyme elevations, myelosuppression, infection, and hypertension.", "source": "DDInter", "management_text": "The manufacturer recommends avoiding concomitant use of lonafarnib with CYP450 2C9 inhibitors. If coadministration is required, patients should be closely monitored for common adverse effects as well as arrhythmias and events such as syncope and heart palpitations, since the effect of increased exposures on the QT interval is unknown.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends avoiding concomitant use of lonafarnib with CYP450 2C9 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145168/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145006, "ingredient1": "Nitisinone", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145169/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "updated_at": 1767369485}, {"id": 145007, "ingredient1": "Olaparib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145170/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145008, "ingredient1": "Oritavancin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145171/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 145009, "ingredient1": "Osilodrostat", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145172/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145010, "ingredient1": "Osimertinib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145173/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 145011, "ingredient1": "Oxcarbazepine", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145174/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 145012, "ingredient1": "Palbociclib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145175/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 145013, "ingredient1": "Paroxetine", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145176/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 145014, "ingredient1": "Pazopanib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145177/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 145015, "ingredient1": "Pentobarbital", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145178/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145016, "ingredient1": "Pexidartinib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145179/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 145017, "ingredient1": "Phenobarbital", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145180/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 145018, "ingredient1": "Phenylbutazone", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145181/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acetylsalicylic acid, Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, More", "updated_at": 1767369485}, {"id": 145019, "ingredient1": "Phenytoin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145182/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145020, "ingredient1": "Pirfenidone", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 may increase the plasma concentrations of pirfenidone, especially when used in addition to a moderate or potent CYP450 1A2 inhibitor. Pirfenidone is primarily (70% to 80%) metabolized by CYP450 1A2, with minor contribution from CYP450 2C9, 2C19, 2D6, and 2E1.", "source": "DDInter", "management_text": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.g., certain fluoroquinolones, oral contraceptives, deferasirox, methoxsalen, mexiletine, thiabendazole, ticlopidine, zileuton) should be avoided. No particular precaution is necessary if pirfenidone and CYP450 2C9, 2C19, 2D6, and/or 2E1 inhibitors are coadministered without a moderate or potent CYP450 1A2 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145183/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "updated_at": 1767369485}, {"id": 145021, "ingredient1": "Piroxicam", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145184/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Rofecoxib, More", "updated_at": 1767369485}, {"id": 145022, "ingredient1": "Pitolisant", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145185/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 145023, "ingredient1": "Posaconazole", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145186/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Caspofungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 145024, "ingredient1": "Prednisone", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145187/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Eliglustat, Laronidase, Imiglucerase, More", "alternatives_b": "Budesonide, Hydrocortisone, Cromoglicic acid, Olsalazine, Sulfasalazine, Prednisolone, Betamethasone, Balsalazide, Beclomethasone dipropionate, Mesalazine, Fludrocortisone, More", "updated_at": 1767369485}, {"id": 145025, "ingredient1": "Primidone", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145188/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 145026, "ingredient1": "Ramelteon", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145189/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 145027, "ingredient1": "Ranolazine", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145190/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 145028, "ingredient1": "Ribociclib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145191/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 145029, "ingredient1": "Rifampicin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145192/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 145030, "ingredient1": "Rifapentine", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145193/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 145031, "ingredient1": "Rucaparib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145194/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145032, "ingredient1": "Rufinamide", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145195/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 145033, "ingredient1": "Secobarbital", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145196/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 145034, "ingredient1": "Selpercatinib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145197/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 145035, "ingredient1": "Sertraline", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145198/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 145036, "ingredient1": "Siponimod", "ingredient2": "Nitisinone", "severity": "Major", "effect": "Coadministration with drugs that cause moderate inhibition of CYP450 2C9 and moderate or strong inhibition of CYP450 3A4 may increase the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/3A4 dual inhibitor or a moderate CYP450 2C9 inhibitor in combination with a separate moderate or strong CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Concomitant use of siponimod with a moderate or strong CYP450 2C9/3A4 dual inhibitor (e.g., fluconazole, mifepristone) or a moderate CYP450 2C9 inhibitor (e.g., abiraterone, amiodarone, fenofibrate, gemfibrozil, nitisinone, oxandrolone) in combination with a moderate or strong CYP450 3A4 inhibitor (e.g., amprenavir, aprepitant, atazanavir, boceprevir, ceritinib, chloramphenicol, ciprofloxacin, clarithromycin, cobicistat, conivaptan, crizotinib, dalfopristin-quinupristin, darunavir, delavirdine, diltiazem, dronedarone, erythromycin, fedratinib, fluvoxamine, fosamprenavir, fosaprepitant, fosnetupitant, fusidic acid, idelalisib, imatinib, indinavir, isavuconazole, itraconazole, ketoconazole, letermovir, mibefradil, nefazodone, nelfinavir, netupitant, posaconazole, ribociclib, ritonavir, saquinavir, stiripentol, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole, voxelotor) is not recommended. Caution is advised if siponimod is used in combination with moderate CYP450 2C9 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of siponimod with a moderate or strong CYP450 2C9/3A4 dual inhibitor (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145199/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "updated_at": 1767369485}, {"id": 145037, "ingredient1": "Somapacitan", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145200/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 145038, "ingredient1": "Somatrem", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145201/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 145039, "ingredient1": "Somatotropin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145202/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145040, "ingredient1": "St. John's Wort", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145203/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Citalopram, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 145041, "ingredient1": "Stiripentol", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145204/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 145042, "ingredient1": "Sulfinpyrazone", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145205/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "updated_at": 1767369485}, {"id": 145043, "ingredient1": "Suprofen (ophthalmic)", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145206/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145044, "ingredient1": "Suvorexant", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145207/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 145045, "ingredient1": "Tazemetostat", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145208/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145046, "ingredient1": "Telaprevir", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145209/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 145047, "ingredient1": "Telithromycin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145210/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 145048, "ingredient1": "Telotristat ethyl", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145211/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145049, "ingredient1": "Thiopental", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145212/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Halothane, Alfentanil, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Propofol, More", "updated_at": 1767369485}, {"id": 145050, "ingredient1": "Ticagrelor", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145213/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Betrixaban, Clopidogrel, Cilostazol, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "updated_at": 1767369485}, {"id": 145051, "ingredient1": "Ticlopidine", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145214/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Betrixaban, Clopidogrel, Cilostazol, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 145052, "ingredient1": "Tolazamide", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145215/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Glipizide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "updated_at": 1767369485}, {"id": 145053, "ingredient1": "Tolbutamide", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145216/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "updated_at": 1767369485}, {"id": 145054, "ingredient1": "Torasemide", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of torsemide. The interaction has not been evaluated in pharmacokinetic studies; however, torsemide has been shown to undergo metabolism by CYP450 2C9.", "source": "DDInter", "management_text": "Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors. Patients should be monitored for potentially increased adverse effects such as dehydration, hypotension, electrolyte imbalances, hyperglycemia, tinnitus, and hearing loss.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145217/", "reference_text": "[1] Vormfelde SV, Engelhardt S, Zirk A, et al. \"CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.\" Clin Pharmacol Ther 76 (2004): 557-66[2] Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ \"Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism.\" J Pharmacol Exp Ther 272 (1995): 1076-81[3] \"Product Information. Demedex (torsemide).\" Boehringer Mannheim, Gaithersburg, MD.[4] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[5] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Etacrynic acid, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 145055, "ingredient1": "Troglitazone", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.", "source": "DDInter", "management_text": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145218/", "reference_text": "[1] \"Product Information. Rezulin (troglitazone).\" Parke-Davis, Morris Plains, NJ.[2] Fraser CG, Fierro L \"Comment: troglitazone.\" Ann Pharmacother 32 (1998): 1111-2[3] Park MH, Pelegrin D, Haug MT, Young JB \"Troglitazone, a new antidiabetic agent, decreases cyclosporine level.\" J Heart Lung Transplant 17 (1998): 1139-40[4] Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP \"Potential interaction of troglitazone and cyclosporine.\" Transplantation 65 (1998): 1399-400[5] Frantz RP, Nguyen TT \"Rezulin (troglitazone) greatly increases cyclosporine metabolism.\" J Heart Lung Transplant 17 (1998): 1037-8[6] Burgess SJ, Singer GG, Brennan DC \"Effect of troglitazone on cyclosporine whole blood levels.\" Transplantation 66 (1998): 272[7] Terra SG, Washam JB, May DB \"Comment: troglitazone drug interactions.\" Ann Pharmacother 32 (1998): 1111[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Glipizide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145056, "ingredient1": "Troleandomycin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145219/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 145057, "ingredient1": "Tucatinib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145220/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 145058, "ingredient1": "Valdecoxib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145221/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Rofecoxib, More", "updated_at": 1767369485}, {"id": 145059, "ingredient1": "Vemurafenib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145222/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 145060, "ingredient1": "Voriconazole", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145223/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Caspofungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 145061, "ingredient1": "Voxelotor", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145224/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 145062, "ingredient1": "Zafirlukast", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145225/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "updated_at": 1767369485}, {"id": 145063, "ingredient1": "Aurothioglucose", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145226/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Penicillamine", "updated_at": 1767369485}, {"id": 145064, "ingredient1": "Bedaquiline", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.", "mechanism_text": "Synergism", "recommendation": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145227/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 145065, "ingredient1": "Belladonna", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145228/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145066, "ingredient1": "Oxybuprocaine (ophthalmic)", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145229/", "reference_text": "[1] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich, Waukegan, IL.[4] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001): 150-3", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145067, "ingredient1": "Benznidazole", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145230/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Miltefosine, Pentamidine, Nifurtimox, Fexinidazole", "updated_at": 1767369485}, {"id": 145068, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145231/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Spectinomycin, Dalbavancin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145069, "ingredient1": "Cerivastatin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145232/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Telavancin, Vancomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145070, "ingredient1": "Dapsone", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145233/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Methylprednisolone, Azelaic acid, Clofazimine", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145071, "ingredient1": "Cinchocaine (topical)", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145234/", "reference_text": "[1] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich, Waukegan, IL.[4] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001): 150-3", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145072, "ingredient1": "Elotuzumab", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145235/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 145073, "ingredient1": "Epirubicin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.", "source": "DDInter", "management_text": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145236/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145074, "ingredient1": "Eribulin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145237/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145075, "ingredient1": "Etanercept", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145238/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145076, "ingredient1": "Ethambutol", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145239/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145077, "ingredient1": "Ethionamide", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145240/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145078, "ingredient1": "Ethotoin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "One patient experienced seizures and a drop in phenytoin levels while taking concurrent nitrofurantoin. Phenytoin levels rose when nitrofurantoin was discontinued. The mechanism is unknown but may be related to induction of hepatic metabolism by nitrofurantoin. A similar reaction may occur with other hydantoins.", "source": "DDInter", "management_text": "Phenytoin serum concentrations should be monitored during coadministration of these agents. Patients should be advised to promptly report loss of seizure control to their caregiver.", "mechanism_text": "Metabolism", "recommendation": "Phenytoin serum concentrations should be monitored during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145241/", "reference_text": "[1] Heipertz R, Pilz H \"Interaction of nitrofurantoin with diphenylhydantoin.\" J Neurol 218 (1978): 297-301[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 145079, "ingredient1": "Etoposide", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145242/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Topotecan, Irinotecan", "updated_at": 1767369485}, {"id": 145080, "ingredient1": "Etravirine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145243/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 145081, "ingredient1": "Flavoxate", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145244/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 145082, "ingredient1": "Fluconazole", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The concomitant administration of nitrofurantoin and fluconazole may increase the risk of hepatic and pulmonary toxicity. The mechanism is unknown. Nitrofurantoin alone is known to cause pulmonary toxicity (usually pulmonary fibrosis or interstitial pneumonitis) and both drugs individually have been associated with hepatic toxicity.", "source": "DDInter", "management_text": "Until more information is available it may be advisable to monitor patients for signs of adverse pulmonary and hepatic effects during concomitant administration. Patients should be advised to notify their physician if they develop cough, dyspnea, fatigue, or pain.", "mechanism_text": "Synergism", "recommendation": "Until more information is available it may be advisable to monitor patients for signs of adverse pulmonary and hepatic effects during concomitant administration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145245/", "reference_text": "[1] Linnebur SA, Parnes BL \"Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment.\" Ann Pharmacother 38 (2004): 612-6", "alternatives_a": "Cefepime, Cefixime, Azithromycin, Amikacin, Levofloxacin, Caspofungin, Micafungin, Amphotericin B, Itraconazole, Posaconazole, Oteseconazole, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145083, "ingredient1": "Fludarabine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145246/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 145084, "ingredient1": "Fluvastatin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145247/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Telavancin, Vancomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 145085, "ingredient1": "Fosphenytoin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "One patient experienced seizures and a drop in phenytoin levels while taking concurrent nitrofurantoin. Phenytoin levels rose when nitrofurantoin was discontinued. The mechanism is unknown but may be related to induction of hepatic metabolism by nitrofurantoin. A similar reaction may occur with other hydantoins.", "source": "DDInter", "management_text": "Phenytoin serum concentrations should be monitored during coadministration of these agents. Patients should be advised to promptly report loss of seizure control to their caregiver.", "mechanism_text": "Metabolism", "recommendation": "Phenytoin serum concentrations should be monitored during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145248/", "reference_text": "[1] Heipertz R, Pilz H \"Interaction of nitrofurantoin with diphenylhydantoin.\" J Neurol 218 (1978): 297-301[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 145086, "ingredient1": "Sodium aurothiomalate", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145249/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Penicillamine", "updated_at": 1767369485}, {"id": 145087, "ingredient1": "Golimumab", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145250/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 145088, "ingredient1": "Hydroxychloroquine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145251/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 145089, "ingredient1": "Idelalisib", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.", "source": "DDInter", "management_text": "The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.", "mechanism_text": "Synergism", "recommendation": "The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145252/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 145090, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145253/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Oritavancin, Telavancin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145091, "ingredient1": "Infliximab", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145254/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145092, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145255/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145093, "ingredient1": "Interferon alfa-n1", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145256/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145094, "ingredient1": "Interferon alfacon-1", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145257/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145095, "ingredient1": "Diiodohydroxyquinoline", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145258/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, More", "updated_at": 1767369485}, {"id": 145096, "ingredient1": "Isoniazid", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145259/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 145097, "ingredient1": "Nitrofurantoin", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145260/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Spectinomycin, Dalbavancin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145098, "ingredient1": "Nitrofurantoin", "ingredient2": "Lomitapide", "severity": "Major", "effect": "Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.", "source": "DDInter", "management_text": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145261/", "reference_text": "[1] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 145099, "ingredient1": "Nitrofurantoin", "ingredient2": "Magaldrate", "severity": "Minor", "effect": "The absorption of nitrofurantoin may be inhibited by magnesium-containing antacids. If a magnesium-containing product must be taken, administration of these agents should be separated by 2 to 3 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145262/", "reference_text": "[1] Naggar VF, Khalil SA \"Effect of magnesium trisilicate on nitrofurantoin absorption.\" Clin Pharmacol Ther 25 (1979): 857-63", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Spectinomycin, Lefamulin, More", "alternatives_b": "Calcium carbonate, Aluminum hydroxide", "updated_at": 1767369485}, {"id": 145100, "ingredient1": "Nitrofurantoin", "ingredient2": "Magnesium carbonate", "severity": "Minor", "effect": "The absorption of nitrofurantoin may be inhibited by magnesium-containing antacids. If a magnesium-containing product must be taken, administration of these agents should be separated by 2 to 3 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145263/", "reference_text": "[1] Naggar VF, Khalil SA \"Effect of magnesium trisilicate on nitrofurantoin absorption.\" Clin Pharmacol Ther 25 (1979): 857-63", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Spectinomycin, Lefamulin, More", "alternatives_b": "Calcium carbonate, Aluminum hydroxide, Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, More", "updated_at": 1767369485}, {"id": 145101, "ingredient1": "Nitrofurantoin", "ingredient2": "Magnesium hydroxide", "severity": "Minor", "effect": "The absorption of nitrofurantoin may be inhibited by magnesium-containing antacids. If a magnesium-containing product must be taken, administration of these agents should be separated by 2 to 3 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145264/", "reference_text": "[1] Naggar VF, Khalil SA \"Effect of magnesium trisilicate on nitrofurantoin absorption.\" Clin Pharmacol Ther 25 (1979): 857-63", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 145102, "ingredient1": "Nitrofurantoin", "ingredient2": "Magnesium oxide", "severity": "Minor", "effect": "The absorption of nitrofurantoin may be inhibited by magnesium-containing antacids. If a magnesium-containing product must be taken, administration of these agents should be separated by 2 to 3 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145265/", "reference_text": "[1] Naggar VF, Khalil SA \"Effect of magnesium trisilicate on nitrofurantoin absorption.\" Clin Pharmacol Ther 25 (1979): 857-63", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Spectinomycin, Lefamulin, More", "alternatives_b": "Calcium carbonate, Aluminum hydroxide, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, More", "updated_at": 1767369485}, {"id": 145103, "ingredient1": "Nitrofurantoin", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "One patient experienced seizures and a drop in phenytoin levels while taking concurrent nitrofurantoin. Phenytoin levels rose when nitrofurantoin was discontinued. The mechanism is unknown but may be related to induction of hepatic metabolism by nitrofurantoin. A similar reaction may occur with other hydantoins.", "source": "DDInter", "management_text": "Phenytoin serum concentrations should be monitored during coadministration of these agents. Patients should be advised to promptly report loss of seizure control to their caregiver.", "mechanism_text": "Metabolism", "recommendation": "Phenytoin serum concentrations should be monitored during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145266/", "reference_text": "[1] Heipertz R, Pilz H \"Interaction of nitrofurantoin with diphenylhydantoin.\" J Neurol 218 (1978): 297-301[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 145104, "ingredient1": "Nitrofurantoin", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145267/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145105, "ingredient1": "Norfloxacin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Nitrofurantoin may antagonize the antibacterial effect of norfloxacin in the urinary tract.", "source": "DDInter", "management_text": "The concomitant use of nitrofurantoin and norfloxacin is not recommended.", "mechanism_text": "Antagonism", "recommendation": "The concomitant use of nitrofurantoin and norfloxacin is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145268/", "reference_text": "[1] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[2] Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Forst RW \"Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.\" Antimicrob Agents Chemother 33 (1989): 1118-20[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[4] Noer BL, Angaran DW \"The effect of enteral feedings on ciprofloxacin pharmacokinetics.\" Pharmacotherapy 10 (1990): 254[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6[7] Neuhofel AL, Wilton JH, Victory JM, Hejmanowsk LG, Amsden GW \"Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction.\" J Clin Pharmacol 42 (2002): 461-6[8] Yuk JH, Nightingale CH, Quintiliani R \"Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition.\" Diagn Microbiol Infect Dis 13 (1990): 99-102", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Cefepime, Cefixime, Azithromycin, Amikacin, Levofloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, More", "updated_at": 1767369485}, {"id": 145106, "ingredient1": "Oxaliplatin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145269/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "alternatives_b": "Oritavancin, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145107, "ingredient1": "Oxybutynin", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145270/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 145108, "ingredient1": "Paclitaxel (protein-bound)", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145271/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145109, "ingredient1": "Pegaspargase", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145272/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 145110, "ingredient1": "Peginterferon alfa-2a", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145273/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145111, "ingredient1": "Peginterferon alfa-2b", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145274/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145112, "ingredient1": "Peginterferon beta-1a", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145275/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "updated_at": 1767369485}, {"id": 145113, "ingredient1": "Pexidartinib", "ingredient2": "Nitrofurantoin", "severity": "Major", "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.", "source": "DDInter", "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145276/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 145114, "ingredient1": "Phenytoin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "One patient experienced seizures and a drop in phenytoin levels while taking concurrent nitrofurantoin. Phenytoin levels rose when nitrofurantoin was discontinued. The mechanism is unknown but may be related to induction of hepatic metabolism by nitrofurantoin. A similar reaction may occur with other hydantoins.", "source": "DDInter", "management_text": "Phenytoin serum concentrations should be monitored during coadministration of these agents. Patients should be advised to promptly report loss of seizure control to their caregiver.", "mechanism_text": "Metabolism", "recommendation": "Phenytoin serum concentrations should be monitored during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145277/", "reference_text": "[1] Heipertz R, Pilz H \"Interaction of nitrofurantoin with diphenylhydantoin.\" J Neurol 218 (1978): 297-301[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145115, "ingredient1": "Pitavastatin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145278/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Telavancin, Vancomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 145116, "ingredient1": "Polatuzumab vedotin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145279/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 145117, "ingredient1": "Pomalidomide", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145280/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 145118, "ingredient1": "Ponatinib", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145281/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 145119, "ingredient1": "Pravastatin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145282/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145120, "ingredient1": "Procyclidine", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145283/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Orphenadrine", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 145121, "ingredient1": "Propantheline", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145284/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Papaverine, Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 145122, "ingredient1": "Remdesivir", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145285/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[3] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 145123, "ingredient1": "Rosuvastatin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145286/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Lefamulin, Dalbavancin", "alternatives_b": "Bempedoic acid, Perindopril, Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, More", "updated_at": 1767369485}, {"id": 145124, "ingredient1": "Scopolamine", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145287/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, More", "updated_at": 1767369485}, {"id": 145125, "ingredient1": "Simvastatin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145288/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145126, "ingredient1": "Solifenacin", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145289/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 145127, "ingredient1": "Telbivudine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145290/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 145128, "ingredient1": "Teniposide", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145291/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Topotecan, Irinotecan", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145129, "ingredient1": "Teriflunomide", "ingredient2": "Nitrofurantoin", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145292/", "reference_text": "[1] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html.\" ([1999 Sept 2]):[2] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 145130, "ingredient1": "Tetracaine (topical)", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145293/", "reference_text": "[1] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich, Waukegan, IL.[4] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001): 150-3", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Isosorbide dinitrate, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate, Clemastine, Mepyramine, Diphenhydramine, More", "updated_at": 1767369485}, {"id": 145131, "ingredient1": "Thalidomide", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible.", "source": "DDInter", "management_text": "Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if thalidomide is used in combination with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145294/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 145132, "ingredient1": "Tioguanine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145295/", "reference_text": "[1] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Tabloid (thioguanine).\" Prasco Laboratories, Cincinnati, OH.", "alternatives_a": "Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, Decitabine, Azacitidine, Capecitabine", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 145133, "ingredient1": "Tinidazole", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145296/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More", "alternatives_b": "Cefepime, Cefixime, Azithromycin, Amikacin, Levofloxacin, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, More", "updated_at": 1767369485}, {"id": 145134, "ingredient1": "Tocilizumab", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145297/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 145135, "ingredient1": "Tolterodine", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145298/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 145136, "ingredient1": "Trabectedin", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145299/", "reference_text": "[1] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Topotecan, Irinotecan", "updated_at": 1767369485}, {"id": 145137, "ingredient1": "Trihexyphenidyl", "ingredient2": "Nitrofurantoin", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145300/", "reference_text": "[1] Mannisto P \"The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers.\" Int J Clin Pharmacol Biopharm 16 (1978): 223-8[2] Jaffe JM \"Effect of propantheline on nitrofurantoin absorption.\" J Pharm Sci 64 (1975): 1729-30", "alternatives_a": "Orphenadrine", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 145138, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Nitrofurantoin", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145301/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Lefamulin, Methenamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145139, "ingredient1": "Vinblastine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145302/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Topotecan, Irinotecan", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145140, "ingredient1": "Vincristine (liposome)", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145303/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Topotecan, Irinotecan", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145141, "ingredient1": "Vinorelbine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145304/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Topotecan, Irinotecan", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145142, "ingredient1": "Zafirlukast", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145305/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145143, "ingredient1": "Zalcitabine", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Zalcitabine can cause peripheral neuropathy in up to one-third of patients with advanced HIV disease, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Zalcitabine-related peripheral neuropathy is a sensorimotor neuropathy characterized initially by numbness and burning dysesthesia involving the distal extremities. These symptoms may be followed by sharp shooting pains or severe continuous burning pain if the drug is not withdrawn, and progress to severe pain requiring narcotic analgesics. The neuropathy is potentially irreversible. However, with prompt discontinuation of zalcitabine, it is usually slowly reversible, although symptoms may initially progress following discontinuation.", "source": "DDInter", "management_text": "Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible. Otherwise, careful monitoring is recommended for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness in the extremities, particularly in patients with a low CD4 cell count or diabetes. Since the development of peripheral neuropathy appears to be dose-related, the recommended dosage of zalcitabine should not be exceeded. Patients should be advised to promptly discontinue zalcitabine therapy and contact their physician if neuropathy develops. Therapy may be reinstituted following resolution of neuropathy symptoms, but dosage should be reduced to one-half the initially recommended dosage. Zalcitabine should be permanently discontinued in patients who develop severe peripheral neuropathy during treatment.", "mechanism_text": "Synergism", "recommendation": "Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145306/", "reference_text": "[1] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[2] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 145144, "ingredient1": "Acetohexamide", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "H2 antagonists such as cimetidine and ranitidine may increase plasma concentrations of sulfonylureas and enhance hypoglycemic effects. The mechanism may be related to inhibition of liver cytochrome P450 enzymes responsible for sulfonylurea metabolism or increased absorption due to altered gastric pH. Cimetidine may also inhibit glucose metabolism. Other H2 antagonists may interact in a similar manner, particularly if increased pH is involved.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended. Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Absorption", "recommendation": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145307/", "reference_text": "[1] Dey NG, Castleden CM, Ward J, et al \"The effect of cimetidine on tolbutamide kinetics.\" Br J Clin Pharmacol 16 (1983): 438-40[2] Kubacka RT, Antal EJ, Juhl RP \"The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics.\" Br J Clin Pharmacol 23 (1987): 743-51[3] Feely J, Collins WCJ, Cullen CM, et al. \"Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists.\" Br J Clin Pharmacol 35 (1993): 321-3[4] Lee K, Mize R, Lowenstein SR \"Glyburide-induced hypoglycemia and ranitidine.\" Ann Intern Med 107 (1987): 261-2[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lansoprazole", "updated_at": 1767369485}, {"id": 145145, "ingredient1": "Aluminum hydroxide", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145308/", "reference_text": "[1] Barzaghi N, Gatti G, Crema F, Perucca E \"Impaired bioavailability of famotidine given concurrently with a potent antacid.\" J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P \"Effect of aluminum phosphate on the bioavailability of ranitidine.\" Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al \"The effects of antacid and propantheline on the absorption of oral ranitidine.\" Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A \"Diminished absorption of cimetidine caused by antacids.\" Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al \"Effect of antacids on predicted steady-state cimetidine concentrations.\" Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J \"Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.\" Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM \"Antacids inhibit absorption of cimetidine.\" N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J \"Effects of antacids and food on absorption of famotidine.\" Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA \"High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.\" Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al \"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.\" Eur J Clin Pharmacol 26 (1984): 271-3", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Clarithromycin, Vonoprazan, Amoxicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145146, "ingredient1": "Aminophylline", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Cimetidine may increase theophylline plasma concentrations by as much as 70%. The mechanism is related to inhibition of liver CYP450 enzymes responsible for theophylline metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145309/", "reference_text": "[1] Schwartz JI, Bachmann KA, Bond LW, Mahajan VK \"Impact of cimetidine on the pharmacokinetics of the theophylline.\" Clin Pharm 1 (1982): 534-8[2] Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R \"Cimetidine decreases theophylline clearance.\" Am Rev Respir Dis 123 (1981): 615-7[3] Anderson JR, Poklis A, Slavin RG \"A fatal case of theophylline intoxication.\" Arch Intern Med 143 (1983): 559-60[4] Weinberger MM, Smith G, Milavetz G, Hendeles L \"Decreased clearance of theophylline due to cimetidine .\" N Engl J Med 304 (1981): 672[5] Skinner MH, Lenert L, Blaschke TF \"Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction.\" Am J Med 86 (1989): 129-32[6] Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ \"Cimetidine-theophylline interaction: report of four patients.\" Ann Allergy 48 (1982): 100-2[7] Lofgren RP, Gilbertson RA \"Cimetidine and theophylline.\" Ann Intern Med 96 (1982): 378[8] Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN \"Inhibition of theophylline clearance by cimetidine but not ranitidine.\" Arch Intern Med 144 (1984): 484-6[9] Kelly HW, Powell JR, Donohue JF \"Ranitidine at very large doses does not inhibit theophylline elimination.\" Clin Pharmacol Ther 39 (1986): 577-81[10] Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J \"Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease.\" J Clin Pharmacol 35 (1995): 529-35[11] Kelly HW \"Lack of evidence for reduction of theophylline clearance by ranitidine.\" Am J Med 86 (1989): 629-32[12] Hegman GW, Gilbert RP \"Ranitidine-theophylline interaction--fact or fiction?\" Ann Pharmacother 25 (1991): 21-5[13] Fernandes E, Melewicz FM \"Ranitidine and theophylline.\" Ann Intern Med 100 (1984): 459[14] Reitberg DP, Bernhard H, Schentag JJ \"Alteration of theophylline clearance and half-life by cimetidine in normal volunteers.\" Ann Intern Med 95 (1981): 582-5[15] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[16] Kehoe WA, Sands CD, Long LF, et al \"Effect of ranitidine on theophylline metabolism in healthy Koreans living in China.\" Ann Pharmacother 30 (1996): 133-7[17] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[18] Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR \"Cimetidine decreases theophylline clearance.\" Ann Intern Med 95 (1981): 68-9[19] Loi CM, Parker BM, Cusack BJ, Vestal RE \"Aging and drug interactions .3. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers.\" J Pharmacol Exp Ther 280 (1997): 627-37[20] Ohashi K, Sakamoto K, Sudo T, Tateishi T, Fujimura A, Shiga T, Ebihara A \"Effects of diltiazem and cimetidine on theophylline oxidative metabolism.\" J Clin Pharmacol 33 (1993): 1233-7[21] Pride M, Deamer RL \"Over-the-counter cimetidine and theophylline interaction.\" Am Fam Physician 52 (1995): 2180[22] Verdiani P, Di Carlo S, Baronti A \"Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD: comparison with cimetidine and placebo.\" Chest 94 (1988): 807-10[23] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[24] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[25] Roy AK, Cuda MP, Levine RA \"Induction of theophylline toxicity and inhibition of clearance rates by ranitidine.\" Am J Med 85 (1988): 525-7[26] Fenje PC, Isles AF, Baltodano A, MacLeod SM, Soldin S \"Interaction of cimetidine and theophylline in two infants.\" Can Med Assoc J 126 (1982): 1178[27] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[28] Dal Negro R, Pomari C, Turco P \"Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.\" Clin Pharmacokinet 24 (1993): 255-8[29] Hsu K, Garton A, Sproule BJ, Tam YK, Leggatt D, Herbert FA \"The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction.\" Am Rev Respir Dis 130 (1984): 740-3[30] Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R \"Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.\" Br J Clin Pharmacol 24 (1987): 669-72", "alternatives_a": "Tinidazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Amoxicillin", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 145147, "ingredient1": "Bacampicillin", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents with acid neutralizing or reducing effects may decrease the oral bioavailability and plasma concentrations of ampicillin from bacampicillin. The exact mechanism of interaction is unknown but may be related to degradation of the prodrug when gastric pH is increased.", "source": "DDInter", "management_text": "The possibility of a reduced or subtherapeutic response to bacampicillin should be considered during coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. Preferably, these agents should be avoided during therapy with bacampicillin, or an alternative antibiotic be prescribed if these medications cannot be discontinued. Patients treated with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) may minimize the effects of the interaction with bacampicillin by separating the times of administration by at least 2 hours.", "mechanism_text": "Absorption", "recommendation": "The possibility of a reduced or subtherapeutic response to bacampicillin should be considered during coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145310/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Tinidazole, Levofloxacin, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Vonoprazan, Amoxicillin", "alternatives_b": "Sulbactam, Oxacillin, Dicloxacillin, Meticillin, Carbenicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, Nafcillin, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 145148, "ingredient1": "Calcium carbonate", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145311/", "reference_text": "[1] Barzaghi N, Gatti G, Crema F, Perucca E \"Impaired bioavailability of famotidine given concurrently with a potent antacid.\" J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P \"Effect of aluminum phosphate on the bioavailability of ranitidine.\" Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al \"The effects of antacid and propantheline on the absorption of oral ranitidine.\" Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A \"Diminished absorption of cimetidine caused by antacids.\" Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al \"Effect of antacids on predicted steady-state cimetidine concentrations.\" Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J \"Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.\" Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM \"Antacids inhibit absorption of cimetidine.\" N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J \"Effects of antacids and food on absorption of famotidine.\" Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA \"High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.\" Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al \"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.\" Eur J Clin Pharmacol 26 (1984): 271-3", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Clarithromycin, Vonoprazan, Amoxicillin, More", "alternatives_b": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate", "updated_at": 1767369485}, {"id": 145149, "ingredient1": "Activated charcoal", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects or of the toxicity of many drugs. Activated charcoal may adsorb any therapeutic agents administered while it is in the gastrointestinal tract.", "source": "DDInter", "management_text": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications. If concomitant use is necessary, the dosage or route of administration may need to be altered.", "mechanism_text": "Absorption", "recommendation": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145312/", "reference_text": "[1] Naveau S, Bonhomme L, Preaux N, Chaput JC \"A pure charcoal suspension for colonoscopic tattoo.\" Gastrointest Endosc 37 (1991): 624-5[2] Ilkhanipour K, Yealy DM, Krenzelok EP \"Activated charcoal surface area and its role in multiple-dose charcoal therapy.\" Am J Emerg Med 11 (1993): 583-5[3] Reed MD \"Oral activated charcoal therapy.\" Am J Emerg Med 6 (1988): 318[4] Neuvonen PJ \"Clinical pharmacokinetics of oral activated charcoal in acute intoxications.\" Clin Pharmacokinet 7 (1982): 465-89[5] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] Kivisto KT, Neuvonen PJ \"The effect of cholestyramine and activated charcoal on glipizide absorption.\" Br J Clin Pharmacol 30 (1990): 733-6[7] Glab WN, Corby DG, Decker WJ, Coldiron VR \"Decreased absorption of propoxyphene by activated charcoal.\" J Toxicol Clin Toxicol 19 (1982): 129-38[8] Watson WA \"Factors influencing the clinical efficacy of activated charcoal.\" Drug Intell Clin Pharm 21 (1987): 160-6[9] Howard CE, Roberts RS, Ely DS, Moye RA \"Use of multiple-dose activated charcoal in phenytoin toxicity.\" Ann Pharmacother 28 (1994): 201-3[10] Herrington AM, Clifton GD \"Toxicology and management of acute drug ingestions in adults.\" Pharmacotherapy 15 (1995): 182-200[11] Scheufler E, Bos I \"Influence of peroral charcoal on pharmacokinetics and intestinal toxicity of intravenously given methotrexate.\" Arch Int Pharmacodyn Ther 261 (1983): 180-5[12] Gadgil SD, Damle SR, Advani SH, Vaidya AB \"Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate.\" Cancer Treat Rep 66 (1982): 1169-71[13] Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A \"Apomorphine test in de novo Parkinson's disease.\" Funct Neurol 7 (1992): 295-8[14] Park GD, Spector R, Goldberg MJ, Johnson GF \"Expanded role of charcoal therapy in the poisoned and overdosed patient.\" Arch Intern Med 146 (1986): 969-73[15] Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A \"Absorption studies of the H2-blocker nizatidine.\" Clin Pharmacol Ther 42 (1987): 514-20[16] Dolgin JG, Nix DE, Sanchez J, Watson WA \"Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning: report of two pediatric cases.\" DICP 25 (1991): 646-9[17] Wakabayashi Y, Maruyama S, Hachimura K, Ohwada T \"Activated charcoal interrupts enteroenteric circulation of phenobarbital.\" J Toxicol Clin Toxicol 32 (1994): 419-24[18] Decker WJ, Shpall RA, Corby DG \"Inhibition of aspirin absorption by activated charcoal and apomorphine.\" Clin Pharmacol Ther 10 (1969): 710-3[19] Chernish SM, Wolen RL, Rodda BE \"Adsorption of propoxyphene hydrochloride by activated charcoal.\" Clin Toxicol 5 (1972): 317-29[20] Orisakwe OE \"Activated charcoal: is failure to use it negligence or ignorance?\" South Med J 87 (1994): 165-8[21] Wing LM, Miners JO, Birkett DJ, et al \"Lidocaine disposition: sex differences and effects of cimetidine.\" Clin Pharmacol Ther 35 (1984): 695-701[22] Saetta JP \"Gastric decontaminating procedures: is it time to call a stop?\" J R Soc Med 86 (1993): 396-9[23] Rowden AM, Spoor JE, Bertino JS, Jr \"The effect of activated charcoal on phenytoin pharmacokinetics.\" Ann Emerg Med 19 (1990): 1144-7[24] Farrar HC, Herold DA, Reed MD \"Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal.\" Crit Care Med 21 (1993): 299-301[25] Karkkainen S, Neuvonen PJ \"Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 219-25", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Pectin, Kaolin, Attapulgite", "updated_at": 1767369485}, {"id": 145150, "ingredient1": "Enoxacin", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Depending on the route of administration, enoxacin effects may be altered by certain histamine-2 (H2) receptor antagonists. Oral enoxacin effects may be decreased due to reduced gastrointestinal solubility and absorption as a result of H2 antagonist-induced reductions in gastric pH. Reports of this interaction exist for parenteral ranitidine. On the other hand, pharmacologic effects of parenteral enoxacin may be increased by cimetidine. The mechanism is speculated to be competition for active renal secretion. Reports of enoxacin interactivity with other H2 antagonists do not exist, although theoretically, all H2 antagonists may produce a similar effect on oral enoxacin. Close clinical monitoring for altered enoxacin effect is recommended in patients receiving concomitant enoxacin and an H2 antagonist.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption, Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145313/", "reference_text": "[1] Misiak PM, Eldon MA, Toothaker RD, Sedman AJ \"Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin.\" J Clin Pharmacol 33 (1993): 53-6[2] Lebsack ME, Nix D, Ryerson B, et al \"Effect of gastric acidity on enoxacin absorption.\" Clin Pharmacol Ther 52 (1992): 252-6", "alternatives_a": "Levofloxacin, Norfloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "updated_at": 1767369485}, {"id": 145151, "ingredient1": "Erlotinib", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of agents that increase gastric pH such as H2-receptor antagonists may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption.", "source": "DDInter", "management_text": "In general, the concomitant use of erlotinib with agents that increase gastric pH should be avoided whenever possible. If acid-suppression therapy is required during erlotinib treatment, an H2-receptor antagonist such as ranitidine may be considered. Available pharmacokinetic data suggest that erlotinib should be administered once a day, at least 2 hours before or 10 hours after dosing of the H2-receptor antagonist. Additionally, the lowest effective dosage of the H2-receptor antagonist should be prescribed. It may be appropriate to avoid using cimetidine for long-term acid suppression, as it may inhibit the CYP450 3A4-mediated metabolism of erlotinib and increase the risk of toxicity.", "mechanism_text": "Metabolism, Absorption", "recommendation": "In general, the concomitant use of erlotinib with agents that increase gastric pH should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145314/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Duong S, Leung M \"Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents.\" J Oncol Pharm Pract 17 (2011): 448-52[4] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.[5] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[6] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Amoxicillin", "updated_at": 1767369485}, {"id": 145152, "ingredient1": "Etodolac", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145315/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Vonoprazan", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone", "updated_at": 1767369485}, {"id": 145153, "ingredient1": "Fenoprofen", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145316/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "updated_at": 1767369485}, {"id": 145154, "ingredient1": "Fingolimod", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "The risk of bradycardia and atrioventricular (AV) block may be increased during initiation of fingolimod treatment in patients receiving beta-blockers, calcium channel blockers, digitalis, or other drugs that can slow the heart rate or AV conduction such as alectinib, atazanavir, flecainide, ivabradine, lacosamide, lithium, mefloquine, moricizine, propafenone, succinylcholine, thalidomide, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents.", "source": "DDInter", "management_text": "Fingolimod has not been adequately studied in patients receiving other drugs that can slow the heart rate or AV conduction. Close monitoring is recommended during initiation of fingolimod treatment in these patients. The first dose should always be administered in a setting where resources to appropriately manage symptomatic bradycardia are available.", "mechanism_text": "Synergism", "recommendation": "Fingolimod has not been adequately studied in patients receiving other drugs that can slow the heart rate or AV conduction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145317/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data.\" ([2012 May 14]):[2] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145155, "ingredient1": "Flurbiprofen", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145318/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "alternatives_b": "Tolazoline, Dimethyl sulfoxide, Phenylbutazone, Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone, Neomycin, Chlorhexidine, Povidone-iodine, Bacitracin, More", "updated_at": 1767369485}, {"id": 145156, "ingredient1": "Fosamprenavir", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or proton pump inhibitors may decrease the oral bioavailability of amprenavir from its prodrug, fosamprenavir. It is possible that fosamprenavir solubility decreases with increasing pH, thus inhibition of gastric acid secretion may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance.", "source": "DDInter", "management_text": "Caution is advised if fosamprenavir is prescribed with H2-receptor antagonists or proton pump inhibitors. Antiretroviral response should be monitored closely during coadministration.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if fosamprenavir is prescribed with H2-receptor antagonists or proton pump inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145319/", "reference_text": "[1] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 145157, "ingredient1": "Gefitinib", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Coadministration with drugs that cause significant, sustained elevations in gastric pH such as H2-receptor antagonists and proton pump inhibitors may decrease the plasma concentrations of gefitinib. The exact mechanism of interaction is unknown.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or proton pump inhibitors. Pharmacologic response to gefitinib should be monitored more closely whenever one of these agents is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or proton pump inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145320/", "reference_text": "[1] \"Product Information. Iressa (gefitinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "alternatives_b": "Tinidazole, Amoxicillin, Tetracycline, Bismuth subcitrate potassium, Levofloxacin", "updated_at": 1767369485}, {"id": 145158, "ingredient1": "Glipizide", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "H2 antagonists such as cimetidine and ranitidine may increase plasma concentrations of sulfonylureas and enhance hypoglycemic effects. The mechanism may be related to inhibition of liver cytochrome P450 enzymes responsible for sulfonylurea metabolism or increased absorption due to altered gastric pH. Cimetidine may also inhibit glucose metabolism. Other H2 antagonists may interact in a similar manner, particularly if increased pH is involved.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended. Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Absorption", "recommendation": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145321/", "reference_text": "[1] Dey NG, Castleden CM, Ward J, et al \"The effect of cimetidine on tolbutamide kinetics.\" Br J Clin Pharmacol 16 (1983): 438-40[2] Kubacka RT, Antal EJ, Juhl RP \"The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics.\" Br J Clin Pharmacol 23 (1987): 743-51[3] Feely J, Collins WCJ, Cullen CM, et al. \"Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists.\" Br J Clin Pharmacol 35 (1993): 321-3[4] Lee K, Mize R, Lowenstein SR \"Glyburide-induced hypoglycemia and ranitidine.\" Ann Intern Med 107 (1987): 261-2[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Vonoprazan", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "updated_at": 1767369485}, {"id": 145159, "ingredient1": "Glyburide", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "H2 antagonists such as cimetidine and ranitidine may increase plasma concentrations of sulfonylureas and enhance hypoglycemic effects. The mechanism may be related to inhibition of liver cytochrome P450 enzymes responsible for sulfonylurea metabolism or increased absorption due to altered gastric pH. Cimetidine may also inhibit glucose metabolism. Other H2 antagonists may interact in a similar manner, particularly if increased pH is involved.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended. Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Absorption", "recommendation": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145322/", "reference_text": "[1] Dey NG, Castleden CM, Ward J, et al \"The effect of cimetidine on tolbutamide kinetics.\" Br J Clin Pharmacol 16 (1983): 438-40[2] Kubacka RT, Antal EJ, Juhl RP \"The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics.\" Br J Clin Pharmacol 23 (1987): 743-51[3] Feely J, Collins WCJ, Cullen CM, et al. \"Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists.\" Br J Clin Pharmacol 35 (1993): 321-3[4] Lee K, Mize R, Lowenstein SR \"Glyburide-induced hypoglycemia and ranitidine.\" Ann Intern Med 107 (1987): 261-2[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Vonoprazan", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "updated_at": 1767369485}, {"id": 145160, "ingredient1": "Indomethacin", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145323/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Betamethasone, Fluorometholone, Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone, Salicylic acid, Fluocinolone acetonide, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan", "updated_at": 1767369485}, {"id": 145161, "ingredient1": "Nizatidine", "ingredient2": "Magaldrate", "severity": "Minor", "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145324/", "reference_text": "[1] Barzaghi N, Gatti G, Crema F, Perucca E \"Impaired bioavailability of famotidine given concurrently with a potent antacid.\" J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P \"Effect of aluminum phosphate on the bioavailability of ranitidine.\" Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al \"The effects of antacid and propantheline on the absorption of oral ranitidine.\" Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A \"Diminished absorption of cimetidine caused by antacids.\" Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al \"Effect of antacids on predicted steady-state cimetidine concentrations.\" Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J \"Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.\" Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM \"Antacids inhibit absorption of cimetidine.\" N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J \"Effects of antacids and food on absorption of famotidine.\" Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA \"High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.\" Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al \"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.\" Eur J Clin Pharmacol 26 (1984): 271-3", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Clarithromycin, Vonoprazan, Amoxicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145162, "ingredient1": "Nizatidine", "ingredient2": "Magnesium carbonate", "severity": "Minor", "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145325/", "reference_text": "[1] Barzaghi N, Gatti G, Crema F, Perucca E \"Impaired bioavailability of famotidine given concurrently with a potent antacid.\" J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P \"Effect of aluminum phosphate on the bioavailability of ranitidine.\" Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al \"The effects of antacid and propantheline on the absorption of oral ranitidine.\" Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A \"Diminished absorption of cimetidine caused by antacids.\" Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al \"Effect of antacids on predicted steady-state cimetidine concentrations.\" Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J \"Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.\" Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM \"Antacids inhibit absorption of cimetidine.\" N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J \"Effects of antacids and food on absorption of famotidine.\" Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA \"High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.\" Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al \"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.\" Eur J Clin Pharmacol 26 (1984): 271-3", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Clarithromycin, Vonoprazan, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 145163, "ingredient1": "Nizatidine", "ingredient2": "Magnesium hydroxide", "severity": "Minor", "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145326/", "reference_text": "[1] Barzaghi N, Gatti G, Crema F, Perucca E \"Impaired bioavailability of famotidine given concurrently with a potent antacid.\" J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P \"Effect of aluminum phosphate on the bioavailability of ranitidine.\" Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al \"The effects of antacid and propantheline on the absorption of oral ranitidine.\" Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A \"Diminished absorption of cimetidine caused by antacids.\" Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al \"Effect of antacids on predicted steady-state cimetidine concentrations.\" Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J \"Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing.\" Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM \"Antacids inhibit absorption of cimetidine.\" N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J \"Effects of antacids and food on absorption of famotidine.\" Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA \"High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.\" Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al \"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.\" Eur J Clin Pharmacol 26 (1984): 271-3", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Vonoprazan, Amoxicillin, Lansoprazole, Omeprazole", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 145164, "ingredient1": "Nizatidine", "ingredient2": "Meclofenamic acid", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145327/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone, Tolazoline, Dimethyl sulfoxide, Phenylbutazone", "updated_at": 1767369485}, {"id": 145165, "ingredient1": "Nizatidine", "ingredient2": "Mecobalamin", "severity": "Minor", "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145328/", "reference_text": "[1] Lavy NW \"Omeprazole and vitamin B12.\" Ann Intern Med 121 (1994): 74[2] Salom IL, Silvis SE, Doscherholmen A \"Effect of cimetidine on the absorption of vitamin B12.\" Scand J Gastroenterol 17 (1982): 129-31[3] Dutta SK \"Vitamin b-12 malabsorption and omeprazole therapy.\" J Am Coll Nutr 13 (1994): 544-5[4] Marcuard SP, Albernaz L, Khazanie PG \"Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin-b12).\" Ann Intern Med 120 (1994): 211-5[5] Bradford GS, Taylor CT \"Omeprazole and vitamin B-12 deficiency.\" Ann Pharmacother 33 (1999): 641-3", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Hydroxocobalamin", "updated_at": 1767369485}, {"id": 145166, "ingredient1": "Nizatidine", "ingredient2": "Nicotine", "severity": "Minor", "effect": "H2 antagonists may reduce the clearance of nicotine. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145329/", "reference_text": "[1] Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM \"Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans.\" Eur J Clin Pharmacol 38 (1990): 165-9", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Buprenorphine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 145167, "ingredient1": "Oxtriphylline", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Cimetidine may increase theophylline plasma concentrations by as much as 70%. The mechanism is related to inhibition of liver CYP450 enzymes responsible for theophylline metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145330/", "reference_text": "[1] Schwartz JI, Bachmann KA, Bond LW, Mahajan VK \"Impact of cimetidine on the pharmacokinetics of the theophylline.\" Clin Pharm 1 (1982): 534-8[2] Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R \"Cimetidine decreases theophylline clearance.\" Am Rev Respir Dis 123 (1981): 615-7[3] Anderson JR, Poklis A, Slavin RG \"A fatal case of theophylline intoxication.\" Arch Intern Med 143 (1983): 559-60[4] Weinberger MM, Smith G, Milavetz G, Hendeles L \"Decreased clearance of theophylline due to cimetidine .\" N Engl J Med 304 (1981): 672[5] Skinner MH, Lenert L, Blaschke TF \"Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction.\" Am J Med 86 (1989): 129-32[6] Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ \"Cimetidine-theophylline interaction: report of four patients.\" Ann Allergy 48 (1982): 100-2[7] Lofgren RP, Gilbertson RA \"Cimetidine and theophylline.\" Ann Intern Med 96 (1982): 378[8] Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN \"Inhibition of theophylline clearance by cimetidine but not ranitidine.\" Arch Intern Med 144 (1984): 484-6[9] Kelly HW, Powell JR, Donohue JF \"Ranitidine at very large doses does not inhibit theophylline elimination.\" Clin Pharmacol Ther 39 (1986): 577-81[10] Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J \"Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease.\" J Clin Pharmacol 35 (1995): 529-35[11] Kelly HW \"Lack of evidence for reduction of theophylline clearance by ranitidine.\" Am J Med 86 (1989): 629-32[12] Hegman GW, Gilbert RP \"Ranitidine-theophylline interaction--fact or fiction?\" Ann Pharmacother 25 (1991): 21-5[13] Fernandes E, Melewicz FM \"Ranitidine and theophylline.\" Ann Intern Med 100 (1984): 459[14] Reitberg DP, Bernhard H, Schentag JJ \"Alteration of theophylline clearance and half-life by cimetidine in normal volunteers.\" Ann Intern Med 95 (1981): 582-5[15] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[16] Kehoe WA, Sands CD, Long LF, et al \"Effect of ranitidine on theophylline metabolism in healthy Koreans living in China.\" Ann Pharmacother 30 (1996): 133-7[17] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[18] Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR \"Cimetidine decreases theophylline clearance.\" Ann Intern Med 95 (1981): 68-9[19] Loi CM, Parker BM, Cusack BJ, Vestal RE \"Aging and drug interactions .3. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers.\" J Pharmacol Exp Ther 280 (1997): 627-37[20] Ohashi K, Sakamoto K, Sudo T, Tateishi T, Fujimura A, Shiga T, Ebihara A \"Effects of diltiazem and cimetidine on theophylline oxidative metabolism.\" J Clin Pharmacol 33 (1993): 1233-7[21] Pride M, Deamer RL \"Over-the-counter cimetidine and theophylline interaction.\" Am Fam Physician 52 (1995): 2180[22] Verdiani P, Di Carlo S, Baronti A \"Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD: comparison with cimetidine and placebo.\" Chest 94 (1988): 807-10[23] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[24] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[25] Roy AK, Cuda MP, Levine RA \"Induction of theophylline toxicity and inhibition of clearance rates by ranitidine.\" Am J Med 85 (1988): 525-7[26] Fenje PC, Isles AF, Baltodano A, MacLeod SM, Soldin S \"Interaction of cimetidine and theophylline in two infants.\" Can Med Assoc J 126 (1982): 1178[27] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[28] Dal Negro R, Pomari C, Turco P \"Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.\" Clin Pharmacokinet 24 (1993): 255-8[29] Hsu K, Garton A, Sproule BJ, Tam YK, Leggatt D, Herbert FA \"The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction.\" Am Rev Respir Dis 130 (1984): 740-3[30] Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R \"Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.\" Br J Clin Pharmacol 24 (1987): 669-72", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 145168, "ingredient1": "Ozanimod", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "The risk of transient bradycardia and atrioventricular (AV) block may be increased during initiation of ozanimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis. Ozanimod can cause a decrease in heart rate during initiation of therapy.", "source": "DDInter", "management_text": "Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate. In addition, advice from a cardiologist should be sought if coadministration of ozanimod is considered in patients with significant QT prolongation (QTcF greater than 450 msec in males or 470 msec in females), patients with arrhythmias requiring treatment with Class 1a or Class III antiarrhythmic agents, patients with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, or uncontrolled hypertension. Use of ozanimod in patients with a history of second-degree Mobitz type II or higher AV block, sick-sinus syndrome, or sinoatrial heart block is considered contraindicated unless the patient has a functioning pacemaker.", "mechanism_text": "Synergism", "recommendation": "Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145331/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145169, "ingredient1": "Pazopanib", "ingredient2": "Nizatidine", "severity": "Major", "effect": "Coadministration with proton pump inhibitors or H2-receptor antagonists may significantly decrease the oral bioavailability of pazopanib and reduce its concentrations in plasma. The solubility of pazopanib is pH-dependent, thus an increase in pH may interfere with its absorption.", "source": "DDInter", "management_text": "Concomitant use of pazopanib with proton pump inhibitors and H2-receptor antagonists should generally be avoided. If acid-suppression therapy is required, short-acting antacids should be considered, with dosing separated by several hours from pazopanib dosing. Similarly, when coadministration with an H2-receptor antagonist is required, it has been recommended that pazopanib be taken without food at least 2 hours before or 10 hours after a dose of the H2-receptor antagonist.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of pazopanib with proton pump inhibitors and H2-receptor antagonists should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145332/", "reference_text": "[1] van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG \"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.\" Lancet Oncol 15 (2014): e315-e326[2] Yu G, Zheng QS, Wang DX, Zhou HH, Li GF \"Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye.\" Lancet Oncol 15 (2014): e469-70[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Tan AR, Gibbon DG, Stein MN, et al. \"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.\" Cancer Chemother Pharmacol 71 (2013): 1635-43[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 145170, "ingredient1": "Pexidartinib", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption.", "source": "DDInter", "management_text": "If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.", "mechanism_text": "Absorption", "recommendation": "If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145333/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Amoxicillin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 145171, "ingredient1": "Piroxicam", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145334/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone, Tolazoline, Dimethyl sulfoxide, Phenylbutazone, Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Clarithromycin, Vonoprazan", "updated_at": 1767369485}, {"id": 145172, "ingredient1": "Ponatinib", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Coadministration with drugs that elevate the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids may decrease the oral bioavailability of ponatinib and reduce its concentrations in plasma. The aqueous solubility of ponatinib has been shown to be pH-dependent, with higher pH resulting in decreased solubility.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145335/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Tetracycline, Levofloxacin, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 145173, "ingredient1": "Posaconazole", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists may decrease the systemic bioavailability of posaconazole from the oral suspension. The proposed mechanism is reduced solubility and absorption of posaconazole due to an increase in gastric pH induced by these agents.", "source": "DDInter", "management_text": "Concomitant use of posaconazole oral suspension with cimetidine should generally be avoided. Until more information is available, this precaution should also be considered for other H2-receptor antagonists, although the manufacturer suggests otherwise. If possible, prescribers may consider suspending the H2 antagonist until completion of posaconazole therapy, or substituting an antifungal agent like fluconazole or voriconazole whose absorption is not affected by stomach pH. Delayed-release tablets of posaconazole may be used with H2 antagonists, as no pharmacokinetic interaction has been demonstrated with ranitidine or other agents affecting gastric pH such as proton pump inhibitors or antacids.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of posaconazole oral suspension with cimetidine should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145336/", "reference_text": "[1] Krishna G, Moton A, Ma L, Medlock MM, McLeod J \"The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.\" Antimicrob Agents Chemother 53 (2009): 958-66[2] Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR \"Omeprazole significantly reduces posaconazole serum trough level.\" Clin Infect Dis 48 (2009): 839[3] Shields RK, Clancy CJ, Vadnerkar A, et al \"Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy.\" Antimicrob Agents Chemother 55 (2011): 1308-11[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Vaes M, Hites M, Cotton F, et al. \"Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome.\" Antimicrob Agents Chemother 56 (2012): 6298-303[6] Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J \"Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole.\" 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20[7] Neubauer WC, Engelhardt M, Konig A, et al. \"Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.\" Antimicrob Agents Chemother 54 (2010): 4029-32[8] Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P \"Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations.\" Clin Pharmacokinet 50 (2011): 725-34[9] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[10] Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ \"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response and factors affecting concentration.\" Antimicrob Agents Chemother 56 (2012): 5503-10[11] Krishna G, Abutarif M, Xuan F, Martinho M, Angulo D, Cornely OA \"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.\" Pharmacotherapy 28 (2008): 1223-32[12] Sansone-Parsons A, Krishna G, Calzetta A, et al. \"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.\" Antimicrob Agents Chemother 50 (2006): 1881-3[13] Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P \"Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations.\" Clin Pharmacokinet 50 (2011): 725-34[14] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[15] Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J \"Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole.\" 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin", "alternatives_b": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole", "updated_at": 1767369485}, {"id": 145174, "ingredient1": "Prasugrel", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors or H2-receptor antagonists may modestly affect the pharmacokinetics of prasugrel, but does not appear to alter its antiplatelet effects. The proposed mechanism is delayed prasugrel dissolution due to increased gastric pH.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145337/", "reference_text": "[1] Small DS, Farid NA, Payne CD, et al. \"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.\" J Clin Pharmacol 48 (2008): 475-84[2] \"Product Information. Effient (prasugrel).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "updated_at": 1767369485}, {"id": 145175, "ingredient1": "Raltegravir", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Since raltegravir solubility is increased at higher pH, coadministration with agents that elevate gastric pH may theoretically increase the plasma concentrations of raltegravir. However, concurrent use of proton pump inhibitors or H2-receptor antagonists in clinical trials did not result in meaningful differences in the safety of raltegravir. Based on these data, no dosage adjustment of raltegravir is necessary when used together with proton pump inhibitors or H2-receptor antagonists.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145338/", "reference_text": "[1] \"Product Information. Isentress (raltegravir).\" Merck & Company Inc, West Point, PA.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 145176, "ingredient1": "Selpercatinib", "ingredient2": "Nizatidine", "severity": "Major", "effect": "Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in plasma.", "source": "DDInter", "management_text": "Concomitant use of selpercatinib with H2-receptor antagonists should generally be avoided. If coadministration is required, the manufacturer recommends taking selpercatinib 2 hours before or 10 hours after the H2 receptor antagonist to minimize the clinical impact of the interaction.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of selpercatinib with H2-receptor antagonists should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145339/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 145177, "ingredient1": "Siponimod", "ingredient2": "Nizatidine", "severity": "Major", "effect": "The risk of severe bradycardia and atrioventricular (AV) block may be increased during initiation of siponimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis.", "source": "DDInter", "management_text": "Siponimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate. Treatment with siponimod should generally not be initiated in patients who are concurrently treated with heart rate-lowering drugs. Advice from a cardiologist should be sought if coadministration of siponimod and drugs that slow heart rate or AV conduction is considered.", "mechanism_text": "Synergism", "recommendation": "Siponimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145340/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Amoxicillin, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145178, "ingredient1": "Sonidegib", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors or H2-receptor antagonists may decrease the plasma concentrations of sonidegib. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145341/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Amoxicillin", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 145179, "ingredient1": "Sulindac", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145342/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone", "updated_at": 1767369485}, {"id": 145180, "ingredient1": "Thalidomide", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions. The clinical significance and underlying etiology of the bradycardia observed with thalidomide treatment have not been established. However, the potential for additive bradycardic effects should be considered when used with other drugs that slow cardiac conduction such as beta-blockers, calcium channel blockers, digitalis, flecainide, moricizine, and propafenone. Non-cardiac drugs that may also cause bradycardia include atazanavir, lacosamide, lithium, mefloquine, succinylcholine, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents. Because bradycardia is a risk factor for torsade de pointes arrhythmia, concerns also exist when thalidomide is used with drugs that prolong the QT interval or cause torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145343/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145181, "ingredient1": "Tolazamide", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "H2 antagonists such as cimetidine and ranitidine may increase plasma concentrations of sulfonylureas and enhance hypoglycemic effects. The mechanism may be related to inhibition of liver cytochrome P450 enzymes responsible for sulfonylurea metabolism or increased absorption due to altered gastric pH. Cimetidine may also inhibit glucose metabolism. Other H2 antagonists may interact in a similar manner, particularly if increased pH is involved.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended. Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Absorption", "recommendation": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145344/", "reference_text": "[1] Dey NG, Castleden CM, Ward J, et al \"The effect of cimetidine on tolbutamide kinetics.\" Br J Clin Pharmacol 16 (1983): 438-40[2] Kubacka RT, Antal EJ, Juhl RP \"The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics.\" Br J Clin Pharmacol 23 (1987): 743-51[3] Feely J, Collins WCJ, Cullen CM, et al. \"Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists.\" Br J Clin Pharmacol 35 (1993): 321-3[4] Lee K, Mize R, Lowenstein SR \"Glyburide-induced hypoglycemia and ranitidine.\" Ann Intern Med 107 (1987): 261-2[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lansoprazole", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "updated_at": 1767369485}, {"id": 145182, "ingredient1": "Tolbutamide", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "H2 antagonists such as cimetidine and ranitidine may increase plasma concentrations of sulfonylureas and enhance hypoglycemic effects. The mechanism may be related to inhibition of liver cytochrome P450 enzymes responsible for sulfonylurea metabolism or increased absorption due to altered gastric pH. Cimetidine may also inhibit glucose metabolism. Other H2 antagonists may interact in a similar manner, particularly if increased pH is involved.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended. Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Absorption", "recommendation": "Clinical monitoring of patient response, tolerance, and glycemic control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145345/", "reference_text": "[1] Dey NG, Castleden CM, Ward J, et al \"The effect of cimetidine on tolbutamide kinetics.\" Br J Clin Pharmacol 16 (1983): 438-40[2] Kubacka RT, Antal EJ, Juhl RP \"The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics.\" Br J Clin Pharmacol 23 (1987): 743-51[3] Feely J, Collins WCJ, Cullen CM, et al. \"Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists.\" Br J Clin Pharmacol 35 (1993): 321-3[4] Lee K, Mize R, Lowenstein SR \"Glyburide-induced hypoglycemia and ranitidine.\" Ann Intern Med 107 (1987): 261-2[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lansoprazole", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "updated_at": 1767369485}, {"id": 145183, "ingredient1": "Tolmetin", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145346/", "reference_text": "[1] Said SA, Foda AM \"Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.\" Arzneimittelforschung 39 (1989): 790-2[2] \"Product Information. Daypro (oxaprozin).\" Searle, Skokie, IL.[3] Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS \"Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.\" Eur J Clin Pharmacol 31 (1986): 371-4", "alternatives_a": "Chondroitin sulfate, Esomeprazole, Glucosamine, Phenylbutazone, Tolazoline, Dimethyl sulfoxide, Phenylbutazone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "updated_at": 1767369485}, {"id": 145184, "ingredient1": "Triamterene", "ingredient2": "Nizatidine", "severity": "Minor", "effect": "Ranitidine, famotidine, and nizatidine may interfere with the absorption of triamterene. The diuretic effect of triamterene may be decreased when it is taken with any of these drugs. No special precaution appears necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145347/", "reference_text": "[1] Muirhead M, Bochner F, Somogyi A \"Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.\" J Pharmacol Exp Ther 244 (1988): 734-9", "alternatives_a": "Eplerenone, Amiloride, Finerenone", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "updated_at": 1767369485}, {"id": 145185, "ingredient1": "Acetohexamide", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145348/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145186, "ingredient1": "Amoxapine", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145349/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145187, "ingredient1": "Carteolol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145350/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "updated_at": 1767369485}, {"id": 145188, "ingredient1": "Deserpidine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145351/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969): 333-5", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine", "updated_at": 1767369485}, {"id": 145189, "ingredient1": "Desflurane", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.", "source": "DDInter", "management_text": "This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient's hemodynamic status should be closely monitored.", "mechanism_text": "Others", "recommendation": "This combination should be avoided or used very cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145352/", "reference_text": "[1] Cooke JE \"Drug interactions in anesthesia.\" Clin Plast Surg 12 (1985): 83-9[2] Smith RB \"Drug interactions and drug reactions.\" Otolaryngol Clin North Am 14 (1981): 615-29[3] \"Product Information. Fluothane (halothane).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Kainuma M, Suzuki A \"Convulsions after adrenaline administration during enflurane anaesthesia.\" Anaesthesia 41 (1986): 874-5[5] Horrigan RW, Eger EI, Wilson C \"Epinephrine-induced arrhythmias during enflurane anesthesia in man: a nonlinear dose-response relationship and dose-dependent protection from lidocaine.\" Anesth Analg 57 (1978): 547-50[6] Gold MI \"Profound hypotension associated with preoperative use of phenothiazines.\" Anesth Analg 53 (1974): 844-8[7] Mostello L, Stueber K, Lake CR \"Is topical application of epinephrine at skin graft donor sites during halothane anesthesia safe?\" Ann Plast Surg 20 (1988): 313-6[8] Johnston RR, Eger EI II, Wilson C \"A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man.\" Anesth Analg 55 (1976): 709-12[9] Reisner LS, Lippmann M \"Ventricular arrhythmias after epinephrine injection in enflurane and in halothane anesthesia.\" Anesth Analg 54 (1975): 468-70[10] Cullen BF, Miller MG \"Drug interactions and anesthesia: a review.\" Anesth Analg 58 (1979): 413-23[11] Hirshom WI, Taylor RG, Sheehan JC \"Arrhythmias produced by combinations of halothane and small amounts of vasopressor.\" Br J Oral Surg 2 (1964): 131-6[12] Pepple J \"Epinephrine-halothane interaction in children versus adults.\" Anesthesiology 60 (1984): 76-8[13] Bennett JA, Eltringham RJ \"Possible dangers of anaesthesia in patients receiving fenfluramine. Results of animal studies following a case of human cardiac arrest.\" Anaesthesia 32 (1977): 8-13[14] Ueda W, Hirakawa M, Mae O \"Appraisal of epinephrine administration to patients under halothane anesthesia for closure of cleft palate.\" Anesthesiology 58 (1983): 574-6[15] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[16] Konchigeri HN, Shaker MH, Winnie AP \"Effect of epinephrine during enflurane anesthesia.\" Anesth Analg 53 (1974): 894-7[17] Forbes AM \"Halothane, adrenaline and cardiac arrest.\" Anaesthesia 21 (1966): 22-7[18] Karl HW, Swedlow DB, Lee KW, Downes JJ \"Epinephrine-halothane interactions in children.\" Anesthesiology 58 (1983): 142-5[19] Snow JC, Shamsai J, Sakarya I \"Effects of epinephrine during halothane anesthesia in mastoidotympanoplastic surgery.\" Anesth Analg 47 (1968): 252-6[20] Reisner LS, Lippmann M \"Further data on epinephrine interactions.\" Anesth Analg 56 (1977): 468[21] Ghoneim MM \"Drug interaction in anaesthesia. A review.\" Can Anaesth Soc J 18 (1971): 353-75", "alternatives_a": "Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate", "updated_at": 1767369485}, {"id": 145190, "ingredient1": "Digitoxin", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The concomitant use of sympathomimetic agents and cardiac glycosides may increase the risk of cardiac arrhythmias. The mechanism of this interaction is not known. Increased ectopic pacemaker activity has been reported to occur in patients taking digoxin in combination with pseudoephedrine.", "source": "DDInter", "management_text": "Caution should be exercised if these two drugs are coadministered. Electrocardiogram monitoring (ECG) is recommended. The use of epinephrine (adrenaline) with high doses of digitalis glycosides is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution should be exercised if these two drugs are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145353/", "reference_text": "[1] \"Product Information. Claritin-D (loratadine-pseudoephedrine).\" Schering-Plough, Liberty Corner, NJ.[2] \"Product Information. Epinephrine Hydrochloride Injection (epinephrine).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Lanoxin (digoxin).\" Glaxo Wellcome, Research Triangle Park, NC.[4] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Allegra-D (fexofenadine-pseudoephedrine).\" Chattem Consumer Products, Chattanooga, TN.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[9] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[10] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145191, "ingredient1": "Enflurane", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.", "source": "DDInter", "management_text": "This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient's hemodynamic status should be closely monitored.", "mechanism_text": "Others", "recommendation": "This combination should be avoided or used very cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145354/", "reference_text": "[1] Cooke JE \"Drug interactions in anesthesia.\" Clin Plast Surg 12 (1985): 83-9[2] Smith RB \"Drug interactions and drug reactions.\" Otolaryngol Clin North Am 14 (1981): 615-29[3] \"Product Information. Fluothane (halothane).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Kainuma M, Suzuki A \"Convulsions after adrenaline administration during enflurane anaesthesia.\" Anaesthesia 41 (1986): 874-5[5] Horrigan RW, Eger EI, Wilson C \"Epinephrine-induced arrhythmias during enflurane anesthesia in man: a nonlinear dose-response relationship and dose-dependent protection from lidocaine.\" Anesth Analg 57 (1978): 547-50[6] Gold MI \"Profound hypotension associated with preoperative use of phenothiazines.\" Anesth Analg 53 (1974): 844-8[7] Mostello L, Stueber K, Lake CR \"Is topical application of epinephrine at skin graft donor sites during halothane anesthesia safe?\" Ann Plast Surg 20 (1988): 313-6[8] Johnston RR, Eger EI II, Wilson C \"A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man.\" Anesth Analg 55 (1976): 709-12[9] Reisner LS, Lippmann M \"Ventricular arrhythmias after epinephrine injection in enflurane and in halothane anesthesia.\" Anesth Analg 54 (1975): 468-70[10] Cullen BF, Miller MG \"Drug interactions and anesthesia: a review.\" Anesth Analg 58 (1979): 413-23[11] Hirshom WI, Taylor RG, Sheehan JC \"Arrhythmias produced by combinations of halothane and small amounts of vasopressor.\" Br J Oral Surg 2 (1964): 131-6[12] Pepple J \"Epinephrine-halothane interaction in children versus adults.\" Anesthesiology 60 (1984): 76-8[13] Bennett JA, Eltringham RJ \"Possible dangers of anaesthesia in patients receiving fenfluramine. Results of animal studies following a case of human cardiac arrest.\" Anaesthesia 32 (1977): 8-13[14] Ueda W, Hirakawa M, Mae O \"Appraisal of epinephrine administration to patients under halothane anesthesia for closure of cleft palate.\" Anesthesiology 58 (1983): 574-6[15] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[16] Konchigeri HN, Shaker MH, Winnie AP \"Effect of epinephrine during enflurane anesthesia.\" Anesth Analg 53 (1974): 894-7[17] Forbes AM \"Halothane, adrenaline and cardiac arrest.\" Anaesthesia 21 (1966): 22-7[18] Karl HW, Swedlow DB, Lee KW, Downes JJ \"Epinephrine-halothane interactions in children.\" Anesthesiology 58 (1983): 142-5[19] Snow JC, Shamsai J, Sakarya I \"Effects of epinephrine during halothane anesthesia in mastoidotympanoplastic surgery.\" Anesth Analg 47 (1968): 252-6[20] Reisner LS, Lippmann M \"Further data on epinephrine interactions.\" Anesth Analg 56 (1977): 468[21] Ghoneim MM \"Drug interaction in anaesthesia. A review.\" Can Anaesth Soc J 18 (1971): 353-75", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate", "alternatives_b": "Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "updated_at": 1767369485}, {"id": 145192, "ingredient1": "Entacapone", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.", "source": "DDInter", "management_text": "The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that caution be exercised when these drugs are given together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145355/", "reference_text": "[1] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A \"The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.\" Clin Pharmacol Ther 58 (1995): 221-7[4] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide", "updated_at": 1767369485}, {"id": 145193, "ingredient1": "Ergometrine", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors. Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents. If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly. Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145356/", "reference_text": "[1] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9[4] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977): 55-6[5] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003): 92-4[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[17] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[25] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[29] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[33] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[34] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[35] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[36] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[37] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[38] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Dobutamine, Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Isoprenaline, Methoxamine, Mephentermine", "alternatives_b": "Misoprostol, Dinoprostone", "updated_at": 1767369485}, {"id": 145194, "ingredient1": "Ergotamine", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors. Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents. If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly. Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145357/", "reference_text": "[1] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9[4] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977): 55-6[5] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003): 92-4[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[17] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[25] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[29] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[33] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[34] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[35] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[36] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[37] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[38] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Dobutamine, Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline", "alternatives_b": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More", "updated_at": 1767369485}, {"id": 145195, "ingredient1": "Ertugliflozin", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145358/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145196, "ingredient1": "Esmolol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145359/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145197, "ingredient1": "Exenatide", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145360/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145198, "ingredient1": "Glimepiride", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145361/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "updated_at": 1767369485}, {"id": 145199, "ingredient1": "Glipizide", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145362/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145200, "ingredient1": "Glyburide", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145363/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145201, "ingredient1": "Guanadrel", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145364/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969): 333-5", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145202, "ingredient1": "Guanethidine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145365/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969): 333-5", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "updated_at": 1767369485}, {"id": 145203, "ingredient1": "Halothane", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.", "source": "DDInter", "management_text": "This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient's hemodynamic status should be closely monitored.", "mechanism_text": "Others", "recommendation": "This combination should be avoided or used very cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145366/", "reference_text": "[1] Cooke JE \"Drug interactions in anesthesia.\" Clin Plast Surg 12 (1985): 83-9[2] Smith RB \"Drug interactions and drug reactions.\" Otolaryngol Clin North Am 14 (1981): 615-29[3] \"Product Information. Fluothane (halothane).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Kainuma M, Suzuki A \"Convulsions after adrenaline administration during enflurane anaesthesia.\" Anaesthesia 41 (1986): 874-5[5] Horrigan RW, Eger EI, Wilson C \"Epinephrine-induced arrhythmias during enflurane anesthesia in man: a nonlinear dose-response relationship and dose-dependent protection from lidocaine.\" Anesth Analg 57 (1978): 547-50[6] Gold MI \"Profound hypotension associated with preoperative use of phenothiazines.\" Anesth Analg 53 (1974): 844-8[7] Mostello L, Stueber K, Lake CR \"Is topical application of epinephrine at skin graft donor sites during halothane anesthesia safe?\" Ann Plast Surg 20 (1988): 313-6[8] Johnston RR, Eger EI II, Wilson C \"A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man.\" Anesth Analg 55 (1976): 709-12[9] Reisner LS, Lippmann M \"Ventricular arrhythmias after epinephrine injection in enflurane and in halothane anesthesia.\" Anesth Analg 54 (1975): 468-70[10] Cullen BF, Miller MG \"Drug interactions and anesthesia: a review.\" Anesth Analg 58 (1979): 413-23[11] Hirshom WI, Taylor RG, Sheehan JC \"Arrhythmias produced by combinations of halothane and small amounts of vasopressor.\" Br J Oral Surg 2 (1964): 131-6[12] Pepple J \"Epinephrine-halothane interaction in children versus adults.\" Anesthesiology 60 (1984): 76-8[13] Bennett JA, Eltringham RJ \"Possible dangers of anaesthesia in patients receiving fenfluramine. Results of animal studies following a case of human cardiac arrest.\" Anaesthesia 32 (1977): 8-13[14] Ueda W, Hirakawa M, Mae O \"Appraisal of epinephrine administration to patients under halothane anesthesia for closure of cleft palate.\" Anesthesiology 58 (1983): 574-6[15] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[16] Konchigeri HN, Shaker MH, Winnie AP \"Effect of epinephrine during enflurane anesthesia.\" Anesth Analg 53 (1974): 894-7[17] Forbes AM \"Halothane, adrenaline and cardiac arrest.\" Anaesthesia 21 (1966): 22-7[18] Karl HW, Swedlow DB, Lee KW, Downes JJ \"Epinephrine-halothane interactions in children.\" Anesthesiology 58 (1983): 142-5[19] Snow JC, Shamsai J, Sakarya I \"Effects of epinephrine during halothane anesthesia in mastoidotympanoplastic surgery.\" Anesth Analg 47 (1968): 252-6[20] Reisner LS, Lippmann M \"Further data on epinephrine interactions.\" Anesth Analg 56 (1977): 468[21] Ghoneim MM \"Drug interaction in anaesthesia. A review.\" Can Anaesth Soc J 18 (1971): 353-75", "alternatives_a": "Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Dopamine, More", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate", "updated_at": 1767369485}, {"id": 145204, "ingredient1": "Imipramine", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145367/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Fenoldopam, Mephentermine", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145205, "ingredient1": "Indacaterol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145368/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 145206, "ingredient1": "Indomethacin", "ingredient2": "Norepinephrine", "severity": "Minor", "effect": "Limited data have shown that indomethacin may enhance the pressor response to norepinephrine. Eicosanoids originating from the cyclooxygenase pathway of arachidonate metabolism may modulate the vascular response to adrenergic stimulation. Indomethacin is a potent cyclooxygenase inhibitor. The clinical significance is unknown. Blood pressure monitoring is recommended during norepinephrine infusion, particularly in patients who have used or are taking indomethacin.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145369/", "reference_text": "[1] Weisser B, Kayser G, Wagner S, Gobel BO, Vetter H, Dusing R \"Inhibition of cyclooxygenase attenuates baroreceptor function and increases the pressor response to norepinephrine in man.\" Eur J Clin Pharmacol 42 (1992): 681-3", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Diclofenac, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Ketoprofen, More", "alternatives_b": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Isoprenaline, More", "updated_at": 1767369485}, {"id": 145207, "ingredient1": "Insulin human", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145370/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145208, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145371/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145209, "ingredient1": "Insulin lispro", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145372/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145210, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145373/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145211, "ingredient1": "Insulin human (zinc)", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145374/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145212, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145375/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145213, "ingredient1": "Isoetharine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145376/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145214, "ingredient1": "Norepinephrine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index. Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145377/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals, Saddle River, NJ.[4] Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT \"S-ketamine concentrations are greatly increased by grapefruit juice.\" Eur J Clin Pharmacol 68 (2012): 979-86[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals, Saddle River, NJ.", "alternatives_a": "Arbutamine, Amrinone, Milrinone, Angiotensin II", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate", "updated_at": 1767369485}, {"id": 145215, "ingredient1": "Norepinephrine", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145378/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145216, "ingredient1": "Norepinephrine", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145379/", "reference_text": "[1] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc, Atlanta, GA.[3] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970): 656[4] \"Product Information. Tenuate (diethylpropion)\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[6] \"Product Information. Sanorex (mazindol)\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979): 45-52[8] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[9] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[10] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin", "updated_at": 1767369485}, {"id": 145217, "ingredient1": "Norepinephrine", "ingredient2": "Methoxyflurane", "severity": "Major", "effect": "The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.", "source": "DDInter", "management_text": "This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient's hemodynamic status should be closely monitored.", "mechanism_text": "Others", "recommendation": "This combination should be avoided or used very cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145380/", "reference_text": "[1] Cooke JE \"Drug interactions in anesthesia.\" Clin Plast Surg 12 (1985): 83-9[2] Smith RB \"Drug interactions and drug reactions.\" Otolaryngol Clin North Am 14 (1981): 615-29[3] \"Product Information. Fluothane (halothane).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Kainuma M, Suzuki A \"Convulsions after adrenaline administration during enflurane anaesthesia.\" Anaesthesia 41 (1986): 874-5[5] Horrigan RW, Eger EI, Wilson C \"Epinephrine-induced arrhythmias during enflurane anesthesia in man: a nonlinear dose-response relationship and dose-dependent protection from lidocaine.\" Anesth Analg 57 (1978): 547-50[6] Gold MI \"Profound hypotension associated with preoperative use of phenothiazines.\" Anesth Analg 53 (1974): 844-8[7] Mostello L, Stueber K, Lake CR \"Is topical application of epinephrine at skin graft donor sites during halothane anesthesia safe?\" Ann Plast Surg 20 (1988): 313-6[8] Johnston RR, Eger EI II, Wilson C \"A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man.\" Anesth Analg 55 (1976): 709-12[9] Reisner LS, Lippmann M \"Ventricular arrhythmias after epinephrine injection in enflurane and in halothane anesthesia.\" Anesth Analg 54 (1975): 468-70[10] Cullen BF, Miller MG \"Drug interactions and anesthesia: a review.\" Anesth Analg 58 (1979): 413-23[11] Hirshom WI, Taylor RG, Sheehan JC \"Arrhythmias produced by combinations of halothane and small amounts of vasopressor.\" Br J Oral Surg 2 (1964): 131-6[12] Pepple J \"Epinephrine-halothane interaction in children versus adults.\" Anesthesiology 60 (1984): 76-8[13] Bennett JA, Eltringham RJ \"Possible dangers of anaesthesia in patients receiving fenfluramine. Results of animal studies following a case of human cardiac arrest.\" Anaesthesia 32 (1977): 8-13[14] Ueda W, Hirakawa M, Mae O \"Appraisal of epinephrine administration to patients under halothane anesthesia for closure of cleft palate.\" Anesthesiology 58 (1983): 574-6[15] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[16] Konchigeri HN, Shaker MH, Winnie AP \"Effect of epinephrine during enflurane anesthesia.\" Anesth Analg 53 (1974): 894-7[17] Forbes AM \"Halothane, adrenaline and cardiac arrest.\" Anaesthesia 21 (1966): 22-7[18] Karl HW, Swedlow DB, Lee KW, Downes JJ \"Epinephrine-halothane interactions in children.\" Anesthesiology 58 (1983): 142-5[19] Snow JC, Shamsai J, Sakarya I \"Effects of epinephrine during halothane anesthesia in mastoidotympanoplastic surgery.\" Anesth Analg 47 (1968): 252-6[20] Reisner LS, Lippmann M \"Further data on epinephrine interactions.\" Anesth Analg 56 (1977): 468[21] Ghoneim MM \"Drug interaction in anaesthesia. A review.\" Can Anaesth Soc J 18 (1971): 353-75", "alternatives_a": "Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Diflunisal, Salsalate, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 145218, "ingredient1": "Norepinephrine", "ingredient2": "Methysergide", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors. Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents. If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly. Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145381/", "reference_text": "[1] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9[4] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977): 55-6[5] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003): 92-4[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[17] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[25] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[29] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[33] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[34] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[35] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[36] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[37] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[38] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More", "alternatives_b": "Dobutamine, Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline", "updated_at": 1767369485}, {"id": 145219, "ingredient1": "Nortriptyline", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145382/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145220, "ingredient1": "Opicapone", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.", "source": "DDInter", "management_text": "The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that caution be exercised when these drugs are given together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145383/", "reference_text": "[1] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A \"The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.\" Clin Pharmacol Ther 58 (1995): 221-7[4] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide", "updated_at": 1767369485}, {"id": 145221, "ingredient1": "Oxytocin", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Concomitant use of oxytocic agents with sympathomimetic amines may increase the risk of hypertension due to additive vasoconstrictive effects. Severe hypertension and headache have been reported when oxytocin was given 3 to 4 hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia.", "source": "DDInter", "management_text": "Close monitoring of blood pressure is recommended during coadministration.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of blood pressure is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145384/", "reference_text": "[1] \"Product Information. Syntocinon (oxytocin).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[4] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Misoprostol, Dinoprostone, Terlipressin", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "updated_at": 1767369485}, {"id": 145222, "ingredient1": "Ozanimod", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145385/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 145223, "ingredient1": "Penbutolol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145386/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145224, "ingredient1": "Phendimetrazine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145387/", "reference_text": "[1] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc, Atlanta, GA.[3] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970): 656[4] \"Product Information. Tenuate (diethylpropion)\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[6] \"Product Information. Sanorex (mazindol)\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979): 45-52[8] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[9] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[10] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145225, "ingredient1": "Phenelzine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145388/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145226, "ingredient1": "Phenylpropanolamine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145389/", "reference_text": "[1] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc, Atlanta, GA.[3] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970): 656[4] \"Product Information. Tenuate (diethylpropion)\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Adderall (amphetamine-dextroamphetamine)\" Shire Richwood Pharmaceutical Company, Florence, KY.[6] \"Product Information. Sanorex (mazindol)\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979): 45-52[8] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[9] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[10] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Pseudoephedrine, Phenylephrine", "updated_at": 1767369485}, {"id": 145227, "ingredient1": "Pindolol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145390/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145228, "ingredient1": "Pramlintide", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145391/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145229, "ingredient1": "Procarbazine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145392/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 145230, "ingredient1": "Propranolol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145393/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 145231, "ingredient1": "Protriptyline", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145394/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "updated_at": 1767369485}, {"id": 145232, "ingredient1": "Racepinephrine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145395/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145233, "ingredient1": "Rasagiline", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145396/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Droxidopa, Arbutamine, Angiotensin II", "alternatives_b": "Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide", "updated_at": 1767369485}, {"id": 145234, "ingredient1": "Reserpine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145397/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969): 333-5", "alternatives_a": "Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "updated_at": 1767369485}, {"id": 145235, "ingredient1": "Ritodrine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145398/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 145236, "ingredient1": "Rosiglitazone", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145399/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145237, "ingredient1": "Salmeterol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145400/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 145238, "ingredient1": "Selegiline", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145401/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Droxidopa, Arbutamine, Angiotensin II", "alternatives_b": "Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide", "updated_at": 1767369485}, {"id": 145239, "ingredient1": "Sevoflurane", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.", "source": "DDInter", "management_text": "This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient's hemodynamic status should be closely monitored.", "mechanism_text": "Others", "recommendation": "This combination should be avoided or used very cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145402/", "reference_text": "[1] Cooke JE \"Drug interactions in anesthesia.\" Clin Plast Surg 12 (1985): 83-9[2] Smith RB \"Drug interactions and drug reactions.\" Otolaryngol Clin North Am 14 (1981): 615-29[3] \"Product Information. Fluothane (halothane).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Kainuma M, Suzuki A \"Convulsions after adrenaline administration during enflurane anaesthesia.\" Anaesthesia 41 (1986): 874-5[5] Horrigan RW, Eger EI, Wilson C \"Epinephrine-induced arrhythmias during enflurane anesthesia in man: a nonlinear dose-response relationship and dose-dependent protection from lidocaine.\" Anesth Analg 57 (1978): 547-50[6] Gold MI \"Profound hypotension associated with preoperative use of phenothiazines.\" Anesth Analg 53 (1974): 844-8[7] Mostello L, Stueber K, Lake CR \"Is topical application of epinephrine at skin graft donor sites during halothane anesthesia safe?\" Ann Plast Surg 20 (1988): 313-6[8] Johnston RR, Eger EI II, Wilson C \"A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man.\" Anesth Analg 55 (1976): 709-12[9] Reisner LS, Lippmann M \"Ventricular arrhythmias after epinephrine injection in enflurane and in halothane anesthesia.\" Anesth Analg 54 (1975): 468-70[10] Cullen BF, Miller MG \"Drug interactions and anesthesia: a review.\" Anesth Analg 58 (1979): 413-23[11] Hirshom WI, Taylor RG, Sheehan JC \"Arrhythmias produced by combinations of halothane and small amounts of vasopressor.\" Br J Oral Surg 2 (1964): 131-6[12] Pepple J \"Epinephrine-halothane interaction in children versus adults.\" Anesthesiology 60 (1984): 76-8[13] Bennett JA, Eltringham RJ \"Possible dangers of anaesthesia in patients receiving fenfluramine. Results of animal studies following a case of human cardiac arrest.\" Anaesthesia 32 (1977): 8-13[14] Ueda W, Hirakawa M, Mae O \"Appraisal of epinephrine administration to patients under halothane anesthesia for closure of cleft palate.\" Anesthesiology 58 (1983): 574-6[15] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[16] Konchigeri HN, Shaker MH, Winnie AP \"Effect of epinephrine during enflurane anesthesia.\" Anesth Analg 53 (1974): 894-7[17] Forbes AM \"Halothane, adrenaline and cardiac arrest.\" Anaesthesia 21 (1966): 22-7[18] Karl HW, Swedlow DB, Lee KW, Downes JJ \"Epinephrine-halothane interactions in children.\" Anesthesiology 58 (1983): 142-5[19] Snow JC, Shamsai J, Sakarya I \"Effects of epinephrine during halothane anesthesia in mastoidotympanoplastic surgery.\" Anesth Analg 47 (1968): 252-6[20] Reisner LS, Lippmann M \"Further data on epinephrine interactions.\" Anesth Analg 56 (1977): 468[21] Ghoneim MM \"Drug interaction in anaesthesia. A review.\" Can Anaesth Soc J 18 (1971): 353-75", "alternatives_a": "Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate", "updated_at": 1767369485}, {"id": 145240, "ingredient1": "Sibutramine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when sibutramine is combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. Sibutramine is a potent inhibitor of norepinephrine and serotonin reuptake, and a less potent inhibitor of dopamine reuptake.", "source": "DDInter", "management_text": "Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating therapy with sibutramine and monitored at regular intervals thereafter. Dose reduction or discontinuation of sibutramine should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145403/", "reference_text": "[1] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[2] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[3] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin", "updated_at": 1767369485}, {"id": 145241, "ingredient1": "Solriamfetol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and/or heart rate may occur when solriamfetol is combined with other drugs that increase blood pressure and/or heart rate. The use of solriamfetol alone has been associated with dose-dependent increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate. Blood pressure should be monitored prior to initiating solriamfetol therapy and regularly during treatment. In addition, hypertension should be controlled prior to treatment, and any new-onset hypertension or exacerbations of pre-existing hypertension that occur during solriamfetol therapy should be treated. Discontinuation of solriamfetol should be considered in patients who experience an increase in blood pressure or heart rate that cannot be managed with dose reduction of solriamfetol or other appropriate medical intervention.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145404/", "reference_text": "[1] \"Product Information. Sunosi (solriamfetol).\" Jazz Pharmaceuticals, Palo Alto, CA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "updated_at": 1767369485}, {"id": 145242, "ingredient1": "Sotalol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145405/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 145243, "ingredient1": "Tapentadol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145406/", "reference_text": "[1] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[4] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR \"Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics.\" Pharmacotherapy 16 (1996): 1046-52", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Ibuprofen, More", "updated_at": 1767369485}, {"id": 145244, "ingredient1": "Terbutaline", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145407/", "reference_text": "[1] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[2] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[3] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[5] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[8] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Ephedrine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, More", "updated_at": 1767369485}, {"id": 145245, "ingredient1": "Timolol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145408/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "updated_at": 1767369485}, {"id": 145246, "ingredient1": "Tolazamide", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145409/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 145247, "ingredient1": "Tolbutamide", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145410/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "updated_at": 1767369485}, {"id": 145248, "ingredient1": "Tolcapone", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.", "source": "DDInter", "management_text": "The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that caution be exercised when these drugs are given together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145411/", "reference_text": "[1] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A \"The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.\" Clin Pharmacol Ther 58 (1995): 221-7[4] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide", "alternatives_b": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "updated_at": 1767369485}, {"id": 145249, "ingredient1": "Tranylcypromine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145412/", "reference_text": "[1] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966): 673-83[2] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[5] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967): 75-8[6] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[7] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982): 482-4[8] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[9] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[10] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[11] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997): 322-3[12] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991): 462-7[14] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[15] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[18] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[19] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[23] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[24] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[25] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[26] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[27] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[28] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[29] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[30] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[31] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Arbutamine, Angiotensin II", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145250, "ingredient1": "Trimipramine", "ingredient2": "Norepinephrine", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145413/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "alternatives_b": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145251, "ingredient1": "Troglitazone", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145414/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "updated_at": 1767369485}, {"id": 145252, "ingredient1": "Vasopressin", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Concomitant use of vasopressin or desmopressin with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. In addition, although the combination noradrenaline (norepinephrine) and vasopressin is clinically used to improve hemodynamic parameters, noradrenaline may also decrease the antidiuretic effect of vasopressin.", "source": "DDInter", "management_text": "The use of injectable vasopressin or large doses of intranasal or oral desmopressin with other pressor agents should only be done with careful hemodynamic monitoring. Vasopressin dosage may need to be adjusted. Consulting local protocols with respect to the dosage of vasopressin and the order of administration when used with noradrenaline is encouraged.", "mechanism_text": "Synergism", "recommendation": "The use of injectable vasopressin or large doses of intranasal or oral desmopressin with other pressor agents should only be done with careful hemodynamic monitoring.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145415/", "reference_text": "[1] Russell JA, Walley KR, Singer J, et al. \"Vasopressin versus norepinephrine infusion in patients with septic shock.\" N Engl J Med 358 (2008): 877-87[2] \"Product Information. Vasostrict (vasopressin).\" Par Pharmaceutical Inc, Chestnut Ridge, NY.[3] \"Product Information. DDAVP (desmopressin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Stimate (desmopressin).\" Forest Pharmaceuticals, St. Louis, MO.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Dellinger RP, Levy MM, Rhodes A, et al. \"Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012.\" Crit Care Med 41 (2013): 580-637[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Rhodes A, Evans LE, Alhazzani W, et.al \"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016\" Intensive Care Med 43 (2017): 304-77[9] \"Product Information. Vasopressin (vasopressin).\" APP (Abraxis Pharmaceutical Products), Schaumberg, IL.[10] Harper KM, Knapp DJ, Criswell HE, Breese GR \"Vasopressin and alcohol: A multifaceted relationship.\" Psychopharmacology (Berl) 235 (2018): 3363-79[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Collins GB, Brosnihan KB, Zuti RA, Messina M, Gupta MK \"Neuroendocrine, fluid balance, and thirst responses to alcohol in alcoholics.\" Alcohol Clin Exp Res 16 (1992): 228-32[13] Hirschl MM, Derfler K, Bieglmayer C, et.al \"Hormonal derangements in patients with severe alcohol intoxication.\" Alcohol Clin Exp Res 18 (1994): 761-6[14] \"Product Information. Vasostrict (vasopressin).\" Par Pharmaceutical Inc, Chestnut Ridge, NY.[15] Taivainen H, Laitinen K, Tahtela R, Kilanmaa K, Valimaki MJ \"Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication.\" Alcohol Clin Exp Res 19 (1995): 759-62[16] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145253, "ingredient1": "Venlafaxine", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145416/", "reference_text": "[1] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[4] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR \"Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics.\" Pharmacotherapy 16 (1996): 1046-52", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "updated_at": 1767369485}, {"id": 145254, "ingredient1": "Abarelix", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145417/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145255, "ingredient1": "Acetohexamide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145418/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 145256, "ingredient1": "Aluminum hydroxide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145419/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145257, "ingredient1": "Aminolevulinic acid", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.", "source": "DDInter", "management_text": "Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.", "mechanism_text": "Synergism", "recommendation": "Photosensitizing agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145420/", "reference_text": "[1] \"Product Information. Gleolan (aminolevulinic acid).\" NX Development Corp, Lexington, KY.[2] \"Product Information. Nulibry (fosdenopterin).\" Origin Biosciences Inc, Boston, MA.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 145258, "ingredient1": "Aminophylline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. This drug combination may increase the risk of seizures, especially in the elderly. Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels during concurrent fluoroquinolone therapy.", "source": "DDInter", "management_text": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels. Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145421/", "reference_text": "[1] Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J \"Effect of norfloxacin on theophyllin metabolism.\" Antimicrob Agents Chemother 33 (1989): 212-4[2] Grasela TH, Dreis MW \"An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system.\" Arch Intern Med 152 (1992): 617-21[3] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988): 109-14[4] Ho G, Tierney MG, Dales RE \"Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.\" Clin Pharmacol Ther 44 (1988): 35-8[5] Bowles SK, Popovski Z, Rybak MJ, Beckman HB, Edwards DJ \"Effect of norfloxacin on theophylline pharmacokinetics at steady state.\" Antimicrob Agents Chemother 32 (1988): 510-12[6] Gregoire SL, Grasela TH Jr, Freer JP, Tack KJ, Schentag JJ \"Inhibition of theophylline clearance by coadministered ofloxacin without alteraction of theophylline effects.\" Antimicrob Agents Chemother 31 (1987): 375-8[7] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[8] Sano M, Yamamoto I, Ueda J, Yoskikawa E, Yamashina H, Goto M \"Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration.\" Eur J Clin Pharmacol 32 (1987): 431-2[9] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[10] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987): 159-69[11] Raoof S, Wollschlager C, Khan FA \"Ciprofloxacin increases serum levels of theophylline.\" Am J Med 82 (1987): 115-8[12] Covelli HD, Knodel AR, Heppner BT \"Predisposing factors to apparent theophylline-induced seizures.\" Ann Allergy 54 (1985): 411-5[13] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[14] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[15] Green L, Clark J \"Fluoroquinolones and theophylline toxicity: norfloxacin.\" JAMA 262 (1989): 2383[16] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21", "alternatives_a": "Tinidazole, Secnidazole, Cefixime, Amikacin, Levofloxacin, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 145259, "ingredient1": "Amoxapine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145422/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145260, "ingredient1": "Anisindione", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.", "source": "DDInter", "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.", "mechanism_text": "Others", "recommendation": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145423/", "reference_text": "[1] Arnold LM, Nissen LR, Ng TM \"Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction.\" Pharmacotherapy 25 (2005): 904-7[2] Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW \"Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation.\" Pharmacotherapy 12 (1992): 435-9[3] Glasheen JJ, Fugit RV, Prochazka AV \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy--a comment.\" Pharmacotherapy 23 (2003): 1079-80; discussion 1080[4] Jolson HM, Tanner LA, Green L, Grasela TH \"Adverse reaction reporting of interaction between warfarin and fluoroquinolones.\" Arch Intern Med 151 (1991): 1003-4[5] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[6] Kaplan DS \"Norfloxacin and protime elevation.\" Am J Gastroenterol 85 (1990): 901[7] Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Pol \"Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.\" Clin Infect Dis 22 (1996): 251-6[8] Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S \"Possible interaction between gatifloxacin and warfarin.\" Am J Health Syst Pharm 59 (2002): 1205-6[9] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[10] Morawiecka I, Djelouah I, Wilcox D \"Fluoroquinolones and warfarin: suspected interactions. Available from: URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adrv14n3_e.html.\" ([2004 July]):[11] Ellis RJ, Mayo MS, Bodensteiner DM \"Ciprofloxacin-warfarin coagulopathy: A case series.\" Am J Hematol 63 (2000): 28-31[12] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002): 705-10[13] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[14] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[15] Davy M, Bird N, Rost KL, Fuder H \"Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.\" Chemotherapy 45 (1999): 491-5[16] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[17] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[18] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[19] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005): 653-6[20] Yildiz F, Kurtaran B, Cayli M, Candevir A, Sumbul Z \"A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve.\" Heart Vessels 23 (2008): 286-8[21] Gleckman R, Alvarez S, Joubert DW, Matthews SJ \"Drug therapy reviews: nalidixic acid.\" Am J Hosp Pharm 36 (1979): 1071-6[22] Jones CB, Fugate SE \"Levofloxacin and warfarin interaction.\" Ann Pharmacother 36 (2002): 1554-7[23] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[24] Potasman I, Bassan H \"Nicoumalone and nalidixic acid interaction.\" Ann Intern Med 92 (1980): 571[25] Millar E, Coles S, Wyld P, Nimmo W \"Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.\" Clin Pharmacokinet 22(Suppl 1) (1992): 102-6[26] Rindone JP, Kelley CL, Jones WN, Garewell HS \"Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin.\" Clin Pharm 10 (1991): 136-8[27] Leor J, Levartowsky D, Sharon C \"Interaction between nalidixic acid and warfarin.\" Ann Intern Med 107 (1987): 601[28] Rocci ML Jr, Vlasses PH, Distelrath LM, et al \"Norfloxacin does not alter warfarin's disposition or anticoagulant effect.\" J Clin Pharmacol 30 (1990): 728-32[29] Efthymiopoulos C, Bramer SL, Maroli A, Blum B \"Theophylline and warfarin interaction studies with grepafloxacin.\" Clin Pharmacokinet 33(Suppl 1) (1997): 39-46[30] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[31] McLeod AD, Burgess C \"Drug interaction between warfarin and enoxacin.\" N Z Med J 101 (1988): 216[32] Gheno G, Cinetto L \"Levofloxacin-warfarin interaction.\" Eur J Clin Pharmacol 57 (2001): 427[33] Chock AW, Stading JA \"Indeterminable International Normalized Ratio with concurrent use of warfarin and gatifloxacin.\" Am J Health Syst Pharm 63 (2006): 1539-42[34] Yamreudeewong W, Lower DL, Kilpatrick DM, Enlow AM, Burrows MM, Greenwood MC \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy.\" Pharmacotherapy 23 (2003): 333-8[35] Liao S, Palmer M, Fowler C, Nayak RK \"Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.\" J Clin Pharmacol 36 (1996): 1072-7[36] Mathews S, Cole J, Ryono RA \"Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin.\" Pharmacotherapy 26 (2006): 1446-52[37] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[38] Baciewicz AM, Ashar BH, Locke TW \"Interaction of ofloxacin and warfarin.\" Ann Intern Med 119 (1993): 1223[39] Loeliger EA, van der Esch B, Mattern MJ, Hemker HC \"The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever.\" Thromb Diath Haemorrh 10 (1963): 267-77[40] Leor J, Matezki S \"Ofloxacin and warfarin.\" Ann Intern Med 109 (1988): 761[41] Kamada AK \"Possible interaction between ciprofloxacin and warfarin.\" DICP 24 (1990): 27-8[42] Linville D, Emory C, Graves L \"Ciprofloxacin and warfarin interaction.\" Am J Med 90 (1991): 765[43] Roush MK, Bussey HL, Bianco TM \"Do fluoroquinolones alter the effects of warfarin therapy?\" Arch Intern Med 152 (1992): 1533-4[44] Renzi R, Finkbeiner S \"Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect.\" Am J Emerg Med 9 (1991): 551-2[45] Toon S, Hopkins KJ, Garstang FM, et al \"Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.\" Clin Pharmacol Ther 42 (1987): 33-41[46] Ravnan SL, Locke C \"Levofloxacin and warfarin interaction.\" Pharmacotherapy 21 (2001): 884-5[47] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[48] \"Product Information. Maxaquin (lomefloxacin).\" Searle, Skokie, IL.[49] Randinitis EJ, Alvey CW, Koup JR, et al. \"Drug interactions with clinafloxacin.\" Antimicrob Agents Chemother 45 (2001): 2543-52[50] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[51] Marchbanks CR \"Drug-drug interactions with fluoroquinolones.\" Pharmacotherapy 13 (1993): s23-8[52] Andriole VT, Haverstock DC, Choudhri SH \"Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.\" Drug Saf 28 (2005): 443-52[53] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005): 439-44[54] Goel K, Menzies D, Cunha BA \"Elevated international normalized ratio associated with trovafloxacin.\" Ann Intern Med 131 (1999): 72[55] \"Product Information. NegGram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[56] McCall KL, Scott JC, Anderson HG \"Retrospective evaluation of a possible interaction between warfarin and levofloxacin.\" Pharmacotherapy 25 (2005): 67-73[57] Mott FE, Murphy S, Hunt V \"Ciprofloxacin and warfarin.\" Ann Intern Med 111 (1989): 542-3[58] Stroud LF, Mamdami MM, Kopp A, Bell CM \"The safety of levofloxacin in elderly patients on warfarin.\" Am J Med 118 (2005): 1417[59] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[60] Elbe DH, Chang SW \"Moxifloxacin-warfarin interaction: a series of five case reports.\" Ann Pharmacother 39 (2005): 361-4[61] Linville T, Matanin D \"Norfloxacin and warfarin.\" Ann Intern Med 110 (1989): 751-2[62] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[63] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[64] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[65] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[66] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[67] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[68] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[69] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[70] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[71] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[72] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[73] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[74] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[75] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[76] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[77] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[78] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[79] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[80] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[81] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[82] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[83] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[84] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[85] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[86] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[87] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[88] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[89] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[90] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[91] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[92] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[93] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[94] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[95] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[96] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[97] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[98] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Amikacin, Secnidazole, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145261, "ingredient1": "Norfloxacin", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145424/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145262, "ingredient1": "Attapulgite", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145425/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Pectin, Activated charcoal", "updated_at": 1767369485}, {"id": 145263, "ingredient1": "Bedaquiline", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145426/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, More", "updated_at": 1767369485}, {"id": 145264, "ingredient1": "Bepridil", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.", "source": "DDInter", "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.", "mechanism_text": "Synergism", "recommendation": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145427/", "reference_text": "[1] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[2] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[3] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[4] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB \"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.\" Clin Infect Dis 34 (2002): 861-3[5] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[6] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[7] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[8] Ansari SR, Chopra N \"Gatifloxacin and Prolonged QT Interval.\" Am J Med Sci 327 (2004): 55-6[9] Siepmann M, Kirch W \"Drug points - Tachycardia associated with moxifloxacin.\" Br Med J 322 (2001): 23[10] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] \"Product Information. Maxaquin (lomefloxacin).\" Searle, Skokie, IL.[12] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[13] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[14] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C \"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.\" Clin Pharmacol Ther 68 (2000): 658-66[15] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[16] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[17] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[18] Dale KM, Lertsburapa K, Kluger J, White CM \"Moxifloxacin and torsade de pointes.\" Ann Pharmacother 41 (2007): 336-40[19] Iannini PB, Circiumaru I \"Gatifloxacin-induced QTc prolongation and ventricular tachycardia.\" Pharmacotherapy 21 (2001): 361-2[20] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[21] White CM, Grant EM, Quintiliani R \"Moxifloxacin does increase the corrected QT interval.\" Clin Infect Dis 33 (2001): 1441-2[22] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P \"Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers.\" Br J Clin Pharmacol 41 (1996): 499-503[23] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[24] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[25] Jaillon P, Morganroth J, Brumpt I, Talbot G \"Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.\" J Antimicrob Chemother 37(suppl a) (1996): 161-7[26] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[27] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[28] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[29] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[30] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[31] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[32] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[33] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF \"Effects of three fluoroquinolones on QT analysis after standard treatment courses.\" Ann Noninvasive Electrocardiol 11 (2006): 52-6[34] Lipsky BA, Dorr MB, Magner DJ, Talbot GH \"Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.\" Clin Ther 21 (1999): 148-59[35] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[36] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[37] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B \"Torsades de pointe probably related to sparfloxacin.\" Eur J Clin Microbiol Infect Dis 15 (1996): 350-1[38] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[39] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[40] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[41] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145265, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145428/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Amikacin, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Famciclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145266, "ingredient1": "Bromfenac", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145429/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Lomefloxacin, More", "updated_at": 1767369485}, {"id": 145267, "ingredient1": "Calcium carbonate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145430/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 145268, "ingredient1": "Calcium citrate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145431/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 145269, "ingredient1": "Calcium glubionate anhydrous", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145432/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride", "updated_at": 1767369485}, {"id": 145270, "ingredient1": "Calcium gluconate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145433/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Cromoglicic acid, Abrocitinib, More", "updated_at": 1767369485}, {"id": 145271, "ingredient1": "Calcium glycerophosphate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145434/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145272, "ingredient1": "Calcium lactate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145435/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride", "updated_at": 1767369485}, {"id": 145273, "ingredient1": "Iron", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145436/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 145274, "ingredient1": "Frangula purshiana bark", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145437/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145275, "ingredient1": "Castor oil", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145438/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 145276, "ingredient1": "Chlorpromazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145439/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145277, "ingredient1": "Chromium picolinate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145440/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145278, "ingredient1": "Cisapride", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145441/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[4] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999): 251[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[7] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[8] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[9] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG \"Red wine-cisapride interaction: Comparison with grapefruit juice.\" Clin Pharmacol Ther 70 (2001): 17-23[10] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[11] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[12] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ \"Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.\" Clin Pharmacol Ther 66 (1999): 448-53[13] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[14] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[15] Gross AS, Goh YD, Addison RS, Shenfield GM \"Influence of grapefruit juice on cisapride pharmacokinetics.\" Clin Pharmacol Ther 65 (1999): 395-401[16] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145279, "ingredient1": "Copper gluconate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145442/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145280, "ingredient1": "Cytarabine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145443/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, More", "alternatives_b": "Tinidazole, Cefixime, Tetracycline, Secnidazole, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 145281, "ingredient1": "Dacarbazine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145444/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145282, "ingredient1": "Dicoumarol", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.", "source": "DDInter", "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.", "mechanism_text": "Others", "recommendation": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145445/", "reference_text": "[1] Arnold LM, Nissen LR, Ng TM \"Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction.\" Pharmacotherapy 25 (2005): 904-7[2] Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW \"Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation.\" Pharmacotherapy 12 (1992): 435-9[3] Glasheen JJ, Fugit RV, Prochazka AV \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy--a comment.\" Pharmacotherapy 23 (2003): 1079-80; discussion 1080[4] Jolson HM, Tanner LA, Green L, Grasela TH \"Adverse reaction reporting of interaction between warfarin and fluoroquinolones.\" Arch Intern Med 151 (1991): 1003-4[5] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[6] Kaplan DS \"Norfloxacin and protime elevation.\" Am J Gastroenterol 85 (1990): 901[7] Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Pol \"Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.\" Clin Infect Dis 22 (1996): 251-6[8] Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S \"Possible interaction between gatifloxacin and warfarin.\" Am J Health Syst Pharm 59 (2002): 1205-6[9] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[10] Morawiecka I, Djelouah I, Wilcox D \"Fluoroquinolones and warfarin: suspected interactions. Available from: URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adrv14n3_e.html.\" ([2004 July]):[11] Ellis RJ, Mayo MS, Bodensteiner DM \"Ciprofloxacin-warfarin coagulopathy: A case series.\" Am J Hematol 63 (2000): 28-31[12] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002): 705-10[13] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[14] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[15] Davy M, Bird N, Rost KL, Fuder H \"Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.\" Chemotherapy 45 (1999): 491-5[16] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[17] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[18] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[19] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005): 653-6[20] Yildiz F, Kurtaran B, Cayli M, Candevir A, Sumbul Z \"A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve.\" Heart Vessels 23 (2008): 286-8[21] Gleckman R, Alvarez S, Joubert DW, Matthews SJ \"Drug therapy reviews: nalidixic acid.\" Am J Hosp Pharm 36 (1979): 1071-6[22] Jones CB, Fugate SE \"Levofloxacin and warfarin interaction.\" Ann Pharmacother 36 (2002): 1554-7[23] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[24] Potasman I, Bassan H \"Nicoumalone and nalidixic acid interaction.\" Ann Intern Med 92 (1980): 571[25] Millar E, Coles S, Wyld P, Nimmo W \"Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.\" Clin Pharmacokinet 22(Suppl 1) (1992): 102-6[26] Rindone JP, Kelley CL, Jones WN, Garewell HS \"Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin.\" Clin Pharm 10 (1991): 136-8[27] Leor J, Levartowsky D, Sharon C \"Interaction between nalidixic acid and warfarin.\" Ann Intern Med 107 (1987): 601[28] Rocci ML Jr, Vlasses PH, Distelrath LM, et al \"Norfloxacin does not alter warfarin's disposition or anticoagulant effect.\" J Clin Pharmacol 30 (1990): 728-32[29] Efthymiopoulos C, Bramer SL, Maroli A, Blum B \"Theophylline and warfarin interaction studies with grepafloxacin.\" Clin Pharmacokinet 33(Suppl 1) (1997): 39-46[30] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[31] McLeod AD, Burgess C \"Drug interaction between warfarin and enoxacin.\" N Z Med J 101 (1988): 216[32] Gheno G, Cinetto L \"Levofloxacin-warfarin interaction.\" Eur J Clin Pharmacol 57 (2001): 427[33] Chock AW, Stading JA \"Indeterminable International Normalized Ratio with concurrent use of warfarin and gatifloxacin.\" Am J Health Syst Pharm 63 (2006): 1539-42[34] Yamreudeewong W, Lower DL, Kilpatrick DM, Enlow AM, Burrows MM, Greenwood MC \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy.\" Pharmacotherapy 23 (2003): 333-8[35] Liao S, Palmer M, Fowler C, Nayak RK \"Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.\" J Clin Pharmacol 36 (1996): 1072-7[36] Mathews S, Cole J, Ryono RA \"Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin.\" Pharmacotherapy 26 (2006): 1446-52[37] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[38] Baciewicz AM, Ashar BH, Locke TW \"Interaction of ofloxacin and warfarin.\" Ann Intern Med 119 (1993): 1223[39] Loeliger EA, van der Esch B, Mattern MJ, Hemker HC \"The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever.\" Thromb Diath Haemorrh 10 (1963): 267-77[40] Leor J, Matezki S \"Ofloxacin and warfarin.\" Ann Intern Med 109 (1988): 761[41] Kamada AK \"Possible interaction between ciprofloxacin and warfarin.\" DICP 24 (1990): 27-8[42] Linville D, Emory C, Graves L \"Ciprofloxacin and warfarin interaction.\" Am J Med 90 (1991): 765[43] Roush MK, Bussey HL, Bianco TM \"Do fluoroquinolones alter the effects of warfarin therapy?\" Arch Intern Med 152 (1992): 1533-4[44] Renzi R, Finkbeiner S \"Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect.\" Am J Emerg Med 9 (1991): 551-2[45] Toon S, Hopkins KJ, Garstang FM, et al \"Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.\" Clin Pharmacol Ther 42 (1987): 33-41[46] Ravnan SL, Locke C \"Levofloxacin and warfarin interaction.\" Pharmacotherapy 21 (2001): 884-5[47] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[48] \"Product Information. Maxaquin (lomefloxacin).\" Searle, Skokie, IL.[49] Randinitis EJ, Alvey CW, Koup JR, et al. \"Drug interactions with clinafloxacin.\" Antimicrob Agents Chemother 45 (2001): 2543-52[50] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[51] Marchbanks CR \"Drug-drug interactions with fluoroquinolones.\" Pharmacotherapy 13 (1993): s23-8[52] Andriole VT, Haverstock DC, Choudhri SH \"Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.\" Drug Saf 28 (2005): 443-52[53] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005): 439-44[54] Goel K, Menzies D, Cunha BA \"Elevated international normalized ratio associated with trovafloxacin.\" Ann Intern Med 131 (1999): 72[55] \"Product Information. NegGram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[56] McCall KL, Scott JC, Anderson HG \"Retrospective evaluation of a possible interaction between warfarin and levofloxacin.\" Pharmacotherapy 25 (2005): 67-73[57] Mott FE, Murphy S, Hunt V \"Ciprofloxacin and warfarin.\" Ann Intern Med 111 (1989): 542-3[58] Stroud LF, Mamdami MM, Kopp A, Bell CM \"The safety of levofloxacin in elderly patients on warfarin.\" Am J Med 118 (2005): 1417[59] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[60] Elbe DH, Chang SW \"Moxifloxacin-warfarin interaction: a series of five case reports.\" Ann Pharmacother 39 (2005): 361-4[61] Linville T, Matanin D \"Norfloxacin and warfarin.\" Ann Intern Med 110 (1989): 751-2[62] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[63] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[64] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[65] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[66] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[67] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[68] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[69] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[70] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[71] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[72] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[73] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[74] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[75] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[76] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[77] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[78] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[79] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[80] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[81] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[82] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[83] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[84] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[85] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[86] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[87] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[88] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[89] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[90] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[91] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[92] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[93] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[94] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[95] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[96] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[97] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[98] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More", "alternatives_b": "Amikacin, Secnidazole, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More", "updated_at": 1767369485}, {"id": 145283, "ingredient1": "Diflunisal", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145446/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Ziconotide, Methoxyflurane", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145284, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145447/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145285, "ingredient1": "Entecavir", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145448/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Secnidazole, Azithromycin, Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 145286, "ingredient1": "Entrectinib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Entrectinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of entrectinib and periodically during treatment as appropriate based on individual risk factors.", "mechanism_text": "Synergism", "recommendation": "Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145449/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145287, "ingredient1": "Enzalutamide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145450/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "updated_at": 1767369485}, {"id": 145288, "ingredient1": "Epirubicin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145451/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145289, "ingredient1": "Eribulin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Eribulin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval. Baseline and periodic monitoring of electrocardiograms and serum electrolytes (potassium, magnesium) should be considered, and hypokalemia or hypomagnesemia corrected prior to initiating treatment with eribulin. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145452/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Halaven (eribulin).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145290, "ingredient1": "Ertugliflozin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145453/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 145291, "ingredient1": "Escitalopram", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145454/", "reference_text": "[1] Castro VM, Clements CC, Murphy SN, et al. \"QT interval and antidepressant use: a cross sectional study of electronic health records.\" BMJ 346 (2013): f288[2] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[9] Health Canada \"Antidepressant Cipralex (escitalopram): Updated information regarding dose-related heart risk. Available from: URL: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_63-eng.php.\" ([2012 May 7]):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "updated_at": 1767369485}, {"id": 145292, "ingredient1": "Etacrynic acid", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145455/", "reference_text": "[1] Sudoh T, Fujimura A, Shiga T, Sasaki M, Harada K, Tateishi T, Ohashi K, Ebihara A \"Renal clearance of lomefloxacin is decreased by furosemide.\" Eur J Clin Pharmacol 46 (1994): 267-9", "alternatives_a": "Tinidazole, Fluconazole, Metronidazole, Secnidazole, Azithromycin, Levofloxacin, Gatifloxacin, Acyclovir, Rifamycin, Ganciclovir, Famciclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145293, "ingredient1": "Etodolac", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145456/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Cefixime, Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145294, "ingredient1": "Etoposide", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145457/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tetracycline, Cefixime, Azithromycin, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, More", "updated_at": 1767369485}, {"id": 145295, "ingredient1": "Exenatide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145458/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 145296, "ingredient1": "Ezogabine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145459/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Brivaracetam, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 145297, "ingredient1": "Fenoprofen", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145460/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145298, "ingredient1": "Tetraferric tricitrate decahydrate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145461/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 145299, "ingredient1": "Ferrous fumarate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145462/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 145300, "ingredient1": "Ferrous gluconate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145463/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 145301, "ingredient1": "Ferrous sulfate anhydrous", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145464/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145302, "ingredient1": "Fingolimod", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of fingolimod treatment in patients receiving drugs that prolong the QT interval. Fingolimod can cause a decrease in heart rate during initiation of therapy that is apparent within an hour of the first dose and maximal at approximately 6 hours postdose in most cases, but occasionally up to 20 hours after the first dose.", "source": "DDInter", "management_text": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).", "mechanism_text": "Synergism", "recommendation": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145465/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data.\" ([2012 May 14]):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 145303, "ingredient1": "Flecainide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145466/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Lidocaine, Moricizine, Bretylium, Tocainide", "updated_at": 1767369485}, {"id": 145304, "ingredient1": "Floxuridine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145467/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145305, "ingredient1": "Fluconazole", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145468/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Secnidazole, Cefixime, Amikacin, Levofloxacin, Micafungin, Caspofungin, Itraconazole, More", "alternatives_b": "Tinidazole, Cefixime, Fluconazole, Secnidazole, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, More", "updated_at": 1767369485}, {"id": 145306, "ingredient1": "Fludarabine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145469/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tetracycline, Cefixime, Azithromycin, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, More", "alternatives_b": "Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine", "updated_at": 1767369485}, {"id": 145307, "ingredient1": "Fludrocortisone", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.", "source": "DDInter", "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145470/", "reference_text": "[1] Khaliq Y, Zhanel GG \"Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature.\" Clin Infect Dis 36 (2003): 1404-1410[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH \"Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids.\" Arch Intern Med 163 (2003): 1801-7[4] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration \"Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm.\" ([7/8/2008]):[7] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 145308, "ingredient1": "Fluorouracil", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145471/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine", "alternatives_b": "Tetracycline, Secnidazole, Cefixime, Azithromycin, Amikacin, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145309, "ingredient1": "Fluphenazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145472/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145310, "ingredient1": "Flurbiprofen", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145473/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Tolazoline, Dimethyl sulfoxide, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Lidocaine, Bacitracin, Chlorhexidine, Povidone-iodine, Neomycin, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, More", "updated_at": 1767369485}, {"id": 145311, "ingredient1": "Flutamide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145474/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145312, "ingredient1": "Foscarnet", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Limited data suggest that coadministration of foscarnet and ciprofloxacin may potentiate the risk of seizures. Both agents are individually epileptogenic and may have additive effects when combined. Specifically, foscarnet can decrease the seizure threshold by chelating ionized calcium and magnesium, while ciprofloxacin inhibits gamma-aminobutyric acid (GABA).", "source": "DDInter", "management_text": "Caution is advised during coadministration of foscarnet and ciprofloxacin, particularly in elderly patients and those with renal impairment, electrolyte and metabolic abnormalities, or underlying neurologic disorders. The same precaution may be applicable during therapy with other quinolones, although clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of foscarnet and ciprofloxacin, particularly in elderly patients and those with renal impairment, electrolyte and metabolic abnormalities, or underlying neurologic disorders.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145475/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[3] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[5] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[7] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[8] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[9] Fan-Havard P, Sanchorawala V, Oh J, Moser EM, Smith SP \"Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.\" Ann Pharmacother 28 (1994): 869-72[10] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "alternatives_b": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Tetracycline, Rifamycin, Oxytetracycline, Polymyxin B, Famciclovir, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 145313, "ingredient1": "Fostemsavir", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Fostemsavir can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if fostemsavir is used in combination with other drugs that can prolong the QT interval. Consider obtaining electrocardiogram and serum electrolyte levels prior to initiating fostemsavir therapy and periodically thereafter, particularly in patients with risk factors for torsade de pointes and/or receiving one or more potent CYP450 3A4 inhibitors (e.g., azole antifungal agents; cobicistat; protease inhibitors; ketolide and certain macrolide antibiotics; ceritinib; idelalisib; nefazodone) or P-gp inhibitors (e.g., cyclosporine; diltiazem; quinidine; quinine; tacrolimus; verapamil). Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if fostemsavir is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145476/", "reference_text": "[1] \"Product Information. Rukobia (fostemsavir).\" ViiV Healthcare, Research Triangle Park, NC.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 145314, "ingredient1": "Furosemide", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145477/", "reference_text": "[1] Sudoh T, Fujimura A, Shiga T, Sasaki M, Harada K, Tateishi T, Ohashi K, Ebihara A \"Renal clearance of lomefloxacin is decreased by furosemide.\" Eur J Clin Pharmacol 46 (1994): 267-9", "alternatives_a": "Metolazone, Trichlormethiazide, Chlorthalidone, Bendroflumethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, More", "alternatives_b": "Tinidazole, Levofloxacin, Secnidazole, Rifamycin, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 145315, "ingredient1": "Galantamine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145478/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Memantine, Aducanumab", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145316, "ingredient1": "Gemcitabine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145479/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine", "alternatives_b": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, More", "updated_at": 1767369485}, {"id": 145317, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145480/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145318, "ingredient1": "Gilteritinib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Gilteritinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145481/", "reference_text": "[1] \"Product Information. Xospata (gilteritinib).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145319, "ingredient1": "Ginkgo biloba", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145482/", "reference_text": "[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002): 325-7[2] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001): 523-5[3] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006): 323-9[6] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005): 755-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Memantine, Aducanumab", "updated_at": 1767369485}, {"id": 145320, "ingredient1": "Glasdegib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Glasdegib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with glasdegib, approximately one week after initiation, and then once monthly for the next two months, although patients with risk factors may require more frequent and ongoing ECG monitoring.", "mechanism_text": "Synergism", "recommendation": "Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145483/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145321, "ingredient1": "Glipizide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145484/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Secnidazole, Cefixime, Amikacin, Tetracycline, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 145322, "ingredient1": "Glyburide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145485/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Secnidazole, Cefixime, Amikacin, Tetracycline, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, More", "updated_at": 1767369485}, {"id": 145323, "ingredient1": "Glycerin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145486/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 145324, "ingredient1": "Goserelin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145487/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Megestrol acetate, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, More", "updated_at": 1767369485}, {"id": 145325, "ingredient1": "Granisetron", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145488/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol", "alternatives_b": "Tinidazole, Tetracycline, Secnidazole, Cefixime, Amikacin, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145326, "ingredient1": "Halofantrine", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145489/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[4] Nosten F, ter Kuile FO, Luxemburger C, et al \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993): 1054-6[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001): 169-70, 179[7] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[8] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[9] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[10] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[11] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[12] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[13] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002): 514-23", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 145327, "ingredient1": "Haloperidol", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Haloperidol treatment alone has been associated with a number of reported cases of torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with haloperidol. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145490/", "reference_text": "[1] Huyse F, van Schijndel RS \"Haloperidol and cardiac arrest.\" Lancet 2 (1988): 568-9[2] \"Product Information. Haldol (haloperidol).\" McNeil Pharmaceutical, Raritan, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] O'Brien JM, Rockwood RP, Suh KI \"Haloperidol-induced torsade de pointes.\" Ann Pharmacother 33 (1999): 1046-9[7] Wilt JL, Minnema AM, Johnson RF, Rosenblum AM \"Torsade de pointes associated with the use of intravenous haloperidol.\" Ann Intern Med 119 (1993): 391-4[8] Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y \"The association between intravenous haloperidol and prolonged QT interval.\" J Clin Psychopharmacol 21 (2001): 257-61[9] Metzger E, Friedman R \"Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.\" J Clin Psychopharmacol 13 (1993): 128-32[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, More", "updated_at": 1767369485}, {"id": 145328, "ingredient1": "Halothane", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145491/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, More", "updated_at": 1767369485}, {"id": 145329, "ingredient1": "Histrelin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145492/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Megestrol acetate, Diethylstilbestrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 145330, "ingredient1": "Hydroxychloroquine", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.", "source": "DDInter", "management_text": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.", "mechanism_text": "Synergism", "recommendation": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145493/", "reference_text": "[1] Mercuro NJ, Yen CF, Shim DJ, et.al \"Risk of QT interval prolongation associated with the use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)\" JAMA Cardiol May 1:e201834 (2020): epub ahead of print[2] \"Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine).\" Prasco Laboratories, Cincinnati, OH.[3] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF HYDROXYCHLOROQUINE SULFATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/\" ({2020, Apr 27]):[4] \"Product Information. Plaquenil (R). (hydroxychloroquine).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] \"Product Information. Chloroquine Phosphate (chloroquine).\" West-Ward Pharmaceutical Corporation, Eatontown, NJ.[6] Bessiere F, Roccia H, Deliniere A, et.al \"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit.\" JAMA Cardiol May 1 (2020): epub ahead of print[7] National Institutes of Health (NIH) \"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: URL: https://covid19treatmentguidelines.nih.gov/\" ([2020, Apr 21]):[8] Sacher F, Fauchier L, Boveda S, et.al \"Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.\" Arch Cardiovasc Dis Apr 24 (2020): epub ahead of print[9] Kapoor A, Pandurangi U, Arora V, et.al \"Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.\" Indian Pacing Electorphysiol J Apr 8 (2020): epub ahead of print[10] Borba MGS, Val FFA, Sampaio VS, et.al \"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-2) infection: A randomized clinical trial.\" JAMA Netw Open Apr 1 (2020): epub ahead of print[11] Sapp JL, Alqarawi W, MacIntyre CJ, et.al \"Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society.\" Can J Cardiol Apr 8 (2020): epub ahead of print[12] Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ \"Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties.\" Clin Pharmacokinet Ar 18 (2020): epub ahead of print[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C \"COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients?\" Br J Clin Pharmacol Apr 29 (2020): epub ahead of print[15] US Food and Drug Administration \"Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Available from: URL: https://www.fda.gov/safety/medical-product-\" ([2020, Apr 24]):[16] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ \"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)\" Mayo Clin Proc Apr 7 (2020): epub ahead of print[17] Roden DM, Harrington RA, Poppas A, Russo AM \"Considerations for drug interactions on QTc in exploratory COVID-19 (Coroanvirus disease 2019) treatment.\" Heart Rhythm Apr 14 (2020): epub ahead of print[18] mitra RL, Greenstein SA, Epstein lm \"An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin; Possible benefits of intravenous lidocaine.\" HeartRythm Case Rep Apr 1 (2020): epub ahead of print[19] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CHLOROQUINE PHOSPHATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/13653\" ([2020, Apr 27]):[20] Saleh M, Gabriels J, ChangD, et.al \"The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection.\" Circ Arrhythm Electrophysiol Apr 29 (2020): epub ahead of print[21] Bonow RO, Hernandez AF, Turakhia M \"Hydroxychloroquine, coronavirus disease 2019, and QT prolongation.\" JAMA Cardiol May 1 (2020): epub ahead of print[22] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Amikacin, Cefixime, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Tobramycin, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 145331, "ingredient1": "Hydroxyurea", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145494/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, More", "updated_at": 1767369485}, {"id": 145332, "ingredient1": "Hydroxyzine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145495/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Clobazam, Halazepam, Clorazepic acid, Buspirone, Chlordiazepoxide", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Famciclovir, More", "updated_at": 1767369485}, {"id": 145333, "ingredient1": "Ibutilide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145496/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Corvert (ibutilide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145334, "ingredient1": "Idarubicin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145497/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Ixabepilone, Valrubicin", "updated_at": 1767369485}, {"id": 145335, "ingredient1": "Ifosfamide", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145498/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Rifamycin, Oxytetracycline, Famciclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145336, "ingredient1": "Iloperidone", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.", "mechanism_text": "Synergism", "recommendation": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145499/", "reference_text": "[1] \"Product Information. Exforge HCT (amlodipine/hydrochlorothiazide/valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 145337, "ingredient1": "Imipramine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145500/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, More", "updated_at": 1767369485}, {"id": 145338, "ingredient1": "Indacaterol", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145501/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 145339, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145502/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Fluconazole, Ganciclovir, Acyclovir, Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145340, "ingredient1": "Indomethacin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145503/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Fluocinolone acetonide, Fluorometholone, Tolazoline, Dimethyl sulfoxide, Regadenoson, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Polymyxin B, Famciclovir, More", "updated_at": 1767369485}, {"id": 145341, "ingredient1": "Insulin human", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145504/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145342, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145505/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145343, "ingredient1": "Insulin lispro", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145506/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145344, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145507/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145345, "ingredient1": "Insulin human (zinc)", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145508/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145346, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145509/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145347, "ingredient1": "Iohexol", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145510/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, More", "alternatives_b": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "updated_at": 1767369485}, {"id": 145348, "ingredient1": "Iron protein succinylate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145511/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 145349, "ingredient1": "Isoetharine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145512/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145350, "ingredient1": "Norfloxacin", "ingredient2": "Kaolin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145513/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Pectin, Activated charcoal", "updated_at": 1767369485}, {"id": 145351, "ingredient1": "Norfloxacin", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145514/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Amikacin, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Famciclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145352, "ingredient1": "Norfloxacin", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145515/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine)\" Organon, West Orange, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Ofloxacin, More", "updated_at": 1767369485}, {"id": 145353, "ingredient1": "Norfloxacin", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Levomethadyl acetate may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of levomethadyl acetate alone have been associated with QT interval prolongation and torsade de pointes.", "source": "DDInter", "management_text": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145516/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] Krantz MJ, Mehler PS \"Synthetic opioids and QT prolongation.\" Arch Intern Med 163 (2003): 1615; author reply 1615[5] Deamer RL, Wilson DR, Clark DS, Prichard JG \"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).\" J Addict Dis 20 (2001): 7-14[6] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "alternatives_b": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene", "updated_at": 1767369485}, {"id": 145354, "ingredient1": "Norfloxacin", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145517/", "reference_text": "[1] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981): 98-9[3] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991): 41-3[7] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977): 1050-4", "alternatives_a": "Disulfiram", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145355, "ingredient1": "Norfloxacin", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145518/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145356, "ingredient1": "Norfloxacin", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145519/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 145357, "ingredient1": "Norfloxacin", "ingredient2": "Magnesium citrate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145520/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Sorbitol, Sulfamethizole, Mannitol, Sodium chloride, Chlorhexidine, Neomycin, Sodium chloride, Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, More", "updated_at": 1767369485}, {"id": 145358, "ingredient1": "Norfloxacin", "ingredient2": "Magnesium gluconate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145521/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Sodium chloride", "updated_at": 1767369485}, {"id": 145359, "ingredient1": "Norfloxacin", "ingredient2": "Magnesium glycinate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145522/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145360, "ingredient1": "Norfloxacin", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145523/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 145361, "ingredient1": "Norfloxacin", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145524/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Sodium chloride, Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 145362, "ingredient1": "Norfloxacin", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145525/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145363, "ingredient1": "Norfloxacin", "ingredient2": "Melatonin", "severity": "Minor", "effect": "Concomitant administration of CYP450 1A1 or 1A2 inhibitors such as estrogens or quinolones may increase the serum concentration of melatonin. The clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145526/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[3] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7[4] Hartter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K \"Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.\" Br J Clin Pharmacol 56 (2003): 679-682", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "updated_at": 1767369485}, {"id": 145364, "ingredient1": "Norfloxacin", "ingredient2": "Mesoridazine", "severity": "Major", "effect": "Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145527/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Serentil (mesoridazine)\" Boehringer-Ingelheim, Ridgefield, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145365, "ingredient1": "Norfloxacin", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145528/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 145366, "ingredient1": "Norfloxacin", "ingredient2": "Mineral oil", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145529/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 145367, "ingredient1": "Nortriptyline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145530/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145368, "ingredient1": "Olanzapine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval.", "source": "DDInter", "management_text": "Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145531/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[4] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[5] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[9] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[10] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[11] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[12] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 145369, "ingredient1": "Oliceridine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145532/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Oxycodone, Butorphanol, Meperidine, Hydromorphone, Dezocine, Opium, Pentazocine, More", "updated_at": 1767369485}, {"id": 145370, "ingredient1": "Ondansetron", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145533/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 145371, "ingredient1": "Osilodrostat", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Osilodrostat can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating osilodrostat therapy and periodically thereafter. Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145534/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145372, "ingredient1": "Osimertinib", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting osimertinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145535/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145373, "ingredient1": "Oxaliplatin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145536/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Cefixime, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, Sulfisoxazole, Povidone-iodine, Enoxacin, More", "updated_at": 1767369485}, {"id": 145374, "ingredient1": "Oxtriphylline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. This drug combination may increase the risk of seizures, especially in the elderly. Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels during concurrent fluoroquinolone therapy.", "source": "DDInter", "management_text": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels. Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145537/", "reference_text": "[1] Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J \"Effect of norfloxacin on theophyllin metabolism.\" Antimicrob Agents Chemother 33 (1989): 212-4[2] Grasela TH, Dreis MW \"An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system.\" Arch Intern Med 152 (1992): 617-21[3] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988): 109-14[4] Ho G, Tierney MG, Dales RE \"Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.\" Clin Pharmacol Ther 44 (1988): 35-8[5] Bowles SK, Popovski Z, Rybak MJ, Beckman HB, Edwards DJ \"Effect of norfloxacin on theophylline pharmacokinetics at steady state.\" Antimicrob Agents Chemother 32 (1988): 510-12[6] Gregoire SL, Grasela TH Jr, Freer JP, Tack KJ, Schentag JJ \"Inhibition of theophylline clearance by coadministered ofloxacin without alteraction of theophylline effects.\" Antimicrob Agents Chemother 31 (1987): 375-8[7] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[8] Sano M, Yamamoto I, Ueda J, Yoskikawa E, Yamashina H, Goto M \"Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration.\" Eur J Clin Pharmacol 32 (1987): 431-2[9] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[10] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987): 159-69[11] Raoof S, Wollschlager C, Khan FA \"Ciprofloxacin increases serum levels of theophylline.\" Am J Med 82 (1987): 115-8[12] Covelli HD, Knodel AR, Heppner BT \"Predisposing factors to apparent theophylline-induced seizures.\" Ann Allergy 54 (1985): 411-5[13] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[14] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[15] Green L, Clark J \"Fluoroquinolones and theophylline toxicity: norfloxacin.\" JAMA 262 (1989): 2383[16] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Levofloxacin, Gatifloxacin, Rifamycin, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 145375, "ingredient1": "Oxytocin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145538/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145376, "ingredient1": "Ozanimod", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.", "mechanism_text": "Synergism", "recommendation": "Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145539/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 145377, "ingredient1": "Paclitaxel (protein-bound)", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145540/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145378, "ingredient1": "Panobinostat", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Panobinostat can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided. Anti-emetic drugs with known QT prolonging risk such as dolasetron, granisetron, ondansetron, palonosetron, and tropisetron may be used with frequent ECG monitoring. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting panobinostat therapy and periodically during treatment as clinically indicated.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145541/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145379, "ingredient1": "Papaverine", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.", "source": "DDInter", "management_text": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145542/", "reference_text": "[1] Vrolix M, Piessens J, De Geest H \"Torsades de pointes after intracoronary papaverine.\" Eur Heart J 12 (1991): 273-6[2] Jain A, Jenkins MG \"Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine.\" Cathet Cardiovasc Diagn 18 (1989): 255-7[3] Goto M, Sato M, Kitzazawa H, et.al \"Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation.\" Intern Med 53 (2014): 1629-31[4] Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML \"Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine.\" J Am Coll Cardiol 15 (1990): 275-8[5] Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T \"Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve.\" Cathet Cardiovasc Diagn 19 (1990): 229-36[6] Nakayama M, Tanaka N, Sakoda K, et.al \"Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease.\" Circ J 79 (2015): 530-6[7] Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y \"QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine.\" Cardiology 84 (1994): 9-13[8] Nakayama M, Saito A, Kitazawa H, et.al \"Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T-U waves in four cases.\" Intern Med 51 (2012): 351-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 145380, "ingredient1": "Pasireotide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Pasireotide can cause bradycardia and QT prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting pasireotide therapy and periodically during treatment in accordance with the product labeling. Hypokalemia and hypomagnesemia must be corrected prior to pasireotide administration.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145543/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 145381, "ingredient1": "Pazopanib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145544/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145382, "ingredient1": "Pemetrexed", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145545/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Azithromycin, Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, Trifluridine, More", "updated_at": 1767369485}, {"id": 145383, "ingredient1": "Pentostatin", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145546/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145384, "ingredient1": "Perflutren", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145547/", "reference_text": "[1] \"Product Information. Definity (perflutren).\" Lantheus Medical Imaging Inc, North Billerica, MA.[2] \"Product Information. Optison (perflutren).\" Mallinckrodt Medical Inc, St. Louis, MO.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145385, "ingredient1": "Perphenazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145548/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145386, "ingredient1": "Phenolphthalein", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145549/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 145387, "ingredient1": "Phenylbutazone", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145550/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Lomefloxacin, More", "updated_at": 1767369485}, {"id": 145388, "ingredient1": "Pimavanserin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Pimavanserin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.", "mechanism_text": "Synergism", "recommendation": "Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145551/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 145389, "ingredient1": "Pimozide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Pimozide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with pimozide. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145552/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[3] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[6] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 145390, "ingredient1": "Piroxicam", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145553/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145391, "ingredient1": "Pitolisant", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Limited data suggest that pitolisant may produce mild to moderate QT interval prolongation (10 to 13 milliseconds) at doses 3 to 6 times the standard therapeutic dose. Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of pitolisant with other agents associated with QT interval prolongation should generally be avoided. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of pitolisant with other agents associated with QT interval prolongation should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145554/", "reference_text": "[1] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Inotersen, Tafamidis", "updated_at": 1767369485}, {"id": 145392, "ingredient1": "Plicamycin", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145555/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Ixabepilone, Valrubicin", "updated_at": 1767369485}, {"id": 145393, "ingredient1": "Polyethylene glycol (3350)", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145556/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145394, "ingredient1": "Porfimer sodium", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145557/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivityan update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Gatifloxacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145395, "ingredient1": "Posaconazole", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145558/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, More", "alternatives_b": "Micafungin, Caspofungin, Itraconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 145396, "ingredient1": "Pramlintide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145559/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 145397, "ingredient1": "Prednisolone", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.", "source": "DDInter", "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145560/", "reference_text": "[1] Khaliq Y, Zhanel GG \"Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature.\" Clin Infect Dis 36 (2003): 1404-1410[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH \"Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids.\" Arch Intern Med 163 (2003): 1801-7[4] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration \"Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm.\" ([7/8/2008]):[7] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, More", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine", "updated_at": 1767369485}, {"id": 145398, "ingredient1": "Prednisone", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.", "source": "DDInter", "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145561/", "reference_text": "[1] Khaliq Y, Zhanel GG \"Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature.\" Clin Infect Dis 36 (2003): 1404-1410[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH \"Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids.\" Arch Intern Med 163 (2003): 1801-7[4] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration \"Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm.\" ([7/8/2008]):[7] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 145399, "ingredient1": "Primaquine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145562/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 145400, "ingredient1": "Probenecid", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Probenecid has been shown to interfere with the urinary excretion of certain quinolone antibiotics, resulting in increased plasma quinolone concentrations in some cases. The clinical relevance of this interaction is unknown but may be greater for quinolones that undergo significant tubular secretion via the renal anion transporter system such as cinoxacin, ciprofloxacin, enoxacin, gemifloxacin, nalidixic acid, and norfloxacin.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145563/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] Weidekamm E, Portmann R, Suter K, et al \"Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.\" Antimicrob Agents Chemother 31 (1987): 1909-14[3] Shimada J, Yamaji T, Ueda Y, Uchida H, Kusajma H, Irikura T \"Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.\" Antimicrob Agents Chemother 23 (1983): 1-7[4] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.\" J Antimicrob Chemother 21 (1988): 67-77[5] Rodriguez N, Madsen PO, Welling PG \"Influence of probenecid on serum levels and urinary excretion of cinoxacin.\" Antimicrob Agents Chemother 15 (1979): 465-9[6] Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W \"Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.\" Clin Pharmacol Ther 58 (1995): 532-41[7] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[8] Stass H, Sachse R \"Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.\" Clin Pharmacokinet 40 Suppl 1 (2001): 71-6[9] Shimada J, Nogita T, Ishibashi Y \"Clinical pharmacokinetics of sparfloxacin.\" Clin Pharmacokinet 25 (1993): 358-69[10] Dash H, Mills J \"Letter: Severe metabolic acidosis associated with nalidixic acid overdose.\" Ann Intern Med 84 (1976): 570-1[11] Nataraj B, Mamidi NVSR, Krishna DR \"Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers.\" Clin Drug Invest 16 (1998): 259-62[12] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[13] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[14] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[15] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[16] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[17] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[18] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[19] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[20] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[21] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[22] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[23] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[24] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[25] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[26] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[27] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[28] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[29] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[30] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "Tinidazole, Tetracycline, Metronidazole, Secnidazole, Azithromycin, Amikacin, Rifamycin, Kanamycin, Azithromycin, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145401, "ingredient1": "Probucol", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145564/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Lovastatin, Cholestyramine, Clofibrate, Cerivastatin, More", "updated_at": 1767369485}, {"id": 145402, "ingredient1": "Procainamide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.", "source": "DDInter", "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.", "mechanism_text": "Synergism", "recommendation": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145565/", "reference_text": "[1] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[2] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[3] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[4] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB \"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.\" Clin Infect Dis 34 (2002): 861-3[5] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[6] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[7] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[8] Ansari SR, Chopra N \"Gatifloxacin and Prolonged QT Interval.\" Am J Med Sci 327 (2004): 55-6[9] Siepmann M, Kirch W \"Drug points - Tachycardia associated with moxifloxacin.\" Br Med J 322 (2001): 23[10] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] \"Product Information. Maxaquin (lomefloxacin).\" Searle, Skokie, IL.[12] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[13] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[14] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C \"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.\" Clin Pharmacol Ther 68 (2000): 658-66[15] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[16] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[17] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[18] Dale KM, Lertsburapa K, Kluger J, White CM \"Moxifloxacin and torsade de pointes.\" Ann Pharmacother 41 (2007): 336-40[19] Iannini PB, Circiumaru I \"Gatifloxacin-induced QTc prolongation and ventricular tachycardia.\" Pharmacotherapy 21 (2001): 361-2[20] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[21] White CM, Grant EM, Quintiliani R \"Moxifloxacin does increase the corrected QT interval.\" Clin Infect Dis 33 (2001): 1441-2[22] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P \"Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers.\" Br J Clin Pharmacol 41 (1996): 499-503[23] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[24] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[25] Jaillon P, Morganroth J, Brumpt I, Talbot G \"Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.\" J Antimicrob Chemother 37(suppl a) (1996): 161-7[26] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[27] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[28] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[29] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[30] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[31] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[32] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[33] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF \"Effects of three fluoroquinolones on QT analysis after standard treatment courses.\" Ann Noninvasive Electrocardiol 11 (2006): 52-6[34] Lipsky BA, Dorr MB, Magner DJ, Talbot GH \"Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.\" Clin Ther 21 (1999): 148-59[35] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[36] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[37] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B \"Torsades de pointe probably related to sparfloxacin.\" Eur J Clin Microbiol Infect Dis 15 (1996): 350-1[38] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[39] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[40] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[41] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145403, "ingredient1": "Procarbazine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145566/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145404, "ingredient1": "Promazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145567/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145405, "ingredient1": "Propafenone", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145568/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Lidocaine, Moricizine, Bretylium, Tocainide", "updated_at": 1767369485}, {"id": 145406, "ingredient1": "Protriptyline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145569/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145407, "ingredient1": "Quetiapine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "There is some concern that quetiapine may have additive cardiovascular effects in combination with other drugs that are known to prolong the QT interval of the electrocardiogram.", "source": "DDInter", "management_text": "Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, if combination therapy with agents with anticholinergic properties is required, caution is advised, particularly in the elderly and those with underlying organic brain disease.", "mechanism_text": "Synergism", "recommendation": "Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145570/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[2] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Vieweg WV \"New generation antipsychotic drugs and QTc interval prolongation.\" Prim Care Companion J Clin Psychiatry 5 (2003): 205-15[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Vieweg WV, Schneider RK, Wood MA \"Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.\" Acta Psychiatr Scand 112 (2005): 318-22[9] Sala M, Vicentini A, Brambilla P, et al. \"QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.\" Ann Gen Psychiatry 4 (2005): 1[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 145408, "ingredient1": "Quinine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145571/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "updated_at": 1767369485}, {"id": 145409, "ingredient1": "Ramelteon", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations and pharmacologic effects of ramelteon, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when ramelteon is used with CYP450 1A2 inhibitors. A reduction in the ramelteon dosage may be necessary in patients who experience excessive sedation or other adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ramelteon is used with CYP450 1A2 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145572/", "reference_text": "[1] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Ofloxacin, More", "updated_at": 1767369485}, {"id": 145410, "ingredient1": "Ranolazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Ranolazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of ranolazine, the maximum recommended dosage of 1000 mg twice daily should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Ranolazine is contraindicated in patients with liver cirrhosis because of the profound effect on QT prolongation in this population.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145573/", "reference_text": "[1] European Medicines Agency \"CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine. Procedure No. EMEA/H/C/805. Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/latixa/H-805-en6.pdf.\" ([cited 2008]):[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[3] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Regadenoson, Alprostadil, Ubidecarenone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145411, "ingredient1": "Rasagiline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of rasagiline, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "In patients receiving CYP450 1A2 inhibitors, it may be appropriate to initiate therapy at 0.5 mg/day, then increase gradually as needed and as tolerated. Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, confusion, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.", "mechanism_text": "Metabolism", "recommendation": "In patients receiving CYP450 1A2 inhibitors, it may be appropriate to initiate therapy at 0.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145574/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[4] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[5] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[6] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[8] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[9] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[10] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[11] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[12] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[13] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[14] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More", "alternatives_b": "Opicapone, Cabergoline, Amantadine, Tolcapone, Selegiline, Entacapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 145412, "ingredient1": "Relugolix", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145575/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, Letrozole, More", "updated_at": 1767369485}, {"id": 145413, "ingredient1": "Ribociclib", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of ribociclib with other drugs that can prolong the QT interval should generally be avoided. However, if concomitant use is required, caution and clinical and laboratory monitoring are recommended. ECGs should be assessed prior to initiation of treatment, during treatment when clinically necessary, and more frequently if QTcF prolongation occurs at any time during treatment. Ribociclib should be permanently discontinued if the QTcF interval prolongation is either greater than 500 msec or there is a greater than 60 msec change from baseline and associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ribociclib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145576/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[8] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Harper KM, Knapp DJ, Criswell HE, Breese GR \"Vasopressin and alcohol: A multifaceted relationship.\" Psychopharmacology (Berl) 235 (2018): 3363-79[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Collins GB, Brosnihan KB, Zuti RA, Messina M, Gupta MK \"Neuroendocrine, fluid balance, and thirst responses to alcohol in alcoholics.\" Alcohol Clin Exp Res 16 (1992): 228-32[12] Hirschl MM, Derfler K, Bieglmayer C, et.al \"Hormonal derangements in patients with severe alcohol intoxication.\" Alcohol Clin Exp Res 18 (1994): 761-6[13] \"Product Information. Vasostrict (vasopressin).\" Par Pharmaceutical Inc, Chestnut Ridge, NY.[14] Taivainen H, Laitinen K, Tahtela R, Kilanmaa K, Valimaki MJ \"Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication.\" Alcohol Clin Exp Res 19 (1995): 759-62[15] Cerner Multum, Inc. \"Australian Product Information.\" O 0[16] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145414, "ingredient1": "Ritodrine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145577/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145415, "ingredient1": "Rivastigmine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145578/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Memantine, Aducanumab", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145416, "ingredient1": "Rofecoxib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145579/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Tinidazole, Cefixime, Cefepime, Secnidazole, Ganciclovir, Rifamycin, Oxytetracycline, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 145417, "ingredient1": "Romidepsin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145580/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145418, "ingredient1": "Rosiglitazone", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145581/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 145419, "ingredient1": "Rucaparib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145582/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145420, "ingredient1": "Salmeterol", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145583/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145421, "ingredient1": "Salsalate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145584/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More", "alternatives_b": "Ziconotide, Methoxyflurane", "updated_at": 1767369485}, {"id": 145422, "ingredient1": "Saxagliptin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145585/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 145423, "ingredient1": "Selpercatinib", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating selpercatinib therapy and periodically during treatment as appropriate based on individual risk factors including diarrhea. Correct hypokalemia, hypomagnesemia, and/or hypocalcemia before starting treatment and during treatment, as they may be risk factors for ventricular arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145586/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145424, "ingredient1": "Sertraline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145587/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "updated_at": 1767369485}, {"id": 145425, "ingredient1": "Sevoflurane", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Sevoflurane may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval. The patient's cardiovascular status and serum electrolytes should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145588/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, More", "updated_at": 1767369485}, {"id": 145426, "ingredient1": "Siponimod", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.", "mechanism_text": "Synergism", "recommendation": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145589/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 145427, "ingredient1": "Sitagliptin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145590/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 145428, "ingredient1": "Salicylic acid (sodium)", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145591/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Lomefloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145429, "ingredient1": "Solifenacin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145592/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 145430, "ingredient1": "Sorafenib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Sorafenib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting sorafenib therapy and periodically during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145593/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "alternatives_b": "Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145431, "ingredient1": "Sotalol", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.", "source": "DDInter", "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.", "mechanism_text": "Synergism", "recommendation": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145594/", "reference_text": "[1] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[2] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[3] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[4] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB \"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.\" Clin Infect Dis 34 (2002): 861-3[5] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[6] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[7] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[8] Ansari SR, Chopra N \"Gatifloxacin and Prolonged QT Interval.\" Am J Med Sci 327 (2004): 55-6[9] Siepmann M, Kirch W \"Drug points - Tachycardia associated with moxifloxacin.\" Br Med J 322 (2001): 23[10] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] \"Product Information. Maxaquin (lomefloxacin).\" Searle, Skokie, IL.[12] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[13] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[14] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C \"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.\" Clin Pharmacol Ther 68 (2000): 658-66[15] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[16] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[17] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[18] Dale KM, Lertsburapa K, Kluger J, White CM \"Moxifloxacin and torsade de pointes.\" Ann Pharmacother 41 (2007): 336-40[19] Iannini PB, Circiumaru I \"Gatifloxacin-induced QTc prolongation and ventricular tachycardia.\" Pharmacotherapy 21 (2001): 361-2[20] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[21] White CM, Grant EM, Quintiliani R \"Moxifloxacin does increase the corrected QT interval.\" Clin Infect Dis 33 (2001): 1441-2[22] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P \"Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers.\" Br J Clin Pharmacol 41 (1996): 499-503[23] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[24] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[25] Jaillon P, Morganroth J, Brumpt I, Talbot G \"Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.\" J Antimicrob Chemother 37(suppl a) (1996): 161-7[26] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[27] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[28] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[29] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[30] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[31] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[32] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[33] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF \"Effects of three fluoroquinolones on QT analysis after standard treatment courses.\" Ann Noninvasive Electrocardiol 11 (2006): 52-6[34] Lipsky BA, Dorr MB, Magner DJ, Talbot GH \"Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.\" Clin Ther 21 (1999): 148-59[35] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[36] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[37] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B \"Torsades de pointe probably related to sparfloxacin.\" Eur J Clin Microbiol Infect Dis 15 (1996): 350-1[38] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[39] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[40] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[41] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Nadolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, Pindolol, Timolol, Nadolol, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "updated_at": 1767369485}, {"id": 145432, "ingredient1": "Stiripentol", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2, 2C19, and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.", "source": "DDInter", "management_text": "Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behaviour, neutropenia, and thrombocytopenia. Dosage adjustments for stiripentol or alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145595/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Ofloxacin, Gatifloxacin, More", "alternatives_b": "Brivaracetam, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 145433, "ingredient1": "Streptozocin", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145596/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145434, "ingredient1": "Sucralfate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145597/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin, Lansoprazole", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Famciclovir, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 145435, "ingredient1": "Sulindac", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145598/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, Rifamycin, More", "updated_at": 1767369485}, {"id": 145436, "ingredient1": "Sunitinib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145599/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145437, "ingredient1": "Tacrine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145600/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Memantine, Aducanumab", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145438, "ingredient1": "Tacrolimus", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145601/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Cromoglicic acid, Abrocitinib, Dupilumab, Tralokinumab, More", "alternatives_b": "Cefixime, Secnidazole, Rifamycin, Oxytetracycline, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine, Enoxacin, Trovafloxacin, More", "updated_at": 1767369485}, {"id": 145439, "ingredient1": "Tasimelteon", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145602/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Ofloxacin, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "updated_at": 1767369485}, {"id": 145440, "ingredient1": "Telavancin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145603/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Cefixime, Tetracycline, Secnidazole, Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Vancomycin, Trifluridine, More", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145441, "ingredient1": "Telithromycin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145604/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Dirithromycin, Lincomycin, Troleandomycin, Clindamycin", "alternatives_b": "Tinidazole, Cefepime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, More", "updated_at": 1767369485}, {"id": 145442, "ingredient1": "Temozolomide", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145605/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145443, "ingredient1": "Teniposide", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145606/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tetracycline, Fluconazole, Cefepime, Cefuroxime, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, More", "updated_at": 1767369485}, {"id": 145444, "ingredient1": "Terbutaline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145607/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145445, "ingredient1": "Terfenadine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145608/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145446, "ingredient1": "Tetrabenazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Tetrabenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145609/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Xenazine (tetrabenazine).\" Prestwick Pharmaceuticals Inc, Washington DC, VA.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[11] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Inotersen, Tafamidis", "updated_at": 1767369485}, {"id": 145447, "ingredient1": "Thalidomide", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible. Thalidomide can cause bradycardia and may potentiate the risk of torsade de pointes arrhythmia associated with the use of drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage. Symptoms may improve or return to baseline in some patients upon discontinuation of thalidomide, although the complete time course of this toxicity has not been fully characterized. Because bradycardia is a risk factor for torsade de pointes arrhythmia, caution is advised when thalidomide is used with drugs that can prolong the QT interval or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if thalidomide is used in combination with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145610/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Tetracycline, Cefixime, Amikacin, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, More", "updated_at": 1767369485}, {"id": 145448, "ingredient1": "Tioguanine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145611/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145449, "ingredient1": "Thioridazine", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Thioridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with thioridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145612/", "reference_text": "[1] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Liberatore MA, Robinson DS \"Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?\" J Clin Psychopharmacol 4 (1984): 143-6[4] Fletcher GF, Kazamias TM \"Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias.\" Am Heart J 78 (1969): 135-8[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[8] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[9] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL \"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.\" Clin Pharmacol Ther 60 (1996): 543-53[10] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[15] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[16] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[17] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[18] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[19] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[20] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[21] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[22] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[23] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[24] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[25] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[26] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145450, "ingredient1": "Thiotepa", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145613/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145451, "ingredient1": "Tizanidine", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 1A2 may significantly increase the plasma concentrations and pharmacologic effects of tizanidine, which is a sensitive substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of tizanidine with CYP450 1A2 inhibitors should generally be avoided. Otherwise, caution is advised if coadministration is required. Dosage adjustments may be necessary in patients who experience excessive adverse effects of tizanidine such as drowsiness, dizziness, lightheadedness, hypotension, and bradycardia.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tizanidine with CYP450 1A2 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145614/", "reference_text": "[1] Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ \"Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction.\" Clin Pharmacol Ther 75 (2004): 331-41[2] \"Product Information. Vioxx (rofecoxib).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.[4] Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ \"Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.\" Clin Pharmacol Ther 76 (2004): 598-606[5] Momo K, Doki K, Hosono H, Homma M, Kohda Y \"Drug interaction of tizanidine and fluvoxamine.\" Clin Pharmacol Ther 76 (2004): 509-10[6] Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa T, Tamaoka A \"Drug interaction of tizanidine and ciprofloxacin: Case report.\" Clin Pharmacol Ther 80 (2006): 717-9[7] Granfors MT, Backman JT, Laitila J, Neuvonen PJ \"Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro.\" Br J Clin Pharmacol 57 (2004): 349-53[8] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145452, "ingredient1": "Tolazamide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145615/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 145453, "ingredient1": "Tolbutamide", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145616/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[2] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[3] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[4] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[5] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[6] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[7] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[8] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[9] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[10] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[11] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[12] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[14] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[15] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[16] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[17] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[18] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[19] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[20] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[21] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[23] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[24] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[25] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[26] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[27] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[28] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[29] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[30] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[31] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[32] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[33] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[35] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[36] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[37] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[38] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[39] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[40] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Vitamin A, Metyrapone, Edrophonium, Histamine, More", "updated_at": 1767369485}, {"id": 145454, "ingredient1": "Tolmetin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145617/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145455, "ingredient1": "Topotecan", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145618/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145456, "ingredient1": "Toremifene", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Toremifene has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided. If treatment with other QT-prolonging drugs is required, interruption of toremifene therapy should be considered. Caution and clinical monitoring are recommended if concomitant use is unavoidable. In patients at increased risk, electrocardiograms (ECGs) are recommended at baseline and as clinically indicated. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145619/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[10] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145457, "ingredient1": "Torasemide", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145620/", "reference_text": "[1] Sudoh T, Fujimura A, Shiga T, Sasaki M, Harada K, Tateishi T, Ohashi K, Ebihara A \"Renal clearance of lomefloxacin is decreased by furosemide.\" Eur J Clin Pharmacol 46 (1994): 267-9", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More", "alternatives_b": "Tinidazole, Levofloxacin, Secnidazole, Azithromycin, Ganciclovir, Rifamycin, Polymyxin B, Famciclovir, Trifluridine, Benzylpenicillin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145458, "ingredient1": "Tretinoin", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145621/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, More", "updated_at": 1767369485}, {"id": 145459, "ingredient1": "Triclabendazole", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145622/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Praziquantel, Oxamniquine", "updated_at": 1767369485}, {"id": 145460, "ingredient1": "Trifluoperazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145623/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145461, "ingredient1": "Triflupromazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145624/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "updated_at": 1767369485}, {"id": 145462, "ingredient1": "Alimemazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145625/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "updated_at": 1767369485}, {"id": 145463, "ingredient1": "Trimipramine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145626/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "updated_at": 1767369485}, {"id": 145464, "ingredient1": "Troglitazone", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145627/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145465, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145628/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Fluconazole, Ganciclovir, Acyclovir, Famciclovir, Chlorhexidine, Povidone-iodine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145466, "ingredient1": "Uracil mustard", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145629/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145467, "ingredient1": "Valbenazine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Valbenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking valbenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required. Valbenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. In patients with other risk factors for QT prolongation, the QT interval should be assessed before increasing the dose of valbenazine. The manufacturer recommends that valbenazine dosage be reduced to 40 mg once daily in patients on concomitant therapy with a strong CYP450 3A4 inhibitor (e.g., itraconazole, ketoconazole, clarithromycin). Valbenazine dose reduction should also be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), or in patients who are poor metabolizers of CYP450 2D6.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145630/", "reference_text": "[1] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[2] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Inotersen, Tafamidis", "updated_at": 1767369485}, {"id": 145468, "ingredient1": "Valdecoxib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145631/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Tinidazole, Cefixime, Cefepime, Secnidazole, Ganciclovir, Rifamycin, Oxytetracycline, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 145469, "ingredient1": "Vandetanib", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Vandetanib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.", "mechanism_text": "Synergism", "recommendation": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145632/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vandetanib (vandetanib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 145470, "ingredient1": "Vasopressin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145633/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145471, "ingredient1": "Vemurafenib", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Vemurafenib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting vemurafenib therapy and after dose modification.", "mechanism_text": "Synergism", "recommendation": "Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145634/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More", "updated_at": 1767369485}, {"id": 145472, "ingredient1": "Venlafaxine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145635/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Amikacin, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 145473, "ingredient1": "Verteporfin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145636/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Visudyne (verteporfin)\" Valeant Pharmaceuticals, Costa Mesa, CA.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Aflibercept, Bevacizumab", "alternatives_b": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 145474, "ingredient1": "Vinblastine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145637/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tetracycline, Cefepime, Cefuroxime, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145475, "ingredient1": "Vincristine (liposome)", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145638/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tetracycline, Cefepime, Cefuroxime, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, More", "updated_at": 1767369485}, {"id": 145476, "ingredient1": "Vinorelbine", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145639/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Tetracycline, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Famciclovir, More", "updated_at": 1767369485}, {"id": 145477, "ingredient1": "Voriconazole", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145640/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Micafungin, Caspofungin, Itraconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Tinidazole, Cefixime, Tetracycline, Secnidazole, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Famciclovir, More", "updated_at": 1767369485}, {"id": 145478, "ingredient1": "Zinc chloride", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145641/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Gatifloxacin, Rifamycin, More", "alternatives_b": "Lidocaine, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Calcium chloride, Sodium acetate, Arginine, Sodium glycerophosphate, More", "updated_at": 1767369485}, {"id": 145479, "ingredient1": "Zinc gluconate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145642/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Lidocaine, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Sodium chloride", "updated_at": 1767369485}, {"id": 145480, "ingredient1": "Ziprasidone", "ingredient2": "Norfloxacin", "severity": "Major", "effect": "Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145643/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 145481, "ingredient1": "Zolmitriptan", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of zolmitriptan, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "It is recommended that not more than 5 mg of zolmitriptan be taken in a 24-hour period during concomitant use with CYP450 1A2 inhibitors. Patients should be advised to notify their doctor promptly if they experience increased sedation, dizziness, paraesthesia, chest pain or tightness, shortness of breath, and/or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "It is recommended that not more than 5 mg of zolmitriptan be taken in a 24-hour period during concomitant use with CYP450 1A2 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145644/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, More", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Rifamycin, More", "updated_at": 1767369485}, {"id": 145482, "ingredient1": "Oxitriptan", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145645/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Esketamine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145483, "ingredient1": "Abarelix", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145646/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "updated_at": 1767369485}, {"id": 145484, "ingredient1": "Acetohexamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Case reports suggest that tricyclic antidepressants may increase the hypoglycemic effects of sulfonylureas.", "source": "DDInter", "management_text": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Synergism", "recommendation": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145647/", "reference_text": "[1] Zogno MG, Tolfo L, Draghi E \"Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics.\" Ann Pharmacother 28 (1994): 406[2] Pond SM, Graham GG, Birkett DJ, Wade DN \"Effects of tricyclic antidepressants on drug metabolism.\" Clin Pharmacol Ther 18 (1975): 191-9[3] True BL, Perry PJ, Burns EA \"Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy.\" Am J Psychiatry 144 (1987): 1220-1[4] Sherman KE, Bornemann M \"Amitriptyline and asymptomatic hypoglycemia.\" Ann Intern Med 109 (1988): 683-4[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "alternatives_b": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "updated_at": 1767369485}, {"id": 145485, "ingredient1": "Ammonium chloride", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "Ammonium chloride may increase urinary excretion of tricyclic antidepressants by acidifying the urine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145648/", "reference_text": "[1] Gram LF, Kofod B, Christiansen J, Rafaelsen OJ \"Imipramine metabolism: pH-dependent distribution and urinary excretion.\" Clin Pharmacol Ther 12 (1971): 239-44", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide, Calcium chloride, Zinc sulfate, More", "updated_at": 1767369485}, {"id": 145486, "ingredient1": "Amoxapine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145649/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amoxapine, Viloxazine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145487, "ingredient1": "Amyl Nitrite", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145650/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 145488, "ingredient1": "Anisindione", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Some reports suggest that tricyclic antidepressants may increase or decrease the anticoagulant effect of warfarin by an unknown mechanism. Similar effects may occur with other oral anticoagulants.", "source": "DDInter", "management_text": "Until more information is available, it may be advisable to monitor the International Normalized Ratio (INR) or prothrombin time and clinical response if these agents are administered concomitantly. Patients should be advised to promptly report possible signs of bleeding (e.g., pain, swelling, headache, dizziness, weakness, nosebleeds, bleeding of gums from brushing, unusual bruising, red or brown urine, or red or black stools) or clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).", "mechanism_text": "Synergism", "recommendation": "Until more information is available, it may be advisable to monitor the International Normalized Ratio (INR) or prothrombin time and clinical response if these agents are administered concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145651/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971): 487-98[2] Vesell ES, Passananti GT, Greene FE \"Impairment of drug metabolism in man by allopurinol and nortriptyline.\" N Engl J Med 283 (1970): 1484-8[3] Pond SM, Graham GG, Birkett DJ, Wade DN \"Effects of tricyclic antidepressants on drug metabolism.\" Clin Pharmacol Ther 18 (1975): 191-9[4] Williams JR, Griffin JP, Parkins A \"Effect of concomitantly administered drugs on the control of long term anticoagulant therapy.\" Q J Med 45 (1976): 63-73[5] Koch-Weser J \"Hemorrhagic reactions and drug interactions in 500 warfarin-treated patients.\" Clin Pharmacol Ther 14 (1973): 139[6] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[7] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[8] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[9] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[10] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[11] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[12] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[13] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[14] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[15] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[16] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[17] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[18] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[19] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[20] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[21] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[22] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[23] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[24] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[25] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[26] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[27] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[28] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[29] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[30] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[31] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[32] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[33] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[34] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[35] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[36] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[37] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[38] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[39] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[40] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[41] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[42] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Phenelzine, Tranylcypromine, Maprotiline, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145489, "ingredient1": "Nortriptyline", "ingredient2": "Arbutamine", "severity": "Major", "effect": "Anticholinergic effects, tachycardia and conduction abnormalities associated with tricyclic antidepressant therapy may increase the risk for cardiotoxicity in patients receiving arbutamine for diagnostic purposes.", "source": "DDInter", "management_text": "Arbutamine should not be administered to patients also receiving tricyclic antidepressants.", "mechanism_text": "Synergism", "recommendation": "Arbutamine should not be administered to patients also receiving tricyclic antidepressants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145652/", "reference_text": "[1] \"Product Information. GenESA (arbutamine).\" Gensia Inc, San Diego, CA.", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "updated_at": 1767369485}, {"id": 145490, "ingredient1": "Nortriptyline", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145653/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145491, "ingredient1": "Azatadine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145654/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145492, "ingredient1": "Bedaquiline", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145655/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Phenelzine, Tranylcypromine, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "updated_at": 1767369485}, {"id": 145493, "ingredient1": "Belladonna", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145656/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145494, "ingredient1": "Bepridil", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Possible QT interval prolongation associated with tricyclic antidepressant drugs and bepridil may be additive. The combination of tricyclic antidepressants and bepridil may result in serious arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.", "source": "DDInter", "management_text": "The manufacturer considers the concurrent use of other QT interval-prolonging drugs contraindicated with bepridil.", "mechanism_text": "Synergism", "recommendation": "The manufacturer considers the concurrent use of other QT interval-prolonging drugs contraindicated with bepridil.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145657/", "reference_text": "[1] Hollingshead LM, Faulds D, Fitton A \"Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.\" Drugs 44 (1992): 835-57[2] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[18] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[19] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[22] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[29] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[30] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[31] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[32] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[34] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Duloxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Paroxetine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145495, "ingredient1": "Berotralstat", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145658/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.", "alternatives_a": "Phenelzine, Tranylcypromine, Sertraline, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 145496, "ingredient1": "Butabarbital", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.", "source": "DDInter", "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.", "mechanism_text": "Antagonism", "recommendation": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145659/", "reference_text": "[1] Garey KW, Amsden GW, Johns CA \"Possible interaction between imipramine and butalbital.\" Pharmacotherapy 17 (1997): 1041-2[2] Burrows GD, Davies B \"Antidepressants and barbiturates.\" Br Med J 4 (1971): 113[3] Silverman G, Braithwaite R \"Interaction of benzodiazepines with tricyclic antidepressants.\" Br Med J 4 (1972): 111[4] Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E \"Phenobarbital induces the 2-hydroxylation of desipramine.\" Ther Drug Monit 18 (1996): 60-4[5] Crocker J, Morton B \"Tricyclic (antidepressant) drug toxicity.\" Clin Toxicol 2 (1969): 397-402", "alternatives_a": "Nitrazepam", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 145497, "ingredient1": "Pentoxyverine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145660/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 145498, "ingredient1": "Carteolol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145661/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, Pindolol", "alternatives_b": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145499, "ingredient1": "Activated charcoal", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects or of the toxicity of many drugs. Activated charcoal may adsorb any therapeutic agents administered while it is in the gastrointestinal tract.", "source": "DDInter", "management_text": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications. If concomitant use is necessary, the dosage or route of administration may need to be altered.", "mechanism_text": "Absorption", "recommendation": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145662/", "reference_text": "[1] Naveau S, Bonhomme L, Preaux N, Chaput JC \"A pure charcoal suspension for colonoscopic tattoo.\" Gastrointest Endosc 37 (1991): 624-5[2] Ilkhanipour K, Yealy DM, Krenzelok EP \"Activated charcoal surface area and its role in multiple-dose charcoal therapy.\" Am J Emerg Med 11 (1993): 583-5[3] Reed MD \"Oral activated charcoal therapy.\" Am J Emerg Med 6 (1988): 318[4] Neuvonen PJ \"Clinical pharmacokinetics of oral activated charcoal in acute intoxications.\" Clin Pharmacokinet 7 (1982): 465-89[5] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] Kivisto KT, Neuvonen PJ \"The effect of cholestyramine and activated charcoal on glipizide absorption.\" Br J Clin Pharmacol 30 (1990): 733-6[7] Glab WN, Corby DG, Decker WJ, Coldiron VR \"Decreased absorption of propoxyphene by activated charcoal.\" J Toxicol Clin Toxicol 19 (1982): 129-38[8] Watson WA \"Factors influencing the clinical efficacy of activated charcoal.\" Drug Intell Clin Pharm 21 (1987): 160-6[9] Howard CE, Roberts RS, Ely DS, Moye RA \"Use of multiple-dose activated charcoal in phenytoin toxicity.\" Ann Pharmacother 28 (1994): 201-3[10] Herrington AM, Clifton GD \"Toxicology and management of acute drug ingestions in adults.\" Pharmacotherapy 15 (1995): 182-200[11] Scheufler E, Bos I \"Influence of peroral charcoal on pharmacokinetics and intestinal toxicity of intravenously given methotrexate.\" Arch Int Pharmacodyn Ther 261 (1983): 180-5[12] Gadgil SD, Damle SR, Advani SH, Vaidya AB \"Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate.\" Cancer Treat Rep 66 (1982): 1169-71[13] Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A \"Apomorphine test in de novo Parkinson's disease.\" Funct Neurol 7 (1992): 295-8[14] Park GD, Spector R, Goldberg MJ, Johnson GF \"Expanded role of charcoal therapy in the poisoned and overdosed patient.\" Arch Intern Med 146 (1986): 969-73[15] Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A \"Absorption studies of the H2-blocker nizatidine.\" Clin Pharmacol Ther 42 (1987): 514-20[16] Dolgin JG, Nix DE, Sanchez J, Watson WA \"Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning: report of two pediatric cases.\" DICP 25 (1991): 646-9[17] Wakabayashi Y, Maruyama S, Hachimura K, Ohwada T \"Activated charcoal interrupts enteroenteric circulation of phenobarbital.\" J Toxicol Clin Toxicol 32 (1994): 419-24[18] Decker WJ, Shpall RA, Corby DG \"Inhibition of aspirin absorption by activated charcoal and apomorphine.\" Clin Pharmacol Ther 10 (1969): 710-3[19] Chernish SM, Wolen RL, Rodda BE \"Adsorption of propoxyphene hydrochloride by activated charcoal.\" Clin Toxicol 5 (1972): 317-29[20] Orisakwe OE \"Activated charcoal: is failure to use it negligence or ignorance?\" South Med J 87 (1994): 165-8[21] Wing LM, Miners JO, Birkett DJ, et al \"Lidocaine disposition: sex differences and effects of cimetidine.\" Clin Pharmacol Ther 35 (1984): 695-701[22] Saetta JP \"Gastric decontaminating procedures: is it time to call a stop?\" J R Soc Med 86 (1993): 396-9[23] Rowden AM, Spoor JE, Bertino JS, Jr \"The effect of activated charcoal on phenytoin pharmacokinetics.\" Ann Emerg Med 19 (1990): 1144-7[24] Farrar HC, Herold DA, Reed MD \"Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal.\" Crit Care Med 21 (1993): 299-301[25] Karkkainen S, Neuvonen PJ \"Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 219-25", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Pectin, Kaolin, Attapulgite", "updated_at": 1767369485}, {"id": 145500, "ingredient1": "Clofedanol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145663/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 145501, "ingredient1": "Chloral hydrate", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145664/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145502, "ingredient1": "Chlorcyclizine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145665/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Duloxetine, Vilazodone, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, More", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145503, "ingredient1": "Chlormezanone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145666/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Doxepin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145504, "ingredient1": "Chlorphenesin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145667/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole", "updated_at": 1767369485}, {"id": 145505, "ingredient1": "Chlorpromazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145668/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145506, "ingredient1": "Cisapride", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145669/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[4] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999): 251[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[7] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[8] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[9] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG \"Red wine-cisapride interaction: Comparison with grapefruit juice.\" Clin Pharmacol Ther 70 (2001): 17-23[10] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[11] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[12] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ \"Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.\" Clin Pharmacol Ther 66 (1999): 448-53[13] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[14] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[15] Gross AS, Goh YD, Addison RS, Shenfield GM \"Influence of grapefruit juice on cisapride pharmacokinetics.\" Clin Pharmacol Ther 65 (1999): 395-401[16] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145507, "ingredient1": "Clidinium", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145670/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145508, "ingredient1": "Conjugated estrogens (topical)", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145671/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 145509, "ingredient1": "Cyclizine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145672/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145510, "ingredient1": "Cyproheptadine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145673/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Bupropion, Viloxazine", "updated_at": 1767369485}, {"id": 145511, "ingredient1": "Demecarium (ophthalmic)", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145674/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145512, "ingredient1": "Deserpidine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145675/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Trimipramine, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145513, "ingredient1": "Dexbrompheniramine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145676/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 145514, "ingredient1": "Dexfenfluramine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145677/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine, Esketamine", "alternatives_b": "Naltrexone", "updated_at": 1767369485}, {"id": 145515, "ingredient1": "Dextrothyroxine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of thyroid hormone replacement therapy with tricyclic antidepressants may accelerate the onset or potentiate the action of tricyclic antidepressants, increasing the risk of cardiac arrhythmias and CNS stimulation. The proposed mechanism may be an increased receptor sensitivity to catecholamines. Some clinicians have used this interaction therapeutically.", "source": "DDInter", "management_text": "Patients receiving concomitant thyroid hormone replacement therapy and tricyclic antidepressant therapy should be closely monitored for cardiac arrhythmias and CNS stimulation. Advise patients to contact their doctor if they experience toxicity symptoms such as: anxiety, agitation, insomnia, shortness of breath, irregular or fast heartbeat, and lightheadedness or dizziness.", "mechanism_text": "Synergism", "recommendation": "Patients receiving concomitant thyroid hormone replacement therapy and tricyclic antidepressant therapy should be closely monitored for cardiac arrhythmias and CNS stimulation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145678/", "reference_text": "[1] \"Product Information. Triostat (liothyronine).\" JHP Pharmaceuticals, Saddle River, NJ.[2] Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA \"Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.\" Am J Psychiatry 139 (1982): 34-8[3] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[4] Prange AJ, Wilson IC, Rabon AM, Lipton MA \"Enhancement of imipramine antidepressant activity by thyroid hormone.\" Am J Psychiatry 126 (1969): 457-69[5] \"Product Information. Anafranil (clomipramine).\" Basel Pharmaceuticals, Summit, NJ.[6] Extein IL, Gold MS \"Thyroid hormone potentiation of tricyclics.\" Psychosomatics 29 (1988): 166-74[7] Cooke RG, Joffe RT, Levitt AJ \"T3 augmentation of antidepressant treatment in T4-replaced thyroid patients.\" J Clin Psychiatry 53 (1992): 16-8[8] \"Product Information. Elavil (amitriptyline).\" Stuart Pharmaceuticals, Wilmington, DE.[9] Posternak M, Novak S, Stern R, et al. \"A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response.\" Int J Neuropsychopharmacol 11 (2008): 15-25[10] Joffe RT, Singer W, Levitt AJ, MacDonald C \"A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.\" Arch Gen Psychiatry 50 (1993): 387-93[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] Altshuler LL, Bauer M, Frye MA, et al. \"Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature.\" Am J Psychiatry 158 (2001): 1617-22[13] Wheatley D \"Potentiation of amitriptyline by thyroid hormone.\" Arch Gen Psychiatry 26 (1972): 229-33[14] Schwarcz G, Halaris A, Baxter L, Escobar J, Thompson M, Young M \"Normal thyroid function in desipramine nonresponders converted to responders by the addition of L-triiodothyronine.\" Am J Psychiatry 141 (1984): 1614-6[15] Joffe RT \"The use of thyroid supplements to augment antidepressant medication.\" J Clin Psychiatry 59 Suppl 5 (1998): 26-9; discussion 30-1[16] Wilson IC, Prange AJ, McClane TK, Rabon AM, Lipton MA \"Thyroid-hormone enhancement of imipramine in nonretarded depressions.\" N Engl J Med 282 (1970): 1063-7[17] Swartz CM \"Dependency of tricyclic antidepressant efficacy on thyroid hormone potentiation: case studies.\" J Nerv Ment Dis 170 (1982): 50-2[18] Cooke RG \"T3 augmentation of a tricyclic antidepressant in a patient receiving T4 maintenance therapy.\" Am J Psychiatry 147 (1990): 255[19] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[20] \"Product Information. Cytomel (liothyronine).\" Monarch Pharmaceuticals Inc, Bristol, TN.", "alternatives_a": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Clofibrate, Cerivastatin, Lomitapide, Colestipol, Bempedoic acid, Colesevelam, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 145516, "ingredient1": "Dezocine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145679/", "reference_text": "[1] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[12] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[16] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf.\" ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.\" J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[28] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015): 112-7[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction.\" Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 145517, "ingredient1": "Dicoumarol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Some reports suggest that tricyclic antidepressants may increase or decrease the anticoagulant effect of warfarin by an unknown mechanism. Similar effects may occur with other oral anticoagulants.", "source": "DDInter", "management_text": "Until more information is available, it may be advisable to monitor the International Normalized Ratio (INR) or prothrombin time and clinical response if these agents are administered concomitantly. Patients should be advised to promptly report possible signs of bleeding (e.g., pain, swelling, headache, dizziness, weakness, nosebleeds, bleeding of gums from brushing, unusual bruising, red or brown urine, or red or black stools) or clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).", "mechanism_text": "Synergism", "recommendation": "Until more information is available, it may be advisable to monitor the International Normalized Ratio (INR) or prothrombin time and clinical response if these agents are administered concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145680/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971): 487-98[2] Vesell ES, Passananti GT, Greene FE \"Impairment of drug metabolism in man by allopurinol and nortriptyline.\" N Engl J Med 283 (1970): 1484-8[3] Pond SM, Graham GG, Birkett DJ, Wade DN \"Effects of tricyclic antidepressants on drug metabolism.\" Clin Pharmacol Ther 18 (1975): 191-9[4] Williams JR, Griffin JP, Parkins A \"Effect of concomitantly administered drugs on the control of long term anticoagulant therapy.\" Q J Med 45 (1976): 63-73[5] Koch-Weser J \"Hemorrhagic reactions and drug interactions in 500 warfarin-treated patients.\" Clin Pharmacol Ther 14 (1973): 139[6] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[7] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[8] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[9] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[10] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[11] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[12] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[13] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[14] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[15] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[16] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[17] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[18] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[19] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[20] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[21] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[22] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[23] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[24] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[25] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[26] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[27] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[28] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[29] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[30] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[31] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[32] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[33] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[34] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[35] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[36] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[37] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[38] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[39] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[40] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[41] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[42] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More", "alternatives_b": "Phenelzine, Tranylcypromine, Maprotiline, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 145518, "ingredient1": "Dienestrol (topical)", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145681/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145519, "ingredient1": "Diethylstilbestrol", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145682/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Bazedoxifene", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 145520, "ingredient1": "Dimenhydrinate", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145683/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145521, "ingredient1": "Dobutamine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145684/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "updated_at": 1767369485}, {"id": 145522, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145685/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 145523, "ingredient1": "Echinacea", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with echinacea may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to echinacea-mediated inhibition of CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever echinacea is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145686/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145524, "ingredient1": "Entrectinib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Entrectinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of entrectinib and periodically during treatment as appropriate based on individual risk factors.", "mechanism_text": "Synergism", "recommendation": "Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145687/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145525, "ingredient1": "Enzalutamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145688/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Esketamine, Paroxetine", "alternatives_b": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "updated_at": 1767369485}, {"id": 145526, "ingredient1": "Ephedrine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145689/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Trazodone, More", "alternatives_b": "Tropicamide, Mupirocin, Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Cromoglicic acid, Hyaluronic acid, Betamethasone, More", "updated_at": 1767369485}, {"id": 145527, "ingredient1": "Epirubicin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145690/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Phenelzine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "updated_at": 1767369485}, {"id": 145528, "ingredient1": "Eplerenone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145691/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 145529, "ingredient1": "Eprosartan", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145692/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 145530, "ingredient1": "Eribulin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Eribulin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval. Baseline and periodic monitoring of electrocardiograms and serum electrolytes (potassium, magnesium) should be considered, and hypokalemia or hypomagnesemia corrected prior to initiating treatment with eribulin. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145693/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Halaven (eribulin).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145531, "ingredient1": "Escitalopram", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures. Due to the potential for additive effects on the QT interval, ECG monitoring may also be appropriate when escitalopram is used with tricyclic antidepressants or other antidepressants like trazodone. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145694/", "reference_text": "[1] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[2] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[6] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[7] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[8] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[9] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[12] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[13] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[14] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[17] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[18] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[21] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[22] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[23] Castro VM, Clements CC, Murphy SN, et al. \"QT interval and antidepressant use: a cross sectional study of electronic health records.\" BMJ 346 (2013): f288[24] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[25] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[26] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[27] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[29] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[30] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[31] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[32] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[35] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[36] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[37] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[38] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[39] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Esketamine, Escitalopram", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145532, "ingredient1": "Eslicarbazepine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145695/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145533, "ingredient1": "Esmolol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145696/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pindolol", "alternatives_b": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145534, "ingredient1": "Estazolam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145697/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145535, "ingredient1": "Esterified estrogens", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145698/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145536, "ingredient1": "Estradiol (topical)", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145699/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Norgestrel, Bazedoxifene, Prasterone, More", "updated_at": 1767369485}, {"id": 145537, "ingredient1": "Estramustine", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145700/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145538, "ingredient1": "Estrone", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145701/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Bazedoxifene", "updated_at": 1767369485}, {"id": 145539, "ingredient1": "Estrone sulfate", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145702/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145540, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145703/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145541, "ingredient1": "Eszopiclone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145704/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 145542, "ingredient1": "Etacrynic acid", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145705/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145543, "ingredient1": "Ethchlorvynol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145706/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam", "alternatives_b": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Viloxazine, Amoxapine, Imipramine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 145544, "ingredient1": "Ethosuximide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145707/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145545, "ingredient1": "Ethotoin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145708/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145546, "ingredient1": "Ezogabine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145709/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145547, "ingredient1": "Fedratinib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145710/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Phenelzine, Tranylcypromine, Isocarboxazid, Oxitriptan, Milnacipran, Tryptophan, Bupropion, Esketamine", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145548, "ingredient1": "Felbamate", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145711/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145549, "ingredient1": "Fenfluramine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The coadministration of fenfluramine and tricyclic antidepressants (TCAs) may result in elevated plasma concentrations of the latter. The mechanism is decreased clearance of TCAs due to inhibition of CYP450 enzymatic activities by fenfluramine. In addition, the combination of fenfluramine with a TCA may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Close monitoring is recommended for signs and symptoms of TCA toxicity as well as excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145712/", "reference_text": "[1] Fogelson DL \"Fenfluramine and the cytochrome P450 system.\" Am J Psychiatry 154 (1997): 436-7[2] Price LH, Charney DS, Delgado PL, Heninger GR \"Fenfluramine augmentation in tricyclic-refractory depression.\" J Clin Psychopharmacol 10 (1990): 312-7[3] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[4] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Viloxazine", "alternatives_b": "Naltrexone, Lacosamide", "updated_at": 1767369485}, {"id": 145550, "ingredient1": "Fenoldopam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145713/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Imipramine, Esketamine, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "updated_at": 1767369485}, {"id": 145551, "ingredient1": "Fesoterodine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145714/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desvenlafaxine, Oxitriptan, Mirtazapine, Trazodone, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Venlafaxine", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 145552, "ingredient1": "Fingolimod", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of fingolimod treatment in patients receiving drugs that prolong the QT interval. Fingolimod can cause a decrease in heart rate during initiation of therapy that is apparent within an hour of the first dose and maximal at approximately 6 hours postdose in most cases, but occasionally up to 20 hours after the first dose.", "source": "DDInter", "management_text": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).", "mechanism_text": "Synergism", "recommendation": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145715/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data.\" ([2012 May 14]):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "St. John's Wort, Vortioxetine, Milnacipran, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Fluvoxamine, Phenelzine, Tranylcypromine, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145553, "ingredient1": "Flavoxate", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145716/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 145554, "ingredient1": "Flecainide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with Class IC antiarrhythmic agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is inhibition of CYP450 2D6, the isoenzyme primarily or partially responsible for the metabolism of most TCAs. Class IC antiarrhythmic agents can cause prolongation of the QT interval. Theoretically, coadministration with other agents such as TCAs that can prolong the QT interval may increase the risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if a class IC antiarrhythmic agent is prescribed in combination with a tricyclic antidepressant. Pharmacologic response and serum TCA levels should be monitored more closely whenever a class IC antiarrhythmic agent is added to or withdrawn from therapy, and the TCA dosage adjusted as necessary. Patients should be advised to notify their physician if they experience possible signs and symptoms of TCA toxicity such as excessive sedation, dry mouth, blurred vision, urinary retention, constipation, tachycardia, arrhythmia, and seizures. Patients should seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution and clinical monitoring are recommended if a class IC antiarrhythmic agent is prescribed in combination with a tricyclic antidepressant.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145717/", "reference_text": "[1] \"Product Information. Sinequan (doxepin).\" Roerig Division, New York, NY.[2] Katz MR \"Raised serum levels of desipramine with the antiarrhythmic propafenone .\" J Clin Psychiatry 52 (1991): 432-3[3] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 145555, "ingredient1": "Flibanserin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.", "source": "DDInter", "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.", "mechanism_text": "Synergism", "recommendation": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145718/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Tryptophan", "alternatives_b": "Bremelanotide, Black cohosh, Cabergoline", "updated_at": 1767369485}, {"id": 145556, "ingredient1": "Fluconazole", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The coadministration with azole antifungal agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). Elevated TCA levels may result in CNS toxicity, anticholinergic symptoms, and QT interval prolongation. The mechanism is decreased TCA clearance due to azole-related inhibition of the CYP450 3A4 isoenzyme, which is partially responsible for the metabolism of TCAs like amitriptyline, clomipramine, imipramine, and possibly others.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary. Serum TCA levels should be monitored following initiation or discontinuation of azole antifungal therapy. Patients should be advised to notify their caregiver if they experience excessive dry mouth, visual disturbances, urinary retention, dizziness, syncope, fast or irregular heartbeat, constipation, or seizures.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145719/", "reference_text": "[1] Dorsey ST, Biblio LA \"Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline.\" Am J Emerg Med 18 (2000): 227-9[2] Gannon RH \"Fluconazole-nortriptyline drug interaction.\" Ann Pharmacother 26 (1992): 1456[3] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E \"Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.\" Br J Clin Pharmacol 43 (1997): 315-8[4] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E \"Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.\" Br J Clin Pharmacol 43 (1997): 315-8[5] Robinson RF, Nahata MC, Olshefski RS \"Syncope associated with concurrent amitriptyline and fluconazole therapy.\" Ann Pharmacother 34 (2000): 1406-9[6] Newberry DL, Bass SN, Mbanefo CO \"A fluconazole/amitriptyline drug interaction in three male adults.\" Clin Infect Dis 24 (1997): 270-1", "alternatives_a": "Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Esketamine", "updated_at": 1767369485}, {"id": 145557, "ingredient1": "Flumazenil", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Severe adverse effects, including fatalities, have been reported following the administration of flumazenil to multiple-drug-overdose patients who have taken large quantities of tricyclic antidepressants. The effects have included seizures and arrhythmias (including ventricular tachycardia). The mechanism of this interaction may be related to a decrease in the protective antiseizure effects of benzodiazepines that patients may have taken concomitantly with overdoses of tricyclic antidepressants.", "source": "DDInter", "management_text": "Administration of flumazenil should be avoided in patients who are known or suspected to have received overdoses of tricyclic antidepressants.", "mechanism_text": "Synergism", "recommendation": "Administration of flumazenil should be avoided in patients who are known or suspected to have received overdoses of tricyclic antidepressants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145720/", "reference_text": "[1] Marchant B, Wray R, Leach A, Nama M \"Flumazenil causing convulsions and ventricular tachycardia.\" BMJ 299 (1989): 860[2] Bodenham AR \"Death after flumazenil.\" BMJ 299 (1989): 457[3] Mordel A, Winkler E, Almog S, Tirosh M, Ezra D \"Seizures after flumazenil administration in a case of combined benzodiazepine and tricyclic antidepressant overdose.\" Crit Care Med 20 (1992): 1733-4[4] \"Flumazenil.\" Med Lett Drugs Ther 34 (1992): 66-8[5] Lheureux P, Vrankx M, Askenasi R \"Administration of flumazenil.\" Ann Emerg Med 20 (1991): 592-3[6] Geller E, Crome P, Schaller MD, Marchant B, Ectors M, Scollo-Lavizzari G \"Risks and benefits of therapy with flumazenil (Anexate) in mixed drug intoxications.\" Eur Neurol 31 (1991): 241-50", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 145558, "ingredient1": "Fluphenazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145721/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145559, "ingredient1": "Flurazepam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145722/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145560, "ingredient1": "Flutamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145723/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Tryptophan, More", "updated_at": 1767369485}, {"id": 145561, "ingredient1": "Fluvoxamine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is fluvoxamine inhibition of multiple hepatic microsomal enzymes involved in the metabolic clearance of TCAs. Pharmacodynamically, the combination of fluvoxamine (or any other selective serotonin reuptake inhibitor) and a TCA may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "In general, the use of fluvoxamine (or other SSRIs) with TCAs should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Pharmacologic response and plasma TCA levels should be monitored more closely whenever fluvoxamine is added to or withdrawn from therapy in patients stabilized on their existing antidepressant regimen, and the TCA dosage adjusted as necessary. Patients should be monitored closely for signs and symptoms of TCA toxicity (e.g., sedation, dry mouth, blurred vision, constipation, urinary retention) and/or excessive serotonergic activity (e.g., CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia).", "mechanism_text": "Metabolism", "recommendation": "In general, the use of fluvoxamine (or other SSRIs) with TCAs should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145724/", "reference_text": "[1] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[2] Ereshefsky L, Riesemman C, Lam YW \"Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.\" Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9[3] Popli AP, Baldessarini RJ, Cole JO \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 51 (1994): 666-7[4] Skjelbo E, Brosen K \"Inhibitors of imipramine metabolism by human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 256-61[5] Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P \"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.\" Pharmacol Res 31 (1995): 347-53[6] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[7] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[8] Taylor D \"Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses.\" Br J Psychiatry 167 (1995): 575-80[9] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[10] Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP \"Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.\" Ther Drug Monit 15 (1993): 243-6[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP \"Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.\" Int J Clin Pharmacol Res 13 (1993): 167-71[13] Maskall DD, Lam RW \"Increased plasma concentration of imipramine following augmentation with fluvoxamine.\" Am J Psychiatry 150 (1993): 1566[14] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[15] Vonmoltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI \"Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.\" J Clin Psychopharmacol 15 (1995): 125-31[16] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S \"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.\" Biochem Pharmacol 45 (1993): 1211-4[17] Seifritz E, Holsboertrachsler E, Hemmeter U, Eap CB, Baumann P \"Increased trimipramine plasma levels during fluvoxamine comedication.\" Eur Neuropsychopharmacol 4 (1994): 15-20[18] Spina E, Campo GM, Avenoso A, et al \"Interaction between fluvoxamine and imipramine/desipramine in four patients.\" Ther Drug Monit 14 (1992): 194-6[19] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[20] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[21] Bertschy G, Vandel S, Vandel B, Allers G, Volmat R \"Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.\" Eur J Clin Pharmacol 40 (1991): 119-20[22] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[23] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[24] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[25] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Nortriptyline", "alternatives_b": "Viloxazine, Fluvoxamine, Esketamine", "updated_at": 1767369485}, {"id": 145562, "ingredient1": "Foscarnet", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145725/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 145563, "ingredient1": "Fosinopril", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145726/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145564, "ingredient1": "Fosphenytoin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may increase serum phenytoin levels. In vitro studies suggest the mechanism may involve inhibition of CYP450 2C19-catalyzed phenytoin p-hydroxylation by tricyclic antidepressants, especially imipramine and amitriptyline. Phenytoin may induce the hepatic metabolism of desipramine resulting in decreased plasma concentrations.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and serum phenytoin concentrations is recommended. Patients should be advised to notify their doctor if they experience loss of seizure control or symptoms of phenytoin toxicity (drowsiness, visual disturbances, change in mental status, nausea, or ataxia). Phenytoin dosage may need to be adjusted.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response, tolerance, and serum phenytoin concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145727/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Houghton GW, Richens A \"Inhibition of phenytoin metabolism by other drugs used in epilepsy.\" Int J Clin Pharmacol 12 (1975): 210-6[5] Fogel BS, Haltzman S \"Desipramine and phenytoin: a potential drug interaction of therapeutic relevance.\" J Clin Psychiatry 48 (1987): 387-8[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Perucca E, Richens A \"Interaction between phenytoin and imipramine.\" Br J Clin Pharmacol 4 (1977): 485-6[9] Shin JG, Park JY, Kim MJ, et al. \"Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.\" Drug Metab Dispos 30 (2002): 1102-7", "alternatives_a": "St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145565, "ingredient1": "Fospropofol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The concomitant use of general anesthetics with tricyclic antidepressants may increase the risk of hypotension and cardiac arrhythmias. The presence of pancuronium may increase the risk of tachyarrhythmias. Enflurane may also increase the risk of seizures when given to patients who have been taking tricyclic antidepressants.", "source": "DDInter", "management_text": "Close monitoring is recommended when these drugs are used together.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended when these drugs are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145728/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Fluvoxamine, Vilazodone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145566, "ingredient1": "Fostemsavir", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Fostemsavir can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if fostemsavir is used in combination with other drugs that can prolong the QT interval. Consider obtaining electrocardiogram and serum electrolyte levels prior to initiating fostemsavir therapy and periodically thereafter, particularly in patients with risk factors for torsade de pointes and/or receiving one or more potent CYP450 3A4 inhibitors (e.g., azole antifungal agents; cobicistat; protease inhibitors; ketolide and certain macrolide antibiotics; ceritinib; idelalisib; nefazodone) or P-gp inhibitors (e.g., cyclosporine; diltiazem; quinidine; quinine; tacrolimus; verapamil). Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if fostemsavir is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145729/", "reference_text": "[1] \"Product Information. Rukobia (fostemsavir).\" ViiV Healthcare, Research Triangle Park, NC.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 145567, "ingredient1": "Furosemide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145730/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, More", "updated_at": 1767369485}, {"id": 145568, "ingredient1": "Gabapentin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145731/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145569, "ingredient1": "Galantamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145732/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Aducanumab", "updated_at": 1767369485}, {"id": 145570, "ingredient1": "Gatifloxacin", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145733/", "reference_text": "[1] Siepmann M, Kirch W \"Drug points - Tachycardia associated with moxifloxacin.\" Br Med J 322 (2001): 23[2] Ansari SR, Chopra N \"Gatifloxacin and Prolonged QT Interval.\" Am J Med Sci 327 (2004): 55-6[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[5] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[6] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[7] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[8] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[9] Dale KM, Lertsburapa K, Kluger J, White CM \"Moxifloxacin and torsade de pointes.\" Ann Pharmacother 41 (2007): 336-40[10] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB \"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.\" Clin Infect Dis 34 (2002): 861-3[11] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[12] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[13] Iannini PB, Circiumaru I \"Gatifloxacin-induced QTc prolongation and ventricular tachycardia.\" Pharmacotherapy 21 (2001): 361-2[14] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF \"Effects of three fluoroquinolones on QT analysis after standard treatment courses.\" Ann Noninvasive Electrocardiol 11 (2006): 52-6[15] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C \"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.\" Clin Pharmacol Ther 68 (2000): 658-66[16] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[17] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[18] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[19] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[20] White CM, Grant EM, Quintiliani R \"Moxifloxacin does increase the corrected QT interval.\" Clin Infect Dis 33 (2001): 1441-2[21] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[24] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[25] Cerner Multum, Inc. \"Australian Product Information.\" O 0[26] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[27] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[28] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "updated_at": 1767369485}, {"id": 145571, "ingredient1": "Gemifloxacin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145734/", "reference_text": "[1] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[2] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[3] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[4] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[5] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "updated_at": 1767369485}, {"id": 145572, "ingredient1": "Gilteritinib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Gilteritinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145735/", "reference_text": "[1] \"Product Information. Xospata (gilteritinib).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145573, "ingredient1": "Ginkgo biloba", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145736/", "reference_text": "[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002): 325-7[2] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001): 523-5[3] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006): 323-9[6] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005): 755-8", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Aducanumab", "updated_at": 1767369485}, {"id": 145574, "ingredient1": "Givosiran", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with givosiran may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2 and/or CYP450 2D6. The proposed mechanism is decreased clearance due to givosiran-mediated inhibition of CYP450 1A2 and 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6. Concomitant use should generally be avoided with CYP450 1A2 or 2D6 substrates that have a narrow therapeutic range where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, the dosage of the CYP450 1A2 or 2D6 substrate should be reduced according to approved product labeling or clinical response and tolerance. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever givosiran is added to or withdrawn from therapy with these drugs.", "mechanism_text": "Metabolism", "recommendation": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145737/", "reference_text": "[1] \"Product Information. Givlaari (givosiran).\" Alnylam Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145575, "ingredient1": "Glasdegib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Glasdegib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with glasdegib, approximately one week after initiation, and then once monthly for the next two months, although patients with risk factors may require more frequent and ongoing ECG monitoring.", "mechanism_text": "Synergism", "recommendation": "Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145738/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145576, "ingredient1": "Glipizide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Case reports suggest that tricyclic antidepressants may increase the hypoglycemic effects of sulfonylureas.", "source": "DDInter", "management_text": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Synergism", "recommendation": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145739/", "reference_text": "[1] Zogno MG, Tolfo L, Draghi E \"Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics.\" Ann Pharmacother 28 (1994): 406[2] Pond SM, Graham GG, Birkett DJ, Wade DN \"Effects of tricyclic antidepressants on drug metabolism.\" Clin Pharmacol Ther 18 (1975): 191-9[3] True BL, Perry PJ, Burns EA \"Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy.\" Am J Psychiatry 144 (1987): 1220-1[4] Sherman KE, Bornemann M \"Amitriptyline and asymptomatic hypoglycemia.\" Ann Intern Med 109 (1988): 683-4[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Esketamine", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "updated_at": 1767369485}, {"id": 145577, "ingredient1": "Glyburide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Case reports suggest that tricyclic antidepressants may increase the hypoglycemic effects of sulfonylureas.", "source": "DDInter", "management_text": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Synergism", "recommendation": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145740/", "reference_text": "[1] Zogno MG, Tolfo L, Draghi E \"Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics.\" Ann Pharmacother 28 (1994): 406[2] Pond SM, Graham GG, Birkett DJ, Wade DN \"Effects of tricyclic antidepressants on drug metabolism.\" Clin Pharmacol Ther 18 (1975): 191-9[3] True BL, Perry PJ, Burns EA \"Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy.\" Am J Psychiatry 144 (1987): 1220-1[4] Sherman KE, Bornemann M \"Amitriptyline and asymptomatic hypoglycemia.\" Ann Intern Med 109 (1988): 683-4[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Desvenlafaxine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Esketamine", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "updated_at": 1767369485}, {"id": 145578, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates. The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145741/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc, South San Francisco, CA.", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 145579, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145742/", "reference_text": "[1] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[2] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[5] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[6] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145580, "ingredient1": "Goserelin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145743/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Megestrol acetate", "alternatives_b": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "updated_at": 1767369485}, {"id": 145581, "ingredient1": "Granisetron", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Treatment with 5-HT3 receptor antagonists has been associated with dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including certain antidepressants and lithium may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is warranted when initiating or increasing the dosages of these agents. In addition, the potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures. Due to the potential for additive effects on the QT interval, ECG monitoring may also be appropriate when 5-HT3 receptor antagonists are used with certain antidepressants or lithium. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145744/", "reference_text": "[1] \"Product Information. Anzemet (dolasetron).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sancuso (granisetron).\" ProStrakan Group, Bedminster, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Akynzeo (netupitant-palonosetron).\" Eisai Inc, Woodcliff Lake, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Aloxi (palonosetron).\" MGI Pharma Inc, Minnetonka, MN.", "alternatives_a": "Viloxazine, Esketamine", "alternatives_b": "Aprepitant", "updated_at": 1767369485}, {"id": 145582, "ingredient1": "Grepafloxacin", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Grepafloxacin can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145745/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[4] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[5] Lode H, Vogel F, Elies W \"Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance.\" Clin Ther 21 (1999): 61-74[6] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Phenelzine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "updated_at": 1767369485}, {"id": 145583, "ingredient1": "Guanabenz", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145746/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Imipramine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145584, "ingredient1": "Guanadrel", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants (TCAs) may reduce the antihypertensive effects of guanethidine. Loss of blood pressure control may result. The mechanism is TCA-induced inhibition of guanethidine uptake into adrenergic neurons. Hypotensive reactions may occur when the tricyclic antidepressant is discontinued. Other adrenergic neurone blockers may also be affected.", "source": "DDInter", "management_text": "Either a different antidepressant or a different antihypertensive agent (such as an ACE inhibitor or beta-blocker) should be considered. If patients do receive this combination, their blood pressure should be closely monitored when initiating or discontinuing either drug.", "mechanism_text": "Antagonism", "recommendation": "Either a different antidepressant or a different antihypertensive agent (such as an ACE inhibitor or beta-blocker) should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145747/", "reference_text": "[1] Gokhale SD, Gulati OD, Udwadia BP \"Antagonism of the adrenergic neurone blocking action of guanethidine by certain antidepressant and antihistamine drugs.\" Arch Int Pharmacodyn Ther 160 (1966): 321-9[2] Stone CA, Porter CC, Stavorski JM, et al \"Antagonism of certain effects of catecholamine-depleting agents by antidepressant and related drugs.\" J Pharmacol Exp Ther 144 (1964): 196-204[3] Koe BK, Constantine JW \"Blocking H 3 -norepinephrine uptake and some guanethidine-induced effects with tricyclic psychotherapeutic drugs.\" Arch Int Pharmacodyn Ther 195 (1972): 71-80[4] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[5] Poe TE, Edwards JL, Taylor RB \"Hypertensive crisis possibly due to drug interaction.\" Postgrad Med 66 (1979): 235-7[6] Meyer JF, McAllister CK, Goldberg LI \"Insidious and prolonged antagonism of guanethidine by amitriptyline.\" JAMA 213 (1970): 1487-8[7] MacLennan WJ \"Drug interactions.\" Gerontol Clin (Basel) 16 (1974): 18-24[8] Leishman AW, Matthews HL, Smith AJ \"Antagonism of guanethidine by imipramine.\" Lancet 1 (1963): 112[9] Ober KF, Wang RI \"Drug interactions with guanethidine.\" Clin Pharmacol Ther 14 (1973): 190-5", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145585, "ingredient1": "Guanethidine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants (TCAs) may reduce the antihypertensive effects of guanethidine. Loss of blood pressure control may result. The mechanism is TCA-induced inhibition of guanethidine uptake into adrenergic neurons. Hypotensive reactions may occur when the tricyclic antidepressant is discontinued. Other adrenergic neurone blockers may also be affected.", "source": "DDInter", "management_text": "Either a different antidepressant or a different antihypertensive agent (such as an ACE inhibitor or beta-blocker) should be considered. If patients do receive this combination, their blood pressure should be closely monitored when initiating or discontinuing either drug.", "mechanism_text": "Antagonism", "recommendation": "Either a different antidepressant or a different antihypertensive agent (such as an ACE inhibitor or beta-blocker) should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145748/", "reference_text": "[1] Gokhale SD, Gulati OD, Udwadia BP \"Antagonism of the adrenergic neurone blocking action of guanethidine by certain antidepressant and antihistamine drugs.\" Arch Int Pharmacodyn Ther 160 (1966): 321-9[2] Stone CA, Porter CC, Stavorski JM, et al \"Antagonism of certain effects of catecholamine-depleting agents by antidepressant and related drugs.\" J Pharmacol Exp Ther 144 (1964): 196-204[3] Koe BK, Constantine JW \"Blocking H 3 -norepinephrine uptake and some guanethidine-induced effects with tricyclic psychotherapeutic drugs.\" Arch Int Pharmacodyn Ther 195 (1972): 71-80[4] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[5] Poe TE, Edwards JL, Taylor RB \"Hypertensive crisis possibly due to drug interaction.\" Postgrad Med 66 (1979): 235-7[6] Meyer JF, McAllister CK, Goldberg LI \"Insidious and prolonged antagonism of guanethidine by amitriptyline.\" JAMA 213 (1970): 1487-8[7] MacLennan WJ \"Drug interactions.\" Gerontol Clin (Basel) 16 (1974): 18-24[8] Leishman AW, Matthews HL, Smith AJ \"Antagonism of guanethidine by imipramine.\" Lancet 1 (1963): 112[9] Ober KF, Wang RI \"Drug interactions with guanethidine.\" Clin Pharmacol Ther 14 (1973): 190-5", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol", "updated_at": 1767369485}, {"id": 145586, "ingredient1": "Guanfacine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "One case report suggests that tricyclic antidepressants may decrease the antihypertensive effect of guanfacine. The mechanism is unknown.", "source": "DDInter", "management_text": "The patient's blood pressure should be monitored during concomitant therapy and after discontinuation or dose change of the antidepressant. An alternative antihypertensive (e.g., beta adrenergic blocking agent, diuretic) may be considered.", "mechanism_text": "Others", "recommendation": "The patient's blood pressure should be monitored during concomitant therapy and after discontinuation or dose change of the antidepressant.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145749/", "reference_text": "[1] Buckley M, Feely J \"Antagonism of antihypertensive effect of guanfacine by tricyclic antidepressants.\" Lancet 337 (1991): 1173-4[2] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.", "alternatives_a": "Duloxetine, Sertraline, Desvenlafaxine, Fluoxetine, Oxitriptan, Tryptophan, Milnacipran, Vortioxetine, Levomilnacipran, Vilazodone, Paroxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145587, "ingredient1": "Halazepam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145750/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145588, "ingredient1": "Halofantrine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145751/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[4] Nosten F, ter Kuile FO, Luxemburger C, et al \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993): 1054-6[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001): 169-70, 179[7] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[8] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[9] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[10] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[11] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[12] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[13] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002): 514-23", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 145589, "ingredient1": "Haloperidol", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction. Haloperidol may increase the serum concentrations of tricyclic antidepressants by inhibiting their metabolism via CYP450 2D6. There have been case reports of seizures associated with this interaction.", "source": "DDInter", "management_text": "Caution is advised if haloperidol is used in combination with other drugs that prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages. Haloperidol is not approved by the FDA for intravenous administration. Lower dosages of the tricyclic antidepressant may be necessary when used with haloperidol. Patients should be advised to notify their physician if they experience excessive tricyclic antidepressant adverse effects such as dry mouth, visual disturbances, urinary retention, dizziness, orthostasis, constipation, and seizures. In addition, patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if haloperidol is used in combination with other drugs that prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145752/", "reference_text": "[1] Alter P, Tontsch D, Grimm W \"Doxepin-induced torsade de pointes tachycardia.\" Ann Intern Med 135 (2001): 384-5[2] Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K \"Doxepin induced torsade de pointes.\" Pacing Clin Electrophysiol 5 (1982): 873-7[3] Nelson JC, Jatlow PI \"Neuroleptic effect on desipramine steady-state plasma concentrations.\" Am J Psychiatry 137 (1980): 1232-4[4] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[5] \"Product Information. Haldol (haloperidol).\" McNeil Pharmaceutical, Raritan, NJ.[6] Sala M, Vicentini A, Brambilla P, et al. \"QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.\" Ann Gen Psychiatry 4 (2005): 1[7] Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH \"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.\" Lancet 355 (2000): 1048-52[8] Gram LF, Overo KF, Kirk L \"Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.\" Am J Psychiatry 131 (1974): 863-6[9] Mahr GC, Berchou R, Balon R \"A grand mal seizure associated with desipramine and haloperidol.\" Can J Psychiatry 32 (1987): 463-4[10] Goodnick PJ, Jerry J, Parra F \"Psychotropic drugs and the ECG: focus on the QTc interval.\" Expert Opin Pharmacother 3 (2002): 479-98[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145590, "ingredient1": "Halothane", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145753/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 145591, "ingredient1": "Diamorphine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145754/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nalmefene, Acamprosate, Naltrexone", "updated_at": 1767369485}, {"id": 145592, "ingredient1": "Histamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic and some atypical antidepressants have antihistaminic properties and may decrease skin reactivity to histamine phosphate for up to several weeks. Mirtazapine, doxepin, trimipramine and amitriptyline have the strongest affinity for H1 receptors.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering histamine phosphate to patients treated with antidepressants.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering histamine phosphate to patients treated with antidepressants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145755/", "reference_text": "[1] Hardman JG, Limbird LE, Gilman AG, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed.\" New York, NY: McGraw-Hill (2001):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, More", "updated_at": 1767369485}, {"id": 145593, "ingredient1": "Histrelin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145756/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Megestrol acetate", "updated_at": 1767369485}, {"id": 145594, "ingredient1": "Hydromorphone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145757/", "reference_text": "[1] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[12] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[16] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf.\" ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.\" J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[28] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015): 112-7[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction.\" Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 145595, "ingredient1": "Hydroxychloroquine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.", "source": "DDInter", "management_text": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.", "mechanism_text": "Synergism", "recommendation": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145758/", "reference_text": "[1] Mercuro NJ, Yen CF, Shim DJ, et.al \"Risk of QT interval prolongation associated with the use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)\" JAMA Cardiol May 1:e201834 (2020): epub ahead of print[2] \"Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine).\" Prasco Laboratories, Cincinnati, OH.[3] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF HYDROXYCHLOROQUINE SULFATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/\" ({2020, Apr 27]):[4] \"Product Information. Plaquenil (R). (hydroxychloroquine).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] \"Product Information. Chloroquine Phosphate (chloroquine).\" West-Ward Pharmaceutical Corporation, Eatontown, NJ.[6] Bessiere F, Roccia H, Deliniere A, et.al \"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit.\" JAMA Cardiol May 1 (2020): epub ahead of print[7] National Institutes of Health (NIH) \"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: URL: https://covid19treatmentguidelines.nih.gov/\" ([2020, Apr 21]):[8] Sacher F, Fauchier L, Boveda S, et.al \"Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.\" Arch Cardiovasc Dis Apr 24 (2020): epub ahead of print[9] Kapoor A, Pandurangi U, Arora V, et.al \"Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.\" Indian Pacing Electorphysiol J Apr 8 (2020): epub ahead of print[10] Borba MGS, Val FFA, Sampaio VS, et.al \"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-2) infection: A randomized clinical trial.\" JAMA Netw Open Apr 1 (2020): epub ahead of print[11] Sapp JL, Alqarawi W, MacIntyre CJ, et.al \"Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society.\" Can J Cardiol Apr 8 (2020): epub ahead of print[12] Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ \"Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties.\" Clin Pharmacokinet Ar 18 (2020): epub ahead of print[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C \"COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients?\" Br J Clin Pharmacol Apr 29 (2020): epub ahead of print[15] US Food and Drug Administration \"Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Available from: URL: https://www.fda.gov/safety/medical-product-\" ([2020, Apr 24]):[16] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ \"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)\" Mayo Clin Proc Apr 7 (2020): epub ahead of print[17] Roden DM, Harrington RA, Poppas A, Russo AM \"Considerations for drug interactions on QTc in exploratory COVID-19 (Coroanvirus disease 2019) treatment.\" Heart Rhythm Apr 14 (2020): epub ahead of print[18] mitra RL, Greenstein SA, Epstein lm \"An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin; Possible benefits of intravenous lidocaine.\" HeartRythm Case Rep Apr 1 (2020): epub ahead of print[19] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CHLOROQUINE PHOSPHATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/13653\" ([2020, Apr 27]):[20] Saleh M, Gabriels J, ChangD, et.al \"The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection.\" Circ Arrhythm Electrophysiol Apr 29 (2020): epub ahead of print[21] Bonow RO, Hernandez AF, Turakhia M \"Hydroxychloroquine, coronavirus disease 2019, and QT prolongation.\" JAMA Cardiol May 1 (2020): epub ahead of print[22] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Phenelzine, Tranylcypromine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 145596, "ingredient1": "Hydroxyzine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145759/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145597, "ingredient1": "Ibutilide", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145760/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Corvert (ibutilide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Moricizine, Tocainide, Bretylium, Mexiletine", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "updated_at": 1767369485}, {"id": 145598, "ingredient1": "Idarubicin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145761/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 145599, "ingredient1": "Ifosfamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.", "source": "DDInter", "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145762/", "reference_text": "[1] Simonian NA, Gilliam FG, Chiappa KH \"Ifosfamide causes a diazepam-sensitive encephalopathy.\" Neurology 43 (1993): 2700-2[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Viloxazine", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More", "updated_at": 1767369485}, {"id": 145600, "ingredient1": "Iloperidone", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.", "mechanism_text": "Synergism", "recommendation": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145763/", "reference_text": "[1] \"Product Information. Exforge HCT (amlodipine/hydrochlorothiazide/valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145601, "ingredient1": "Imatinib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.", "source": "DDInter", "management_text": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145764/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Phenelzine, Tranylcypromine, Maprotiline, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Esketamine", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145602, "ingredient1": "Imipramine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145765/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nortriptyline", "alternatives_b": "Imipramine", "updated_at": 1767369485}, {"id": 145603, "ingredient1": "Indacaterol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145766/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[3] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[5] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[8] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[9] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "St. John's Wort, Oxitriptan, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Paroxetine", "alternatives_b": "Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 145604, "ingredient1": "Iohexol", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145767/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "updated_at": 1767369485}, {"id": 145605, "ingredient1": "Isoetharine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145768/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[3] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[5] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[8] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[9] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145606, "ingredient1": "Isoflurophate (ophthalmic)", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145769/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145607, "ingredient1": "Nortriptyline", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145770/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145608, "ingredient1": "Nortriptyline", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Levomethadyl acetate may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of levomethadyl acetate alone have been associated with QT interval prolongation and torsade de pointes.", "source": "DDInter", "management_text": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145771/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] Krantz MJ, Mehler PS \"Synthetic opioids and QT prolongation.\" Arch Intern Med 163 (2003): 1615; author reply 1615[5] Deamer RL, Wilson DR, Clark DS, Prichard JG \"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).\" J Addict Dis 20 (2001): 7-14[6] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Nalmefene, Acamprosate, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145609, "ingredient1": "Nortriptyline", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145772/", "reference_text": "[1] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981): 98-9[3] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991): 41-3[7] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977): 1050-4", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145610, "ingredient1": "Nortriptyline", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145773/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "updated_at": 1767369485}, {"id": 145611, "ingredient1": "Nortriptyline", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.", "source": "DDInter", "management_text": "Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close monitoring of cardiovascular status is recommended for patients receiving this combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145774/", "reference_text": "[1] Haritos VS, Ghabrial H, Ahokas JT, Ching MS \"Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.\" Pharmacogenetics 10 (2000): 591-603[2] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[3] Raisfeld IH \"Cardiovascular complications of antidepressant therapy: interactions at the adrenergic neuron.\" Am Heart J 83 (1972): 129-33[4] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[5] Nielsen KK, Flinois JP, Beaune P, Brosen K \"The biotransformation of clomipramine in vitro, identification of the cytochrome p450s responsible for the separate metabolic pathways.\" J Pharmacol Exp Ther 277 (1996): 1659-64[6] Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J \"Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.\" J Clin Psychopharmacol 23 (2003): 459-66[7] Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J \"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.\" Pharmacogenetics 12 (2002): 571-80[8] Gunne LM, Antonijevic S, Jonsson J \"Effect of fenfluramine on steady state plasma levels of amitriptyline.\" Postgrad Med J 51 Suppl 1 (1975): 117[9] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[10] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan", "alternatives_b": "Naltrexone", "updated_at": 1767369485}, {"id": 145612, "ingredient1": "Nortriptyline", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145775/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 145613, "ingredient1": "Nortriptyline", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145776/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Doxepin", "updated_at": 1767369485}, {"id": 145614, "ingredient1": "Nortriptyline", "ingredient2": "Mesoridazine", "severity": "Major", "effect": "Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145777/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Serentil (mesoridazine)\" Boehringer-Ingelheim, Ridgefield, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Fluvoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145615, "ingredient1": "Nortriptyline", "ingredient2": "Metaraminol", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145778/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Trazodone, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "updated_at": 1767369485}, {"id": 145616, "ingredient1": "Nortriptyline", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145779/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Sertraline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145617, "ingredient1": "Nortriptyline", "ingredient2": "Methohexital", "severity": "Moderate", "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.", "source": "DDInter", "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.", "mechanism_text": "Antagonism", "recommendation": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145780/", "reference_text": "[1] Garey KW, Amsden GW, Johns CA \"Possible interaction between imipramine and butalbital.\" Pharmacotherapy 17 (1997): 1041-2[2] Burrows GD, Davies B \"Antidepressants and barbiturates.\" Br Med J 4 (1971): 113[3] Silverman G, Braithwaite R \"Interaction of benzodiazepines with tricyclic antidepressants.\" Br Med J 4 (1972): 111[4] Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E \"Phenobarbital induces the 2-hydroxylation of desipramine.\" Ther Drug Monit 18 (1996): 60-4[5] Crocker J, Morton B \"Tricyclic (antidepressant) drug toxicity.\" Clin Toxicol 2 (1969): 397-402", "alternatives_a": "Nitrazepam, Desflurane, Enflurane, Etomidate, Nitrous oxide", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 145618, "ingredient1": "Nortriptyline", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145781/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Fluvoxamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145619, "ingredient1": "Nortriptyline", "ingredient2": "Methoxamine", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145782/", "reference_text": "[1] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979): 198-205[2] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980): 1251-4[3] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965): 403-16[4] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973): 311-5[5] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992): 692-7[6] Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG, ed. \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press (1977): 275-83[7] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968): 77-84[8] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982): 1025-8[9] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977): 238-53[10] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970): 1596-604[11] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988): 566-8", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine", "updated_at": 1767369485}, {"id": 145620, "ingredient1": "Nortriptyline", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145783/", "reference_text": "[1] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[12] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[16] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf.\" ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.\" J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[28] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015): 112-7[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction.\" Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Diphenoxylate, Difenoxin, Naloxone, Naltrexone", "alternatives_b": "Oxitriptan, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 145621, "ingredient1": "Nortriptyline", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145784/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desipramine, Vilazodone, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More", "alternatives_b": "Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 145622, "ingredient1": "Ofloxacin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145785/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, More", "updated_at": 1767369485}, {"id": 145623, "ingredient1": "Olanzapine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145786/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145624, "ingredient1": "Oliceridine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145787/", "reference_text": "[1] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[12] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[16] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf.\" ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.\" J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[28] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015): 112-7[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction.\" Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145625, "ingredient1": "Olodaterol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145788/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[3] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[5] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[8] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[9] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 145626, "ingredient1": "Olopatadine (nasal)", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145789/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145627, "ingredient1": "Ondansetron", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Treatment with 5-HT3 receptor antagonists has been associated with dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including certain antidepressants and lithium may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is warranted when initiating or increasing the dosages of these agents. In addition, the potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures. Due to the potential for additive effects on the QT interval, ECG monitoring may also be appropriate when 5-HT3 receptor antagonists are used with certain antidepressants or lithium. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if 5-HT3 receptor antagonists are prescribed with other agents that affect the serotonergic neurotransmitter system.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145790/", "reference_text": "[1] \"Product Information. Anzemet (dolasetron).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sancuso (granisetron).\" ProStrakan Group, Bedminster, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Akynzeo (netupitant-palonosetron).\" Eisai Inc, Woodcliff Lake, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Aloxi (palonosetron).\" MGI Pharma Inc, Minnetonka, MN.", "alternatives_a": "Esketamine", "alternatives_b": "Aprepitant", "updated_at": 1767369485}, {"id": 145628, "ingredient1": "Opicapone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145791/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 145629, "ingredient1": "Opium", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145792/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Diphenoxylate, Difenoxin, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 145630, "ingredient1": "Osilodrostat", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Osilodrostat can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating osilodrostat therapy and periodically thereafter. Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145793/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145631, "ingredient1": "Osimertinib", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting osimertinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145794/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145632, "ingredient1": "Oxaliplatin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145795/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "updated_at": 1767369485}, {"id": 145633, "ingredient1": "Oxazepam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145796/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145634, "ingredient1": "Oxcarbazepine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145797/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145635, "ingredient1": "Oxybutynin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145798/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 145636, "ingredient1": "Oxymorphone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145799/", "reference_text": "[1] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[12] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[16] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf.\" ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.\" J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[28] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015): 112-7[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction.\" Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 145637, "ingredient1": "Oxytocin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145800/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "updated_at": 1767369485}, {"id": 145638, "ingredient1": "Ozanimod", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of adrenergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may precipitate severe hypertensive reactions and hyperpyrexia. Coadministration of serotonergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible. Blood pressure and other vitals should be monitored if coadministration is required.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145801/", "reference_text": "[1] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[2] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[3] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[5] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[6] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[7] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[8] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[9] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[10] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[11] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[12] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[13] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[14] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[15] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[16] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[19] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[20] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[21] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[22] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[25] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[26] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[27] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[28] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[29] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[30] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[31] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[32] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[33] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[34] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[35] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[36] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[37] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[38] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[39] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[40] James WA, Lippmann S \"Bupropion: overview and prescribing guidelines in depression.\" South Med J 84 (1991): 222-4[41] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[42] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[43] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[44] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[45] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[46] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[47] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[48] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[49] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[50] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[51] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[52] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[53] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[54] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[55] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[56] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[57] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[58] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[59] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[60] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[61] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[62] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[63] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[64] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[65] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[66] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[67] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[68] \"Product Information. Comtan (entacapone)\" Novartis Pharmaceuticals, East Hanover, NJ.[69] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[70] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[71] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[72] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[73] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[74] \"Product Information. Ongentys (opicapone).\" Neurocrine Biosciences, Inc., San Diego, CA.[75] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[76] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[77] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[78] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[79] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[80] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[81] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[82] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[83] \"Product Information. Wellbutrin (bupropion).\" Glaxo Wellcome, Research Triangle Park, NC.[84] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[85] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[86] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[87] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[88] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[89] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[90] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[91] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[92] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[93] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[94] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[95] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[96] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[97] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[98] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[99] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[100] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Viloxazine, Esketamine", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145639, "ingredient1": "Panobinostat", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Panobinostat can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided. Anti-emetic drugs with known QT prolonging risk such as dolasetron, granisetron, ondansetron, palonosetron, and tropisetron may be used with frequent ECG monitoring. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting panobinostat therapy and periodically during treatment as clinically indicated.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145802/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145640, "ingredient1": "Papaverine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.", "source": "DDInter", "management_text": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145803/", "reference_text": "[1] Vrolix M, Piessens J, De Geest H \"Torsades de pointes after intracoronary papaverine.\" Eur Heart J 12 (1991): 273-6[2] Jain A, Jenkins MG \"Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine.\" Cathet Cardiovasc Diagn 18 (1989): 255-7[3] Goto M, Sato M, Kitzazawa H, et.al \"Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation.\" Intern Med 53 (2014): 1629-31[4] Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML \"Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine.\" J Am Coll Cardiol 15 (1990): 275-8[5] Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T \"Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve.\" Cathet Cardiovasc Diagn 19 (1990): 229-36[6] Nakayama M, Tanaka N, Sakoda K, et.al \"Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease.\" Circ J 79 (2015): 530-6[7] Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y \"QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine.\" Cardiology 84 (1994): 9-13[8] Nakayama M, Saito A, Kitazawa H, et.al \"Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T-U waves in four cases.\" Intern Med 51 (2012): 351-6", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide, Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 145641, "ingredient1": "Paraldehyde", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145804/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145642, "ingredient1": "Paramethadione", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145805/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145643, "ingredient1": "Paroxetine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration with paroxetine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is paroxetine inhibition of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of many antidepressant and psychotropic drugs.", "source": "DDInter", "management_text": "In general, the use of paroxetine (or other SSRIs) with TCAs should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Pharmacologic response and plasma TCA levels should be monitored more closely whenever paroxetine is added to or withdrawn from therapy in patients stabilized on their existing antidepressant regimen, and the TCA dosage adjusted as necessary. Patients should be monitored closely for signs and symptoms of TCA toxicity (e.g., sedation, dry mouth, blurred vision, constipation, urinary retention) and/or excessive serotonergic activity (e.g., CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia).", "mechanism_text": "Metabolism", "recommendation": "In general, the use of paroxetine (or other SSRIs) with TCAs should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145806/", "reference_text": "[1] Venkatakrishnan K, Schmider J, Harmatz JS, et al. \"Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies.\" J Clin Pharmacol 41 (2001): 1043-54[2] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[3] Popli AP, Baldessarini RJ, Cole JO \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 51 (1994): 666-7[4] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[5] Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R \"Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients.\" Psychopharmacology 147 (2000): 378-83[6] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[7] Laine K, Tybring G, Hartter S, et al. \"Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.\" Clin Pharmacol Ther 70 (2001): 327-35[8] Vonmoltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI \"Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.\" J Clin Psychopharmacol 15 (1995): 125-31[9] Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT \"Cytochromes p450 mediating the n-demethylation of amitriptyline.\" Br J Clin Pharmacol 43 (1997): 137-44[10] Taylor D \"Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses.\" Br J Psychiatry 167 (1995): 575-80[11] Ereshefsky L, Riesemman C, Lam YW \"Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.\" Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9[12] Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF \"Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.\" Eur J Clin Pharmacol 44 (1993): 349-55[13] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[14] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[15] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[16] Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, Gelbon HV \"Eight inhibitory monoclonal antibodies define the role of individual P-450S in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism.\" Drug Metab Dispos 27 (1999): 102-9[17] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[18] Albers LJ, Reist C, Helmeste D, Vu R, Tang SW \"Paroxetine shifts imipramine metabolism.\" Psychiatry Res 59 (1996): 189-96[19] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[20] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[21] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[22] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[23] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Esketamine, Paroxetine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145644, "ingredient1": "Pasireotide", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Pasireotide can cause bradycardia and QT prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting pasireotide therapy and periodically during treatment in accordance with the product labeling. Hypokalemia and hypomagnesemia must be corrected prior to pasireotide administration.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145807/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 145645, "ingredient1": "Pazopanib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145808/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145646, "ingredient1": "Penbutolol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145809/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Pindolol, Pindolol", "updated_at": 1767369485}, {"id": 145647, "ingredient1": "Pentobarbital", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.", "source": "DDInter", "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.", "mechanism_text": "Antagonism", "recommendation": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145810/", "reference_text": "[1] Garey KW, Amsden GW, Johns CA \"Possible interaction between imipramine and butalbital.\" Pharmacotherapy 17 (1997): 1041-2[2] Burrows GD, Davies B \"Antidepressants and barbiturates.\" Br Med J 4 (1971): 113[3] Silverman G, Braithwaite R \"Interaction of benzodiazepines with tricyclic antidepressants.\" Br Med J 4 (1972): 111[4] Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E \"Phenobarbital induces the 2-hydroxylation of desipramine.\" Ther Drug Monit 18 (1996): 60-4[5] Crocker J, Morton B \"Tricyclic (antidepressant) drug toxicity.\" Clin Toxicol 2 (1969): 397-402", "alternatives_a": "Nitrazepam", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 145648, "ingredient1": "Perampanel", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145811/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145649, "ingredient1": "Perflutren", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145812/", "reference_text": "[1] \"Product Information. Definity (perflutren).\" Lantheus Medical Imaging Inc, North Billerica, MA.[2] \"Product Information. Optison (perflutren).\" Mallinckrodt Medical Inc, St. Louis, MO.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145650, "ingredient1": "Pergolide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145813/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 145651, "ingredient1": "Perphenazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145814/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145652, "ingredient1": "Phenacemide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145815/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145653, "ingredient1": "Phendimetrazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.", "source": "DDInter", "management_text": "Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close monitoring of cardiovascular status is recommended for patients receiving this combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145816/", "reference_text": "[1] Haritos VS, Ghabrial H, Ahokas JT, Ching MS \"Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.\" Pharmacogenetics 10 (2000): 591-603[2] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[3] Raisfeld IH \"Cardiovascular complications of antidepressant therapy: interactions at the adrenergic neuron.\" Am Heart J 83 (1972): 129-33[4] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[5] Nielsen KK, Flinois JP, Beaune P, Brosen K \"The biotransformation of clomipramine in vitro, identification of the cytochrome p450s responsible for the separate metabolic pathways.\" J Pharmacol Exp Ther 277 (1996): 1659-64[6] Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J \"Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.\" J Clin Psychopharmacol 23 (2003): 459-66[7] Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J \"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.\" Pharmacogenetics 12 (2002): 571-80[8] Gunne LM, Antonijevic S, Jonsson J \"Effect of fenfluramine on steady state plasma levels of amitriptyline.\" Postgrad Med J 51 Suppl 1 (1975): 117[9] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[10] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145654, "ingredient1": "Phenelzine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145817/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Phenelzine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145655, "ingredient1": "Phenindamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145818/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Sertraline, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, More", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145656, "ingredient1": "Phenobarbital", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.", "source": "DDInter", "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.", "mechanism_text": "Antagonism", "recommendation": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145819/", "reference_text": "[1] Garey KW, Amsden GW, Johns CA \"Possible interaction between imipramine and butalbital.\" Pharmacotherapy 17 (1997): 1041-2[2] Burrows GD, Davies B \"Antidepressants and barbiturates.\" Br Med J 4 (1971): 113[3] Silverman G, Braithwaite R \"Interaction of benzodiazepines with tricyclic antidepressants.\" Br Med J 4 (1972): 111[4] Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E \"Phenobarbital induces the 2-hydroxylation of desipramine.\" Ther Drug Monit 18 (1996): 60-4[5] Crocker J, Morton B \"Tricyclic (antidepressant) drug toxicity.\" Clin Toxicol 2 (1969): 397-402", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Nitrazepam, Lacosamide", "updated_at": 1767369485}, {"id": 145657, "ingredient1": "Phenoxybenzamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145820/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Cyclandelate, Isoxsuprine, Tolazoline, Pentoxifylline", "updated_at": 1767369485}, {"id": 145658, "ingredient1": "Phensuximide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145821/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145659, "ingredient1": "Phentermine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.", "source": "DDInter", "management_text": "Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close monitoring of cardiovascular status is recommended for patients receiving this combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145822/", "reference_text": "[1] Haritos VS, Ghabrial H, Ahokas JT, Ching MS \"Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.\" Pharmacogenetics 10 (2000): 591-603[2] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[3] Raisfeld IH \"Cardiovascular complications of antidepressant therapy: interactions at the adrenergic neuron.\" Am Heart J 83 (1972): 129-33[4] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[5] Nielsen KK, Flinois JP, Beaune P, Brosen K \"The biotransformation of clomipramine in vitro, identification of the cytochrome p450s responsible for the separate metabolic pathways.\" J Pharmacol Exp Ther 277 (1996): 1659-64[6] Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J \"Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.\" J Clin Psychopharmacol 23 (2003): 459-66[7] Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J \"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.\" Pharmacogenetics 12 (2002): 571-80[8] Gunne LM, Antonijevic S, Jonsson J \"Effect of fenfluramine on steady state plasma levels of amitriptyline.\" Postgrad Med J 51 Suppl 1 (1975): 117[9] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[10] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Naltrexone", "alternatives_b": "Maprotiline, St. John's Wort, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan", "updated_at": 1767369485}, {"id": 145660, "ingredient1": "Phenylpropanolamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.", "source": "DDInter", "management_text": "Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close monitoring of cardiovascular status is recommended for patients receiving this combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145823/", "reference_text": "[1] Haritos VS, Ghabrial H, Ahokas JT, Ching MS \"Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.\" Pharmacogenetics 10 (2000): 591-603[2] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[3] Raisfeld IH \"Cardiovascular complications of antidepressant therapy: interactions at the adrenergic neuron.\" Am Heart J 83 (1972): 129-33[4] Markowitz JS, Patrick KS \"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.\" Clin Pharmacokinet 40 (2001): 753-72[5] Nielsen KK, Flinois JP, Beaune P, Brosen K \"The biotransformation of clomipramine in vitro, identification of the cytochrome p450s responsible for the separate metabolic pathways.\" J Pharmacol Exp Ther 277 (1996): 1659-64[6] Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J \"Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.\" J Clin Psychopharmacol 23 (2003): 459-66[7] Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J \"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.\" Pharmacogenetics 12 (2002): 571-80[8] Gunne LM, Antonijevic S, Jonsson J \"Effect of fenfluramine on steady state plasma levels of amitriptyline.\" Postgrad Med J 51 Suppl 1 (1975): 117[9] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[10] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Pseudoephedrine", "alternatives_b": "Maprotiline, Nefazodone, St. John's Wort, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 145661, "ingredient1": "Phenytoin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may increase serum phenytoin levels. In vitro studies suggest the mechanism may involve inhibition of CYP450 2C19-catalyzed phenytoin p-hydroxylation by tricyclic antidepressants, especially imipramine and amitriptyline. Phenytoin may induce the hepatic metabolism of desipramine resulting in decreased plasma concentrations.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and serum phenytoin concentrations is recommended. Patients should be advised to notify their doctor if they experience loss of seizure control or symptoms of phenytoin toxicity (drowsiness, visual disturbances, change in mental status, nausea, or ataxia). Phenytoin dosage may need to be adjusted.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response, tolerance, and serum phenytoin concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145824/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Houghton GW, Richens A \"Inhibition of phenytoin metabolism by other drugs used in epilepsy.\" Int J Clin Pharmacol 12 (1975): 210-6[5] Fogel BS, Haltzman S \"Desipramine and phenytoin: a potential drug interaction of therapeutic relevance.\" J Clin Psychiatry 48 (1987): 387-8[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Perucca E, Richens A \"Interaction between phenytoin and imipramine.\" Br J Clin Pharmacol 4 (1977): 485-6[9] Shin JG, Park JY, Kim MJ, et al. \"Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.\" Drug Metab Dispos 30 (2002): 1102-7", "alternatives_a": "Lacosamide", "alternatives_b": "Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran", "updated_at": 1767369485}, {"id": 145662, "ingredient1": "Physostigmine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145825/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, Hydroxocobalamin, Fomepizole, More", "updated_at": 1767369485}, {"id": 145663, "ingredient1": "Physostigmine (ophthalmic)", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145826/", "reference_text": "[1] \"Product Information. Pilopine HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145664, "ingredient1": "Pimavanserin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Pimavanserin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.", "mechanism_text": "Synergism", "recommendation": "Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145827/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145665, "ingredient1": "Pimozide", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Pimozide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with pimozide. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145828/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[3] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[6] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145666, "ingredient1": "Pitolisant", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Because pitolisant enhances the activity of histaminergic neurons in the brain, centrally acting histamine H1-receptor antagonists or medicines with H1-receptor antagonist properties (e.g., tri- and tetracyclic antidepressants) may impair the efficacy of pitolisant.", "source": "DDInter", "management_text": "According to the manufacturer, coadministration of pitolisant with centrally acting H1-receptor antagonists or tri- and tetracyclic antidepressants should be avoided.", "mechanism_text": "Antagonism", "recommendation": "According to the manufacturer, coadministration of pitolisant with centrally acting H1-receptor antagonists or tri- and tetracyclic antidepressants should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145829/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "updated_at": 1767369485}, {"id": 145667, "ingredient1": "Porfimer sodium", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145830/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivityan update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Maprotiline, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145668, "ingredient1": "Potassium chloride", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium chloride. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of certain oral solid formulations of potassium chloride is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium chloride should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Others", "recommendation": "The use of certain oral solid formulations of potassium chloride is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145831/", "reference_text": "[1] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[2] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[3] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[4] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[5] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[6] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[9] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[14] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate, Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Sodium bicarbonate, Sodium chloride, More", "updated_at": 1767369485}, {"id": 145669, "ingredient1": "Pramipexole", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145832/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cabergoline", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 145670, "ingredient1": "Prazosin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145833/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, Desipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145671, "ingredient1": "Primaquine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145834/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 145672, "ingredient1": "Primidone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.", "source": "DDInter", "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.", "mechanism_text": "Antagonism", "recommendation": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145835/", "reference_text": "[1] Garey KW, Amsden GW, Johns CA \"Possible interaction between imipramine and butalbital.\" Pharmacotherapy 17 (1997): 1041-2[2] Burrows GD, Davies B \"Antidepressants and barbiturates.\" Br Med J 4 (1971): 113[3] Silverman G, Braithwaite R \"Interaction of benzodiazepines with tricyclic antidepressants.\" Br Med J 4 (1972): 111[4] Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E \"Phenobarbital induces the 2-hydroxylation of desipramine.\" Ther Drug Monit 18 (1996): 60-4[5] Crocker J, Morton B \"Tricyclic (antidepressant) drug toxicity.\" Clin Toxicol 2 (1969): 397-402", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Nitrazepam, Lacosamide", "updated_at": 1767369485}, {"id": 145673, "ingredient1": "Probucol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145836/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Clofibrate, Cerivastatin, Lomitapide, Colestipol, Bempedoic acid, Colesevelam, More", "updated_at": 1767369485}, {"id": 145674, "ingredient1": "Procainamide", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145837/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 145675, "ingredient1": "Procarbazine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145838/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Esketamine", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145676, "ingredient1": "Procyclidine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145839/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145677, "ingredient1": "Promazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145840/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145678, "ingredient1": "Promethazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145841/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Azelastine, Ketotifen, Desloratadine, Tetracaine, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, More", "updated_at": 1767369485}, {"id": 145679, "ingredient1": "Propafenone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with Class IC antiarrhythmic agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is inhibition of CYP450 2D6, the isoenzyme primarily or partially responsible for the metabolism of most TCAs. Class IC antiarrhythmic agents can cause prolongation of the QT interval. Theoretically, coadministration with other agents such as TCAs that can prolong the QT interval may increase the risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if a class IC antiarrhythmic agent is prescribed in combination with a tricyclic antidepressant. Pharmacologic response and serum TCA levels should be monitored more closely whenever a class IC antiarrhythmic agent is added to or withdrawn from therapy, and the TCA dosage adjusted as necessary. Patients should be advised to notify their physician if they experience possible signs and symptoms of TCA toxicity such as excessive sedation, dry mouth, blurred vision, urinary retention, constipation, tachycardia, arrhythmia, and seizures. Patients should seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution and clinical monitoring are recommended if a class IC antiarrhythmic agent is prescribed in combination with a tricyclic antidepressant.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145842/", "reference_text": "[1] \"Product Information. Sinequan (doxepin).\" Roerig Division, New York, NY.[2] Katz MR \"Raised serum levels of desipramine with the antiarrhythmic propafenone .\" J Clin Psychiatry 52 (1991): 432-3[3] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 145680, "ingredient1": "Propantheline", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145843/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 145681, "ingredient1": "Propiomazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145844/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145682, "ingredient1": "Protriptyline", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145845/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nortriptyline", "alternatives_b": "Protriptyline, Viloxazine", "updated_at": 1767369485}, {"id": 145683, "ingredient1": "Quazepam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145846/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145684, "ingredient1": "Quetiapine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "There is some concern that quetiapine may have additive cardiovascular effects in combination with other drugs that are known to prolong the QT interval of the electrocardiogram.", "source": "DDInter", "management_text": "Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, if combination therapy with agents with anticholinergic properties is required, caution is advised, particularly in the elderly and those with underlying organic brain disease.", "mechanism_text": "Synergism", "recommendation": "Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145847/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[2] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Vieweg WV \"New generation antipsychotic drugs and QTc interval prolongation.\" Prim Care Companion J Clin Psychiatry 5 (2003): 205-15[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Vieweg WV, Schneider RK, Wood MA \"Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.\" Acta Psychiatr Scand 112 (2005): 318-22[9] Sala M, Vicentini A, Brambilla P, et al. \"QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.\" Ann Gen Psychiatry 4 (2005): 1[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145685, "ingredient1": "Quinapril", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145848/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145686, "ingredient1": "Quinestrol", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.", "source": "DDInter", "management_text": "The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "The clinical significance of this interaction has not been established.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145849/", "reference_text": "[1] Somani SM, Khurana RC \"Mechanism of estrogen-imipramine interaction.\" JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB \"Estrogen may well affect response to antidepressant.\" JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA \"Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women.\" Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr \"Tricyclic-induced akathisia in patients taking conjugated estrogens.\" Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI \"Imipramine disposition in users of oral contraceptive steroids.\" Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC \"Estrogen-imipramine interaction.\" JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145687, "ingredient1": "Quinidine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Quinidine may markedly increase the serum levels of some tricyclic antidepressants (TCAs). The mechanism is related to inhibition of CYP450 2D6 metabolism. Extensive metabolizers of debrisoquine may be at greater risk of developing significant TCA toxicity. Desipramine, nortriptyline, and imipramine have been specifically implicated in this interaction. In addition, both quinidine and TCAs may cause prolongation of the QT interval which could result in torsades de pointes.", "source": "DDInter", "management_text": "If possible, this combination should be avoided. Close clinical, electrocardiographic, and laboratory monitoring is recommended for patients who do receive these drugs concurrently. Patients should be advised to promptly notify their physicians if they experience irregular heartbeats or palpitations, syncope, drowsiness, confusion, weakness, or seizures.", "mechanism_text": "Metabolism", "recommendation": "If possible, this combination should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145850/", "reference_text": "[1] Brosen K, Gram LF \"Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.\" Eur J Clin Pharmacol 37 (1989): 155-60[2] Roos JC \"Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine.\" Br J Clin Pharmacol 15 Suppl 3 (1983): s439-45[3] von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI \"Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.\" J Pharmacol Exp Ther 268 (1994): 1278-83[4] Caporaso NE, Shaw GL \"Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.\" Arch Intern Med 151 (1991): 1985-92[5] Steiner E, Dumont E, Spina E, Dahlqvist R \"Inhibition of desipramine 2-hydroxylation by quinidine and quinine.\" Clin Pharmacol Ther 43 (1987): 577-81[6] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[7] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 145688, "ingredient1": "Quinine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145851/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "updated_at": 1767369485}, {"id": 145689, "ingredient1": "Racepinephrine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145852/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[3] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[5] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[8] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[9] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145690, "ingredient1": "Ramelteon", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145853/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145691, "ingredient1": "Ramipril", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145854/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Bempedoic acid", "alternatives_b": "Desipramine, Vilazodone, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, Esketamine, More", "updated_at": 1767369485}, {"id": 145692, "ingredient1": "Ranolazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Ranolazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of ranolazine, the maximum recommended dosage of 1000 mg twice daily should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Ranolazine is contraindicated in patients with liver cirrhosis because of the profound effect on QT prolongation in this population.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145855/", "reference_text": "[1] European Medicines Agency \"CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine. Procedure No. EMEA/H/C/805. Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/latixa/H-805-en6.pdf.\" ([cited 2008]):[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[3] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Regadenoson, Alprostadil, Ubidecarenone", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 145693, "ingredient1": "Rasagiline", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145856/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145694, "ingredient1": "Relugolix", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145857/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "updated_at": 1767369485}, {"id": 145695, "ingredient1": "Remifentanil", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145858/", "reference_text": "[1] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007): 919[2] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[3] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004): 150-1[4] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[5] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[6] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[7] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999): 474-5[8] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[9] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[10] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[11] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[12] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[13] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[14] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981): 319-21[15] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[16] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[17] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf.\" ([2016, Mar 22]):[18] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002): 440-1[19] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001): 964-5[20] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[21] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.\" J Clin Psychopharmacol (2015):[22] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[23] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[24] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013): 52-4[25] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014): 562-4[26] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998): 343-5[27] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[28] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004): 57[29] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005): 265-9[30] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004): 411-3[31] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015): 112-7[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[34] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth (2009):[35] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction.\" Pharmacotherapy (2015):[36] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[37] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005): 934-5[38] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[39] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004): 1129[40] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015): 247-51[41] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 145696, "ingredient1": "Remimazolam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145859/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145697, "ingredient1": "Reserpine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145860/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145698, "ingredient1": "Revefenacin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145861/", "reference_text": "[1] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[2] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[5] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[6] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[8] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Ciclesonide, Mometasone furoate, Flunisolide, Cromoglicic acid, Betamethasone, Nedocromil, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 145699, "ingredient1": "Ribociclib", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of ribociclib with other drugs that can prolong the QT interval should generally be avoided. However, if concomitant use is required, caution and clinical and laboratory monitoring are recommended. ECGs should be assessed prior to initiation of treatment, during treatment when clinically necessary, and more frequently if QTcF prolongation occurs at any time during treatment. Ribociclib should be permanently discontinued if the QTcF interval prolongation is either greater than 500 msec or there is a greater than 60 msec change from baseline and associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ribociclib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145862/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[8] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Harper KM, Knapp DJ, Criswell HE, Breese GR \"Vasopressin and alcohol: A multifaceted relationship.\" Psychopharmacology (Berl) 235 (2018): 3363-79[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Collins GB, Brosnihan KB, Zuti RA, Messina M, Gupta MK \"Neuroendocrine, fluid balance, and thirst responses to alcohol in alcoholics.\" Alcohol Clin Exp Res 16 (1992): 228-32[12] Hirschl MM, Derfler K, Bieglmayer C, et.al \"Hormonal derangements in patients with severe alcohol intoxication.\" Alcohol Clin Exp Res 18 (1994): 761-6[13] \"Product Information. Vasostrict (vasopressin).\" Par Pharmaceutical Inc, Chestnut Ridge, NY.[14] Taivainen H, Laitinen K, Tahtela R, Kilanmaa K, Valimaki MJ \"Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication.\" Alcohol Clin Exp Res 19 (1995): 759-62[15] Cerner Multum, Inc. \"Australian Product Information.\" O 0[16] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145700, "ingredient1": "Rifampicin", "ingredient2": "Nortriptyline", "severity": "Minor", "effect": "Rifampin may decrease the serum concentration of tricyclic antidepressants and their therapeutic effects. The proposed mechanism is metabolic induction. The clinical significance is unknown. Dosage adjustments may be required if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145863/", "reference_text": "[1] Bebchuk JM, Stewart DE \"Drug interaction between rifampin and nortriptyline: a case report.\" Int J Psychiatry Med 21 (1991): 183-7", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "updated_at": 1767369485}, {"id": 145701, "ingredient1": "Ritodrine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145864/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[3] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[5] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[8] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[9] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Bremelanotide, Black cohosh, Cabergoline", "updated_at": 1767369485}, {"id": 145702, "ingredient1": "Rivastigmine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145865/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Aducanumab", "updated_at": 1767369485}, {"id": 145703, "ingredient1": "Rolapitant", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. Rolapitant is a moderate CYP450 2D6 inhibitor, with inhibitory effect lasting at least 7 days after a single dose.", "source": "DDInter", "management_text": "Caution is advised when rolapitant is prescribed with drugs that are significantly metabolized by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when rolapitant is prescribed with drugs that are significantly metabolized by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145866/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, More", "alternatives_b": "Aprepitant", "updated_at": 1767369485}, {"id": 145704, "ingredient1": "Romidepsin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145867/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145705, "ingredient1": "Rotigotine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145868/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 145706, "ingredient1": "Rucaparib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145869/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 145707, "ingredient1": "Rufinamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145870/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145708, "ingredient1": "Safinamide", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs), including safinamide, may potentiate the pharmacologic activity of serotonergic agents including serotonin norepinephrine reuptake inhibitors (SNRIs), St. John's wort, cyclobenzaprine, trazodone, and tricyclic and tetracyclic antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Clinically, the interaction has been reported primarily in patients treated with MAOIs (including reversible, irreversible, selective, and nonselective) and tricyclic antidepressants, especially imipramine and clomipramine, which are the most potent serotonin reuptake inhibitors of the class. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "Coadministration of safinamide with these serotonergic agents is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of safinamide with these serotonergic agents is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145871/", "reference_text": "[1] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[2] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[3] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[4] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[5] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[6] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[7] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[8] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[9] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[10] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[11] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[12] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[13] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[14] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[15] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[16] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[17] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[18] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[19] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[20] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[21] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[22] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[23] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[24] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[25] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[26] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[27] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[28] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[29] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[30] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[31] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[32] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[33] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[34] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[35] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[36] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[37] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[38] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[39] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[40] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[41] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[42] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[43] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[44] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[45] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[46] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[47] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[48] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[49] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[50] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[51] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[52] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[53] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[54] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[55] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[56] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[57] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[58] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[59] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[60] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[61] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[62] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[63] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[64] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[65] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[66] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[67] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[68] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[69] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[70] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[71] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[72] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[73] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[74] Cerner Multum, Inc. \"Australian Product Information.\" O 0[75] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[76] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[77] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[78] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[79] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[80] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[81] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[82] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[83] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[84] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[85] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[86] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[87] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[88] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[89] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[90] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[91] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[92] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[93] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145709, "ingredient1": "Salmeterol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145872/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[3] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[5] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[8] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[9] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 145710, "ingredient1": "Scopolamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145873/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam, Tropicamide, Aprepitant", "updated_at": 1767369485}, {"id": 145711, "ingredient1": "Secobarbital", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.", "source": "DDInter", "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.", "mechanism_text": "Antagonism", "recommendation": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145874/", "reference_text": "[1] Garey KW, Amsden GW, Johns CA \"Possible interaction between imipramine and butalbital.\" Pharmacotherapy 17 (1997): 1041-2[2] Burrows GD, Davies B \"Antidepressants and barbiturates.\" Br Med J 4 (1971): 113[3] Silverman G, Braithwaite R \"Interaction of benzodiazepines with tricyclic antidepressants.\" Br Med J 4 (1972): 111[4] Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E \"Phenobarbital induces the 2-hydroxylation of desipramine.\" Ther Drug Monit 18 (1996): 60-4[5] Crocker J, Morton B \"Tricyclic (antidepressant) drug toxicity.\" Clin Toxicol 2 (1969): 397-402", "alternatives_a": "Nitrazepam", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 145712, "ingredient1": "Selegiline", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145875/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145713, "ingredient1": "Selpercatinib", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating selpercatinib therapy and periodically during treatment as appropriate based on individual risk factors including diarrhea. Correct hypokalemia, hypomagnesemia, and/or hypocalcemia before starting treatment and during treatment, as they may be risk factors for ventricular arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145876/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145714, "ingredient1": "Sertraline", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration with sertraline may increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is sertraline inhibition of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of many antidepressant and psychotropic drugs. Pharmacodynamically, the combination of sertraline (or any other selective serotonin reuptake inhibitor) and a TCA may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors. The syndrome has been reported in a case involving sertraline and amitriptyline.", "source": "DDInter", "management_text": "Caution is advised if sertraline (or other SSRIs) is prescribed with TCAs. Pharmacologic response and plasma TCA levels should be monitored more closely whenever sertraline is added to or withdrawn from therapy in patients stabilized on their existing antidepressant regimen, and the TCA dosage adjusted as necessary. Patients should be monitored closely for signs and symptoms of TCA toxicity (e.g., sedation, dry mouth, blurred vision, constipation, urinary retention) and/or excessive serotonergic activity (e.g., CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia).", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution is advised if sertraline (or other SSRIs) is prescribed with TCAs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145877/", "reference_text": "[1] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[2] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[3] Popli AP, Baldessarini RJ, Cole JO \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 51 (1994): 666-7[4] Barros J, Asnis G \"An interaction of sertraline and desipramine.\" Am J Psychiatry 150 (1993): 1751[5] Ereshefsky L, Riesemman C, Lam YW \"Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.\" Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9[6] Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ \"The effect of sertraline on the pharmacokinetics of desipramine and imipramine.\" Clin Pharmacol Ther 62 (1997): 145-56[7] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[8] Taylor D \"Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses.\" Br J Psychiatry 167 (1995): 575-80[9] von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI \"Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.\" J Pharmacol Exp Ther 268 (1994): 1278-83[10] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[11] Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S \"Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.\" J Clin Psychopharmacol 14 (1994): 90-8[12] Alderman CP, Lee PC \"Serotonin syndrome associated with combined sertraline-amitriptyline treatment.\" Ann Pharmacother 30 (1996): 1499-500[13] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[14] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[15] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[16] Lydiard RB, Anton RF, Cunningham T \"Interactions between sertraline and tricyclic antidepressants.\" Am J Psychiatry 150 (1993): 1125-6[17] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[18] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[19] Ueda N, Yoshimura R, Umene-Nakano W, et al. \"Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.\" World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9", "alternatives_a": "Viloxazine, Sertraline, Esketamine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145715, "ingredient1": "Sevoflurane", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The concomitant use of general anesthetics with tricyclic antidepressants may increase the risk of hypotension and cardiac arrhythmias. The presence of pancuronium may increase the risk of tachyarrhythmias. Enflurane may also increase the risk of seizures when given to patients who have been taking tricyclic antidepressants.", "source": "DDInter", "management_text": "Close monitoring is recommended when these drugs are used together.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended when these drugs are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145878/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Fluvoxamine", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide", "updated_at": 1767369485}, {"id": 145716, "ingredient1": "Sibutramine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of sibutramine with other serotonin reuptake inhibitors or other agents that possess or enhance serotonergic activity such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John's wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is recommended following use of fluoxetine and 3 weeks following use of vortioxetine before administering another serotonergic agent such as sibutramine. At least 14 days should elapse between discontinuation of other serotonergic agents and initiation of treatment with sibutramine. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145879/", "reference_text": "[1] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[2] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[6] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[7] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[8] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[10] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[11] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Esketamine", "alternatives_b": "Naltrexone", "updated_at": 1767369485}, {"id": 145717, "ingredient1": "Silodosin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145880/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Desvenlafaxine, Fluoxetine, Oxitriptan, Tryptophan, Milnacipran, Vortioxetine, Levomilnacipran, Vilazodone, More", "alternatives_b": "Dutasteride", "updated_at": 1767369485}, {"id": 145718, "ingredient1": "Siponimod", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.", "mechanism_text": "Synergism", "recommendation": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145881/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145719, "ingredient1": "Solifenacin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145882/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine, Paroxetine", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide, Dutasteride", "updated_at": 1767369485}, {"id": 145720, "ingredient1": "Sorafenib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Sorafenib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting sorafenib therapy and periodically during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145883/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "updated_at": 1767369485}, {"id": 145721, "ingredient1": "Sotalol", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145884/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Pindolol", "alternatives_b": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine", "updated_at": 1767369485}, {"id": 145722, "ingredient1": "Sparfloxacin", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145885/", "reference_text": "[1] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[2] Jaillon P, Morganroth J, Brumpt I, Talbot G \"Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.\" J Antimicrob Chemother 37(suppl a) (1996): 161-7[3] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B \"Torsades de pointe probably related to sparfloxacin.\" Eur J Clin Microbiol Infect Dis 15 (1996): 350-1[4] Lipsky BA, Dorr MB, Magner DJ, Talbot GH \"Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.\" Clin Ther 21 (1999): 148-59[5] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[6] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[7] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[8] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[9] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[11] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[12] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[13] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[14] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[15] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[16] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P \"Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers.\" Br J Clin Pharmacol 41 (1996): 499-503[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[21] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "updated_at": 1767369485}, {"id": 145723, "ingredient1": "St. John's Wort", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145886/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine, Bupropion, St. John's Wort, Esketamine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145724, "ingredient1": "Stiripentol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6. The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use. Dosage adjustments may be required if increased plasma levels or effects are observed.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145887/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145725, "ingredient1": "Sunitinib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Sunitinib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145888/", "reference_text": "[1] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145726, "ingredient1": "Suvorexant", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145889/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145727, "ingredient1": "Tacrine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145890/", "reference_text": "[1] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998): 8-13[2] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002): 1165-6[3] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004): 2082-7[4] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003): 2716-2724[5] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991): 1825-32[6] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002): 836-42", "alternatives_a": "Aducanumab", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, More", "updated_at": 1767369485}, {"id": 145728, "ingredient1": "Tacrolimus", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145891/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, More", "updated_at": 1767369485}, {"id": 145729, "ingredient1": "Tapentadol", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145892/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 145730, "ingredient1": "Tasimelteon", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145893/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145731, "ingredient1": "Telavancin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145894/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 145732, "ingredient1": "Telithromycin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Telithromycin has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of telithromycin, the recommended dosage should not be exceeded, particularly in patients with renal or hepatic impairment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145895/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Demolis JL, Vacheron F, Cardus S, Funck-Brentano C \"Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects.\" Clin Pharmacol Ther 73 (2003): 242-52[5] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Esketamine, Fluvoxamine", "alternatives_b": "Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 145733, "ingredient1": "Temazepam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145896/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 145734, "ingredient1": "Terazosin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145897/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desipramine, Vilazodone, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More", "alternatives_b": "Dutasteride", "updated_at": 1767369485}, {"id": 145735, "ingredient1": "Terbinafine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with terbinafine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by terbinafine, which is expected to occur in patients who are CYP450 2D6 extensive metabolizers (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever terbinafine is added to or withdrawn from therapy. Due to the long elimination half-life of terbinafine, especially following prolonged use, such interactions may be observed for several months after discontinuation of terbinafine therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145898/", "reference_text": "[1] Van der Kuy PH, Hooymans PM, Verkaaik AJ \"Nortriptyline intoxication induced by terbinafine.\" BMJ 316 (1998): 441[2] \"Product Information. Lamisil (terbinafine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL \"Investigation of terbinafine as a CYP2D6 inhibitor in vivo.\" Clin Pharmacol Ther 65 (1999): 465-72[4] Gupta AK, Katz HI, Shear NH \"Terbinafine and potential drug interactions - Reply.\" J Am Acad Dermatol 43 (2000): 883-4[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole, Griseofulvin", "updated_at": 1767369485}, {"id": 145736, "ingredient1": "Terbutaline", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145899/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[3] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[5] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Alupent (metaproterenol).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[8] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[9] \"Product Information. Tornalate Metered Dose (bitolterol).\" Dura Pharmaceuticals, San Diego, CA.[10] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 145737, "ingredient1": "Terfenadine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145900/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "updated_at": 1767369485}, {"id": 145738, "ingredient1": "Tetrabenazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tetrabenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145901/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Xenazine (tetrabenazine).\" Prestwick Pharmaceuticals Inc, Washington DC, VA.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[11] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "updated_at": 1767369485}, {"id": 145739, "ingredient1": "Thalidomide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression. Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145902/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145740, "ingredient1": "Thiethylperazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145903/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Sertraline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "updated_at": 1767369485}, {"id": 145741, "ingredient1": "Thiopental", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.", "source": "DDInter", "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.", "mechanism_text": "Antagonism", "recommendation": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145904/", "reference_text": "[1] Garey KW, Amsden GW, Johns CA \"Possible interaction between imipramine and butalbital.\" Pharmacotherapy 17 (1997): 1041-2[2] Burrows GD, Davies B \"Antidepressants and barbiturates.\" Br Med J 4 (1971): 113[3] Silverman G, Braithwaite R \"Interaction of benzodiazepines with tricyclic antidepressants.\" Br Med J 4 (1972): 111[4] Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E \"Phenobarbital induces the 2-hydroxylation of desipramine.\" Ther Drug Monit 18 (1996): 60-4[5] Crocker J, Morton B \"Tricyclic (antidepressant) drug toxicity.\" Clin Toxicol 2 (1969): 397-402", "alternatives_a": "Vilazodone, Sertraline, Maprotiline, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Trazodone, Levomilnacipran, More", "alternatives_b": "Desflurane, Enflurane, Etomidate, Nitrous oxide, Nitrazepam", "updated_at": 1767369485}, {"id": 145742, "ingredient1": "Thioridazine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration of thioridazine with another phenothiazine or a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of both drugs. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered. In addition, these agents individually can cause prolongation of the QT interval, thus concomitant administration may result in elevated risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes.", "source": "DDInter", "management_text": "The use of thioridazine with drugs that can inhibit CYP450 2D6 and/or prolong the QT interval is considered contraindicated.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of thioridazine with drugs that can inhibit CYP450 2D6 and/or prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145905/", "reference_text": "[1] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[2] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[3] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[4] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[5] Fletcher GF, Kazamias TM \"Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias.\" Am Heart J 78 (1969): 135-8[6] Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K \"Doxepin induced torsade de pointes.\" Pacing Clin Electrophysiol 5 (1982): 873-7[7] Bluhm RE, Wilkinson GR, Shelton R, Branch RA \"Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report.\" Clin Pharmacol Ther 53 (1993): 89-95[8] Kumar BB \"Letter: Acute hypotension from thioridazine.\" JAMA 234 (1975): 1321[9] Christensen P, Thomsen HY, Pedersen OL, et al \"Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients.\" Psychopharmacology (Berl) 87 (1985): 212-5[10] Kantor SJ, Glassman AH, Bigger JT, Jr Perel JM, Giardina EV \"The cardiac effects of therapeutic plasma concentrations of imipramine.\" Am J Psychiatry 135 (1978): 534-8[11] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[12] Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A \"Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals.\" Neuropsychobiology 9 (1983): 113-8[13] Linnoila M, Jobson KO, Gilliam JH, Paine RL \"Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder .\" J Clin Psychopharmacol 2 (1982): 433-4[14] Carpenter P, Gobel FL, Hulsing DJ \"Desipramine cardiac toxicity.\" Minn Med 65 (1982): 231-4[15] Brosen K, Zeugin T, Meyer UA \"Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.\" Clin Pharmacol Ther 49 (1991): 609-17[16] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[17] Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB \"Major adverse reactions during desipramine treatment.\" Arch Gen Psychiatry 39 (1982): 1055-61[18] Veith RC, Bloom V, Bielski R, Friedel RO \"ECG effects of comparable plasma concentrations of desipramine and amitriptyline.\" J Clin Psychopharmacol 2 (1982): 394-8[19] Van Sweden B \"Rebound antidepressant cardiac arrhythmia.\" Biol Psychiatry 24 (1988): 363-4[20] Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B \"Cardiac effects of different tricyclic antidepressant drugs.\" Br J Psychiatry 129 (1976): 335-41[21] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[22] Rudorfer MV, Young RC \"Desipramine: cardiovascular effects and plasma levels.\" Am J Psychiatry 137 (1980): 984-6[23] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[24] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[25] Luchins DJ \"Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants.\" Am J Psychiatry 140 (1983): 1006-9[26] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL \"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.\" Clin Pharmacol Ther 60 (1996): 543-53[27] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[28] Ramanathan KB, Davidson C \"Cardiac arrhythmia and imipramine therapy.\" Br Med J 1 (1975): 661-2", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145743, "ingredient1": "Thiothixene", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145906/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145744, "ingredient1": "Tiagabine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145907/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145745, "ingredient1": "Timolol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145908/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pindolol, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "updated_at": 1767369485}, {"id": 145746, "ingredient1": "Tizanidine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.", "source": "DDInter", "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145909/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145747, "ingredient1": "Tolazamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Case reports suggest that tricyclic antidepressants may increase the hypoglycemic effects of sulfonylureas.", "source": "DDInter", "management_text": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Synergism", "recommendation": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145910/", "reference_text": "[1] Zogno MG, Tolfo L, Draghi E \"Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics.\" Ann Pharmacother 28 (1994): 406[2] Pond SM, Graham GG, Birkett DJ, Wade DN \"Effects of tricyclic antidepressants on drug metabolism.\" Clin Pharmacol Ther 18 (1975): 191-9[3] True BL, Perry PJ, Burns EA \"Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy.\" Am J Psychiatry 144 (1987): 1220-1[4] Sherman KE, Bornemann M \"Amitriptyline and asymptomatic hypoglycemia.\" Ann Intern Med 109 (1988): 683-4[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, Lixisenatide, More", "updated_at": 1767369485}, {"id": 145748, "ingredient1": "Tolbutamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Case reports suggest that tricyclic antidepressants may increase the hypoglycemic effects of sulfonylureas.", "source": "DDInter", "management_text": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. The sulfonylurea dosage may require reduction in affected patients.", "mechanism_text": "Synergism", "recommendation": "Patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145911/", "reference_text": "[1] Zogno MG, Tolfo L, Draghi E \"Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics.\" Ann Pharmacother 28 (1994): 406[2] Pond SM, Graham GG, Birkett DJ, Wade DN \"Effects of tricyclic antidepressants on drug metabolism.\" Clin Pharmacol Ther 18 (1975): 191-9[3] True BL, Perry PJ, Burns EA \"Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy.\" Am J Psychiatry 144 (1987): 1220-1[4] Sherman KE, Bornemann M \"Amitriptyline and asymptomatic hypoglycemia.\" Ann Intern Med 109 (1988): 683-4[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "updated_at": 1767369485}, {"id": 145749, "ingredient1": "Tolcapone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145912/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cabergoline", "alternatives_b": "Vilazodone, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 145750, "ingredient1": "Tolterodine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145913/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 145751, "ingredient1": "Toremifene", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Toremifene has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided. If treatment with other QT-prolonging drugs is required, interruption of toremifene therapy should be considered. Caution and clinical monitoring are recommended if concomitant use is unavoidable. In patients at increased risk, electrocardiograms (ECGs) are recommended at baseline and as clinically indicated. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145914/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[10] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "updated_at": 1767369485}, {"id": 145752, "ingredient1": "Torasemide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145915/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 145753, "ingredient1": "Trandolapril", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145916/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Duloxetine, Desipramine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145754, "ingredient1": "Tranylcypromine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism of interaction is unknown, but may involve excessive serotonergic activity in the central nervous system (i.e., serotonin syndrome).", "source": "DDInter", "management_text": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versa.", "mechanism_text": "Others", "recommendation": "In general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145917/", "reference_text": "[1] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[2] de la Fuente JR, Berlanga C, Leon-Andrade C \"Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.\" J Clin Psychiatry 47 (1986): 40-1[3] Yatham LN, Barry S, Mobayed M, Dinan TG \"Is the carbamazepine-phenelzine combination safe?.\" Am J Psychiatry 147 (1990): 367[4] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[5] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[6] Otte W, Birkenhager TK, van den Broek WW \"Fatal interaction between tranylcypromine and imipramine.\" Eur Psychiatry 18 (2003): 264-5[7] Lader M \"Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.\" J Clin Psychiatry 44 (1983): 20-4[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[10] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[11] Waghray SN, Francis K \"Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics.\" J R Soc Med 77 (1984): 346[12] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[13] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[14] Tackley RM, Tregaskis B \"Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.\" Anaesthesia 42 (1987): 760-3[15] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[16] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978): 284-5[17] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[18] Lydiard RB, White D, Harvey B, Taylor A \"Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine.\" J Clin Psychopharmacol 7 (1987): 360[19] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[20] Joffe RT, Post RM, Uhde TW \"Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine.\" Arch Gen Psychiatry 42 (1985): 738[21] Zetin M \"Combined use of trimipramine and phenelzine in depression.\" J Nerv Ment Dis 170 (1982): 246-7[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[24] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[25] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[26] Dardennes RM, Even C, Ballon N, Bange F \"Serotonin syndrome caused by a clomipramine-moclobemide interaction.\" J Clin Psychiatry 59 (1998): 382-3[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[29] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[30] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[31] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[32] Pascual J, Combarros O, Berciano J \"Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment.\" Clin Neuropharmacol 10 (1987): 565-7[33] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc, Shirley, NY.[34] Ketter TA, Post RM, Parekh PI, Worthington K \"Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.\" J Clin Psychiatry 56 (1995): 471-5[35] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[36] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[37] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[38] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[39] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[40] Kay DW, Garside RF, Fahy TJ \"A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms.\" Br J Psychiatry 123 (1973): 63-7[41] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[42] Feighner JP, Herbstein J, Damlouji N \"Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression.\" J Clin Psychiatry 46 (1985): 206-9[43] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[44] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[45] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[46] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[47] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[48] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[49] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[50] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[51] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[52] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[53] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[54] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[55] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[56] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[57] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[58] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[59] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[60] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[61] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[62] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[63] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tranylcypromine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145755, "ingredient1": "Triazolam", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145918/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145756, "ingredient1": "Trichlormethiazide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145919/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, More", "updated_at": 1767369485}, {"id": 145757, "ingredient1": "Triclabendazole", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145920/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Praziquantel, Oxamniquine", "updated_at": 1767369485}, {"id": 145758, "ingredient1": "Trifluoperazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145921/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145759, "ingredient1": "Triflupromazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145922/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145760, "ingredient1": "Trihexyphenidyl", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145923/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145761, "ingredient1": "Alimemazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration of a phenothiazine with a tricyclic antidepressant (TCA) may result in elevated plasma concentrations of one or both drugs as well as additive adverse effects. Most phenothiazines and TCAs have been found to undergo metabolism by CYP450 2D6, thus competitive inhibition of the enzyme may occur when more than one of these agents are administered.", "source": "DDInter", "management_text": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication (e.g., abdominal pain, fever, heat intolerance, blurred vision, confusion, hallucinations) or cardiovascular toxicity (e.g., dizziness, palpitations, arrhythmias, syncope). Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Concurrent use of phenothiazines and TCAs should be approached with caution, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145924/", "reference_text": "[1] Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA \"Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.\" Am J Psychiatry 139 (1982): 104-6[2] Vandel S, Sandoz M, Vandel B, Bonin B, Allers G, Volmat R \"Biotransformation of amitriptyline in man: interaction with phenothiazines.\" Neuropsychobiology 15 (1986): 15-9[3] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[4] Bock JL, Nelson JC, Gray S, Jatlow PI \"Desipramine hydroxylation: variability and effect of antipsychotic drugs.\" Clin Pharmacol Ther 33 (1983): 322-8[5] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[6] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[7] Gram LF, Overo KF \"Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.\" Br Med J 1 (1972): 463-5[8] Maynard GL, Soni P \"Thioridazine interferences with imipramine metabolism and measurement.\" Ther Drug Monit 18 (1996): 729-31[9] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[10] Loga S, Curry S, Lader M \"Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.\" Clin Pharmacokinet 6 (1981): 454-62[11] El-Yousef MK, Manier DH \"Tricyclic antidepressants and phenothiazines.\" JAMA 229 (1974): 1419[12] Hirschowitz J, Bennett JA, Zemlan FP, Garver DL \"Thioridazine effect on desipramine plasma levels.\" J Clin Psychopharmacol 3 (1983): 376-9[13] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[14] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[15] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[16] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145762, "ingredient1": "Trimethadione", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145925/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "updated_at": 1767369485}, {"id": 145763, "ingredient1": "Trimethaphan", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145926/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Mecamylamine", "updated_at": 1767369485}, {"id": 145764, "ingredient1": "Trimethobenzamide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145927/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen, Desloratadine", "updated_at": 1767369485}, {"id": 145765, "ingredient1": "Trimipramine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145928/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Trimipramine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145766, "ingredient1": "Tripelennamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145929/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Duloxetine, Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen, Desloratadine, Tetracaine", "updated_at": 1767369485}, {"id": 145767, "ingredient1": "Triprolidine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145930/", "reference_text": "[1] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986): 339-41[10] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983): 957-9[13] \"Product Information. Cogentin (benztropine).\" Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981): 313-7[15] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Azelastine, Ketotifen, Desloratadine", "alternatives_b": "Vilazodone, Trimipramine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 145768, "ingredient1": "Tryptophan", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145931/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Nortriptyline", "alternatives_b": "Bupropion, Viloxazine, Esketamine, Tryptophan", "updated_at": 1767369485}, {"id": 145769, "ingredient1": "Valbenazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Valbenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking valbenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required. Valbenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. In patients with other risk factors for QT prolongation, the QT interval should be assessed before increasing the dose of valbenazine. The manufacturer recommends that valbenazine dosage be reduced to 40 mg once daily in patients on concomitant therapy with a strong CYP450 3A4 inhibitor (e.g., itraconazole, ketoconazole, clarithromycin). Valbenazine dose reduction should also be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), or in patients who are poor metabolizers of CYP450 2D6.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145932/", "reference_text": "[1] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[2] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "updated_at": 1767369485}, {"id": 145770, "ingredient1": "Valerian", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145933/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145771, "ingredient1": "Vandetanib", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Vandetanib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.", "mechanism_text": "Synergism", "recommendation": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145934/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vandetanib (vandetanib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 145772, "ingredient1": "Vasopressin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145935/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Bupropion, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145773, "ingredient1": "Vemurafenib", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Vemurafenib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting vemurafenib therapy and after dose modification.", "mechanism_text": "Synergism", "recommendation": "Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145936/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, More", "updated_at": 1767369485}, {"id": 145774, "ingredient1": "Venlafaxine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145937/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Nortriptyline", "alternatives_b": "Esketamine, Venlafaxine", "updated_at": 1767369485}, {"id": 145775, "ingredient1": "Vigabatrin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145938/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 145776, "ingredient1": "Vilazodone", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145939/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Vilazodone, Esketamine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145777, "ingredient1": "Voriconazole", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145940/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Bupropion, Esketamine, Fluvoxamine", "alternatives_b": "Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 145778, "ingredient1": "Vortioxetine", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145941/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine, Vortioxetine, Esketamine", "alternatives_b": "Nortriptyline", "updated_at": 1767369485}, {"id": 145779, "ingredient1": "Xylometazoline (nasal)", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with tri- or tetra-cyclic antidepressants may theoretically potentiate the sympathomimetic effects (e.g., hypertension, tachycardia) of systemically absorbed xylometazoline following topical (i.e., nasal) administration. The proposed mechanism may involve additive or synergistic increases in circulating catecholamines, such as noradrenaline (norepinephrine).", "source": "DDInter", "management_text": "Until further information is available, caution is advised if a tri- or tetra-cyclic antidepressant is used concomitantly with topical xylometazoline. Blood pressure and heart rate should be monitored at regular intervals during concomitant therapy. A dose reduction or discontinuation of concomitant therapy should be considered in patients who experience a sustained increase in blood pressure or heart rate.", "mechanism_text": "Synergism", "recommendation": "Until further information is available, caution is advised if a tri- or tetra-cyclic antidepressant is used concomitantly with topical xylometazoline.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145942/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Trazodone, Tryptophan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145780, "ingredient1": "Yohimbine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Some antidepressants such as the tricyclics may potentiate the pressor effect of yohimbine. The mechanism is a synergistic sympathomimetic effect due to stimulation of norepinephrine release by yohimbine and inhibition of norepinephrine reuptake by certain antidepressants.", "source": "DDInter", "management_text": "Yohimbine should be avoided in patients undergoing concurrent treatment with tricyclic antidepressants or other drugs that interfere with neuronal uptake or metabolism of norepinephrine.", "mechanism_text": "Synergism", "recommendation": "Yohimbine should be avoided in patients undergoing concurrent treatment with tricyclic antidepressants or other drugs that interfere with neuronal uptake or metabolism of norepinephrine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145943/", "reference_text": "[1] Mansoor GA \"Herbs and alternative therapies in the hypertension clinic.\" Am J Hypertens 14(9 Pt 1) (2001): 971-5[2] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[3] \"Product Information. Yocon (yohimbine).\" Glenwood Inc, Tenafly, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Phenyl salicylate, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 145781, "ingredient1": "Zaleplon", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145944/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 145782, "ingredient1": "Ziconotide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145945/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Salicylic acid, Salsalate, Choline salicylate, Diflunisal, Methoxyflurane", "updated_at": 1767369485}, {"id": 145783, "ingredient1": "Ziprasidone", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145946/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145784, "ingredient1": "Zolpidem", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145947/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam", "alternatives_b": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 145785, "ingredient1": "Zonisamide", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, disopyramide) may potentiate the risk of oligohidrosis and hyperthermia associated occasionally with the use of zonisamide, particularly in pediatric patients. These agents may alter electrolyte and fluid balance (carbonic anhydrase inhibition), inhibit peripheral sweating mechanisms (anticholinergic effect), and/or interfere with core body temperature regulation in the hypothalamus (neuroleptics and phenothiazines), resulting in the inability to adjust to temperature changes, especially in hot weather. Also, agents with anticholinergic activity frequently cause drowsiness and other central nervous system-depressant effects, which may be additively or synergistically increased in patients also treated with zonisamide.", "source": "DDInter", "management_text": "Caution is advised when zonisamide is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. Patients, particularly pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended. Patients (or their guardians or caregivers) should contact their physician immediately if they are not sweating as usual, with or without a fever. Ambulatory patients treated with zonisamide and agents with anticholinergic activity should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when zonisamide is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145948/", "reference_text": "[1] \"Product Information. Zonegran (zonisamide)\" Elan Pharmaceuticals, S. San Francisco, CA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Tryptophan", "alternatives_b": "Lacosamide, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 145786, "ingredient1": "Fosphenytoin", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration of ritonavir and phenytoin may result in decreased plasma concentrations of both drugs. The proposed mechanism involves ritonavir induction of phenytoin metabolism via CYP450 2C9 and, conversely, phenytoin induction of ritonavir metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "The potential for reduced therapeutic effects of phenytoin should be considered during coadministration with ritonavir. Phenytoin serum levels and pharmacologic effects should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of ritonavir in patients who are stabilized on their anticonvulsant regimen. In addition, it may be necessary to monitor patients for potentially reduced antiretroviral response due to decreased plasma levels of ritonavir and other antiretroviral agents induced by phenytoin.", "mechanism_text": "Metabolism", "recommendation": "The potential for reduced therapeutic effects of phenytoin should be considered during coadministration with ritonavir.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145949/", "reference_text": "[1] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[2] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[3] Lim ML, Min SS, Eron JJ, et al \"Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.\" J Acquir Immune Defic Syndr 36 (2004): 1034-40[4] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[5] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[6] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[7] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[11] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[12] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[13] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[16] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[17] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[18] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[19] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[21] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[22] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[23] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[24] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[25] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "alternatives_b": "Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Vigabatrin, Mephenytoin", "updated_at": 1767369485}, {"id": 145787, "ingredient1": "Ritonavir", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Coadministration of ritonavir and phenytoin may result in decreased plasma concentrations of both drugs. The proposed mechanism involves ritonavir induction of phenytoin metabolism via CYP450 2C9 and, conversely, phenytoin induction of ritonavir metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "The potential for reduced therapeutic effects of phenytoin should be considered during coadministration with ritonavir. Phenytoin serum levels and pharmacologic effects should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of ritonavir in patients who are stabilized on their anticonvulsant regimen. In addition, it may be necessary to monitor patients for potentially reduced antiretroviral response due to decreased plasma levels of ritonavir and other antiretroviral agents induced by phenytoin.", "mechanism_text": "Metabolism", "recommendation": "The potential for reduced therapeutic effects of phenytoin should be considered during coadministration with ritonavir.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145950/", "reference_text": "[1] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[2] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[3] Lim ML, Min SS, Eron JJ, et al \"Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.\" J Acquir Immune Defic Syndr 36 (2004): 1034-40[4] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[5] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[6] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[7] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[11] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[12] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[13] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[16] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[17] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[18] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[19] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[21] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[22] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[23] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[24] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[25] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Vigabatrin, Mephenytoin", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, More", "updated_at": 1767369485}, {"id": 145788, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145951/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145789, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145952/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145790, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145953/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145791, "ingredient1": "Candida albicans", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145954/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145792, "ingredient1": "Vibrio cholerae CVD 103-HgR strain live antigen", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145955/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145793, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145956/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145794, "ingredient1": "Efalizumab", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145957/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145795, "ingredient1": "Etanercept", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145958/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 145796, "ingredient1": "Filgrastim", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145959/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 145797, "ingredient1": "Fingolimod", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145960/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145798, "ingredient1": "Ganciclovir", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145961/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 145799, "ingredient1": "Golimumab", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145962/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 145800, "ingredient1": "Hepatitis A Vaccine", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145963/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145801, "ingredient1": "Hepatitis B Vaccine (Recombinant)", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145964/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145802, "ingredient1": "Human papillomavirus type 11 L1 capsid protein antigen", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145965/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145803, "ingredient1": "Idelalisib", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.", "source": "DDInter", "management_text": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145966/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Olaratumab, Avelumab, Tafasitamab, Amivantamab, Belantamab mafodotin, Ofatumumab, Pembrolizumab, Rituximab, Cemiplimab", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 145804, "ingredient1": "Infliximab", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145967/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 145805, "ingredient1": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145968/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145806, "ingredient1": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145969/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145807, "ingredient1": "Obinutuzumab", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145970/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145808, "ingredient1": "Obinutuzumab", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145971/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145809, "ingredient1": "Obinutuzumab", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145972/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145810, "ingredient1": "Ocrelizumab", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145973/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145811, "ingredient1": "Olaparib", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145974/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 145812, "ingredient1": "Omacetaxine mepesuccinate", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145975/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Pertuzumab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 145813, "ingredient1": "Ozanimod", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145976/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145814, "ingredient1": "Pegfilgrastim", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145977/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 145815, "ingredient1": "Poliovirus type 1 antigen (formaldehyde inactivated)", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145978/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145816, "ingredient1": "Radium Ra 223 dichloride", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145979/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145817, "ingredient1": "Rilonacept", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145980/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145818, "ingredient1": "Roflumilast", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.", "source": "DDInter", "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).", "mechanism_text": "Synergism", "recommendation": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145981/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[5] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145819, "ingredient1": "Rubella virus vaccine", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145982/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145820, "ingredient1": "Samarium (153Sm) lexidronam", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.", "source": "DDInter", "management_text": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145983/", "reference_text": "[1] \"Product Information. Quadramet (samarium sm 153 lexidronam)\" Berlex Laboratories, Richmond, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145821, "ingredient1": "Sargramostim", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145984/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 145822, "ingredient1": "Pfizer-BioNTech Covid-19 Vaccine", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145985/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145823, "ingredient1": "Siponimod", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145986/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145824, "ingredient1": "Sipuleucel-T", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.", "source": "DDInter", "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "mechanism_text": "Others", "recommendation": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145987/", "reference_text": "[1] \"Product Information. Provenge (sipuleucel-T).\" Dendreon Corporation, Seattle, WA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145825, "ingredient1": "Smallpox (Vaccinia) Vaccine, Live", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145988/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145826, "ingredient1": "Sodium phosphate, monobasic (p32)", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145989/", "reference_text": "[1] AnazaoHealth Corporation \"P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78\" ([2012 Jun]):", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145827, "ingredient1": "Strontium chloride Sr-89", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145990/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145828, "ingredient1": "Talimogene laherparepvec", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145991/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 145829, "ingredient1": "Teriflunomide", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145992/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 145830, "ingredient1": "Tofacitinib", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145993/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145831, "ingredient1": "Topotecan", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145994/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Irinotecan, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145832, "ingredient1": "Trichophyton mentagrophytes", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145995/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145833, "ingredient1": "Tuberculin purified protein derivative", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145996/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145834, "ingredient1": "Typhoid vaccine (inactivated)", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145997/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145835, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145998/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145836, "ingredient1": "Upadacitinib", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/145999/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145837, "ingredient1": "Ustekinumab", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146000/", "reference_text": "[1] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145838, "ingredient1": "Valganciclovir", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146001/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 145839, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146002/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145840, "ingredient1": "Yellow Fever Vaccine", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146003/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145841, "ingredient1": "Acetohydroxamic acid", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146004/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, More", "updated_at": 1767369485}, {"id": 145842, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146005/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145843, "ingredient1": "Aurothioglucose", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146006/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145844, "ingredient1": "Axicabtagene ciloleucel", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146007/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "updated_at": 1767369485}, {"id": 145845, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The administration of live, attenuated virus or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Additionally, there is a lack of data on the safety of immunization following discontinuation of ocrelizumab. Ocrelizumab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered.", "source": "DDInter", "management_text": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs. Immunization status should be assessed prior to initiating ocrelizumab and recommended immunization with live or attenuated live vaccines should be completed at least 4 weeks prior to ocrelizumab initiation (some authorities have recommended at least 6 weeks). For infants of mothers exposed to ocrelizumab during pregnancy, live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19 positive B-cell levels prior to vaccination in these infants is recommended.", "mechanism_text": "Others", "recommendation": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146008/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145846, "ingredient1": "Belinostat", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146009/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145847, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146010/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145848, "ingredient1": "Brexucabtagene autoleucel", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146011/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145849, "ingredient1": "Candida albicans", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146012/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145850, "ingredient1": "Vibrio cholerae CVD 103-HgR strain live antigen", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146013/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145851, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146014/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145852, "ingredient1": "Copanlisib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146015/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 145853, "ingredient1": "Cytarabine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146016/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145854, "ingredient1": "Dacarbazine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146017/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145855, "ingredient1": "Dapsone", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146018/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Clofazimine", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, More", "updated_at": 1767369485}, {"id": 145856, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146019/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145857, "ingredient1": "Echinacea", "ingredient2": "Ocrelizumab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146020/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Methotrexate, Alemtuzumab, Pegcetacoplan, Cladribine, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Emapalumab, Ofatumumab, Baricitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145858, "ingredient1": "Efalizumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146021/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Efalizumab", "updated_at": 1767369485}, {"id": 145859, "ingredient1": "Elotuzumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146022/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145860, "ingredient1": "Epirubicin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146023/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145861, "ingredient1": "Eribulin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146024/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145862, "ingredient1": "Etanercept", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146025/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Etanercept, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145863, "ingredient1": "Ethotoin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146026/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "alternatives_b": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 145864, "ingredient1": "Etoposide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146027/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145865, "ingredient1": "Everolimus", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146028/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 145866, "ingredient1": "Trastuzumab deruxtecan", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146029/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145867, "ingredient1": "Felbamate", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146030/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "alternatives_b": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 145868, "ingredient1": "Fingolimod", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146031/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Fingolimod, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145869, "ingredient1": "Floxuridine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146032/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145870, "ingredient1": "Flucytosine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146033/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Fluconazole, Caspofungin, Amphotericin B, Itraconazole, Miconazole, Micafungin, Posaconazole, Oteseconazole, Ketoconazole, Anidulafungin, Voriconazole, More", "alternatives_b": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 145871, "ingredient1": "Fludarabine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146034/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145872, "ingredient1": "Fludrocortisone", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146035/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "updated_at": 1767369485}, {"id": 145873, "ingredient1": "Fluorouracil", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146036/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145874, "ingredient1": "Gemcitabine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146037/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145875, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146038/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145876, "ingredient1": "Sodium aurothiomalate", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146039/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145877, "ingredient1": "Golimumab", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146040/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Golimumab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145878, "ingredient1": "Guanidine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146041/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145879, "ingredient1": "Guselkumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146042/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "updated_at": 1767369485}, {"id": 145880, "ingredient1": "Hepatitis A Vaccine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146043/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145881, "ingredient1": "Hepatitis B Vaccine (Recombinant)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146044/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145882, "ingredient1": "Human papillomavirus type 11 L1 capsid protein antigen", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146045/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145883, "ingredient1": "Hydroxyurea", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146046/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145884, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146047/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Iodide I-131", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145885, "ingredient1": "Ibrutinib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146048/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "updated_at": 1767369485}, {"id": 145886, "ingredient1": "Idarubicin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146049/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Valrubicin", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145887, "ingredient1": "Idelalisib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146050/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145888, "ingredient1": "Ifosfamide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146051/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145889, "ingredient1": "Imatinib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146052/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Ozanimod, More", "updated_at": 1767369485}, {"id": 145890, "ingredient1": "Inebilizumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146053/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145891, "ingredient1": "Infliximab", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146054/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Infliximab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145892, "ingredient1": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146055/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145893, "ingredient1": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146056/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145894, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146057/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145895, "ingredient1": "Interferon alfa-n1", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146058/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 145896, "ingredient1": "Interferon alfa-n3", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146059/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145897, "ingredient1": "Interferon alfacon-1", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146060/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 145898, "ingredient1": "Tositumomab (I-131)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146061/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145899, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146062/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145900, "ingredient1": "Ocrelizumab", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146063/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145901, "ingredient1": "Ocrelizumab", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146064/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 145902, "ingredient1": "Ocrelizumab", "ingredient2": "Lisocabtagene maraleucel", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146065/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145903, "ingredient1": "Ocrelizumab", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146066/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Eculizumab, Anifrolumab, Deucravacitinib, Ponesimod, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145904, "ingredient1": "Ocrelizumab", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146067/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145905, "ingredient1": "Ocrelizumab", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated virus or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Additionally, there is a lack of data on the safety of immunization following discontinuation of ocrelizumab. Ocrelizumab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered.", "source": "DDInter", "management_text": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs. Immunization status should be assessed prior to initiating ocrelizumab and recommended immunization with live or attenuated live vaccines should be completed at least 4 weeks prior to ocrelizumab initiation (some authorities have recommended at least 6 weeks). For infants of mothers exposed to ocrelizumab during pregnancy, live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19 positive B-cell levels prior to vaccination in these infants is recommended.", "mechanism_text": "Others", "recommendation": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146068/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145906, "ingredient1": "Ocrelizumab", "ingredient2": "Muromonab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146069/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 145907, "ingredient1": "Ocrelizumab", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146070/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145908, "ingredient1": "Olaparib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146071/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145909, "ingredient1": "Omacetaxine mepesuccinate", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146072/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145910, "ingredient1": "Osimertinib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146073/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145911, "ingredient1": "Oxaliplatin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146074/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145912, "ingredient1": "Ozanimod", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146075/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145913, "ingredient1": "Paclitaxel (protein-bound)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146076/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145914, "ingredient1": "Palbociclib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146077/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145915, "ingredient1": "Panobinostat", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146078/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145916, "ingredient1": "Paramethadione", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146079/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "alternatives_b": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "updated_at": 1767369485}, {"id": 145917, "ingredient1": "Pazopanib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146080/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145918, "ingredient1": "Peginterferon alfa-2a", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146081/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 145919, "ingredient1": "Peginterferon alfa-2b", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146082/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 145920, "ingredient1": "Pemetrexed", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146083/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145921, "ingredient1": "Penicillamine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146084/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145922, "ingredient1": "Pentostatin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146085/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 145923, "ingredient1": "Phenylbutazone", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146086/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 145924, "ingredient1": "Plicamycin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146087/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 145925, "ingredient1": "Polatuzumab vedotin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146088/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145926, "ingredient1": "Pomalidomide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146089/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "updated_at": 1767369485}, {"id": 145927, "ingredient1": "Ponatinib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146090/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145928, "ingredient1": "Pralatrexate", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146091/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145929, "ingredient1": "Prednisolone", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146092/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluorometholone, Indomethacin, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145930, "ingredient1": "Prednisone", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146093/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145931, "ingredient1": "Primaquine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146094/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Proguanil, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, More", "updated_at": 1767369485}, {"id": 145932, "ingredient1": "Procainamide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146095/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145933, "ingredient1": "Procarbazine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146096/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145934, "ingredient1": "Ribociclib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146097/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145935, "ingredient1": "Rilonacept", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146098/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Rilonacept, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145936, "ingredient1": "Roflumilast", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.", "source": "DDInter", "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).", "mechanism_text": "Synergism", "recommendation": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146099/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[5] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Voclosporin, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145937, "ingredient1": "Romidepsin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146100/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 145938, "ingredient1": "Rubella virus vaccine", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The administration of live, attenuated virus or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Additionally, there is a lack of data on the safety of immunization following discontinuation of ocrelizumab. Ocrelizumab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered.", "source": "DDInter", "management_text": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs. Immunization status should be assessed prior to initiating ocrelizumab and recommended immunization with live or attenuated live vaccines should be completed at least 4 weeks prior to ocrelizumab initiation (some authorities have recommended at least 6 weeks). For infants of mothers exposed to ocrelizumab during pregnancy, live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19 positive B-cell levels prior to vaccination in these infants is recommended.", "mechanism_text": "Others", "recommendation": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146101/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145939, "ingredient1": "Rucaparib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146102/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "updated_at": 1767369485}, {"id": 145940, "ingredient1": "Ruxolitinib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146103/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 145941, "ingredient1": "Sacituzumab govitecan", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146104/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145942, "ingredient1": "Samarium (153Sm) lexidronam", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146105/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Strontium chloride Sr-89", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 145943, "ingredient1": "Sarilumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146106/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145944, "ingredient1": "Pfizer-BioNTech Covid-19 Vaccine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146107/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Eculizumab, Anifrolumab, Deucravacitinib, Ponesimod, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145945, "ingredient1": "Satralizumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146108/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145946, "ingredient1": "Secukinumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146109/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "updated_at": 1767369485}, {"id": 145947, "ingredient1": "Selinexor", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146110/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145948, "ingredient1": "Siltuximab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146111/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "updated_at": 1767369485}, {"id": 145949, "ingredient1": "Siponimod", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146112/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Siponimod, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145950, "ingredient1": "Sipuleucel-T", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.", "source": "DDInter", "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "mechanism_text": "Others", "recommendation": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146113/", "reference_text": "[1] \"Product Information. Provenge (sipuleucel-T).\" Dendreon Corporation, Seattle, WA.", "alternatives_a": "Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145951, "ingredient1": "Sirolimus", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146114/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 145952, "ingredient1": "Smallpox (Vaccinia) Vaccine, Live", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146115/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145953, "ingredient1": "Streptozocin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146116/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145954, "ingredient1": "Tacrolimus", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146117/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 145955, "ingredient1": "Tafasitamab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146118/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 145956, "ingredient1": "Talazoparib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146119/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Inebilizumab, Belumosudil, Thalidomide, More", "updated_at": 1767369485}, {"id": 145957, "ingredient1": "Talimogene laherparepvec", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146120/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "updated_at": 1767369485}, {"id": 145958, "ingredient1": "Temozolomide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146121/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145959, "ingredient1": "Temsirolimus", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146122/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "updated_at": 1767369485}, {"id": 145960, "ingredient1": "Teniposide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146123/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145961, "ingredient1": "Teriflunomide", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146124/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Teriflunomide, Apremilast, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145962, "ingredient1": "Thalidomide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146125/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 145963, "ingredient1": "Tioguanine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146126/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145964, "ingredient1": "Thiotepa", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146127/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145965, "ingredient1": "Tisagenlecleucel", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146128/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "updated_at": 1767369485}, {"id": 145966, "ingredient1": "Tocainide", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146129/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "updated_at": 1767369485}, {"id": 145967, "ingredient1": "Tocilizumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146130/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 145968, "ingredient1": "Tofacitinib", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146131/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Baricitinib, Tofacitinib, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145969, "ingredient1": "Topotecan", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146132/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145970, "ingredient1": "Tositumomab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146133/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Iodide I-131", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 145971, "ingredient1": "Trabectedin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146134/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145972, "ingredient1": "Triamcinolone (ophthalmic)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146135/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Anifrolumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 145973, "ingredient1": "Trichophyton mentagrophytes", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146136/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145974, "ingredient1": "Trimethadione", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146137/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "alternatives_b": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "updated_at": 1767369485}, {"id": 145975, "ingredient1": "Trimetrexate", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146138/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Tinidazole, Quinacrine, Metronidazole, Secnidazole, Atovaquone, Furazolidone, Nitazoxanide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 145976, "ingredient1": "Tuberculin purified protein derivative", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146139/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145977, "ingredient1": "Typhoid vaccine (inactivated)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.", "source": "DDInter", "management_text": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.", "mechanism_text": "Others", "recommendation": "Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146140/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145978, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The administration of live, attenuated virus or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Additionally, there is a lack of data on the safety of immunization following discontinuation of ocrelizumab. Ocrelizumab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered.", "source": "DDInter", "management_text": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs. Immunization status should be assessed prior to initiating ocrelizumab and recommended immunization with live or attenuated live vaccines should be completed at least 4 weeks prior to ocrelizumab initiation (some authorities have recommended at least 6 weeks). For infants of mothers exposed to ocrelizumab during pregnancy, live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19 positive B-cell levels prior to vaccination in these infants is recommended.", "mechanism_text": "Others", "recommendation": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146141/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, Voclosporin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145979, "ingredient1": "Upadacitinib", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146142/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Upadacitinib, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145980, "ingredient1": "Uracil mustard", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146143/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145981, "ingredient1": "Ustekinumab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146144/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ustekinumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 145982, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The administration of live, attenuated virus or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Additionally, there is a lack of data on the safety of immunization following discontinuation of ocrelizumab. Ocrelizumab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered.", "source": "DDInter", "management_text": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs. Immunization status should be assessed prior to initiating ocrelizumab and recommended immunization with live or attenuated live vaccines should be completed at least 4 weeks prior to ocrelizumab initiation (some authorities have recommended at least 6 weeks). For infants of mothers exposed to ocrelizumab during pregnancy, live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19 positive B-cell levels prior to vaccination in these infants is recommended.", "mechanism_text": "Others", "recommendation": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146145/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145983, "ingredient1": "Venetoclax", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146146/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 145984, "ingredient1": "Vinblastine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146147/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145985, "ingredient1": "Vincristine (liposome)", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146148/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145986, "ingredient1": "Vinorelbine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146149/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145987, "ingredient1": "Vitamin E", "ingredient2": "Ocrelizumab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146150/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Alemtuzumab, Siponimod, Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Pomalidomide, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145988, "ingredient1": "Yellow Fever Vaccine", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The administration of live, attenuated virus or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Additionally, there is a lack of data on the safety of immunization following discontinuation of ocrelizumab. Ocrelizumab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered.", "source": "DDInter", "management_text": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs. Immunization status should be assessed prior to initiating ocrelizumab and recommended immunization with live or attenuated live vaccines should be completed at least 4 weeks prior to ocrelizumab initiation (some authorities have recommended at least 6 weeks). For infants of mothers exposed to ocrelizumab during pregnancy, live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19 positive B-cell levels prior to vaccination in these infants is recommended.", "mechanism_text": "Others", "recommendation": "Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146151/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145989, "ingredient1": "Zanubrutinib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146152/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 145990, "ingredient1": "Zinc chloride", "ingredient2": "Ocrelizumab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146153/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Calcium chloride, Potassium chloride, More", "updated_at": 1767369485}, {"id": 145991, "ingredient1": "Zinc gluconate", "ingredient2": "Ocrelizumab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146154/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Magnesium gluconate, Magnesium sulfate, More", "alternatives_b": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "updated_at": 1767369485}, {"id": 145992, "ingredient1": "Aflibercept", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146155/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Bevacizumab, Verteporfin, Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 145993, "ingredient1": "Acetohexamide", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).", "source": "DDInter", "management_text": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer's product labeling, and the antidiabetic treatment adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146156/", "reference_text": "[1] Williams G, Fuessl HS, Burrin JM, Chilvers E, Bloom SR \"Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin diabetes mellitus.\" Horm Metab Res 20 (1988): 168-70[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Hadjidakis DJ, Halvatsiotis PG, Ioannou YJ, Mavrokefalos PJ, Raptis SA \"The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.\" Diabetes Res Clin Pract 5 (1988): 91-8[5] Rios MS, Navascues I, Saban J, Ordonez A, Sevilla F, Del Pozo E \"Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.\" J Clin Endocrinol Metab 63 (1986): 1071-4[6] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Giustina A, Girelli A, Buffoli MG, et al \"Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin.\" Diabetes Res Clin Pract 14 (1991): 47-54[8] Davies RR, Miller M, Turner SJ, et al \"Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.\" Clin Endocrinol (Oxf) 25 (1986): 739-47[9] Di Mauro M, Le Moli R, Nicoletti F, Lunetta F \"Effects of octreotide on the glycemic levels in insulin-dependent diabetic patients. Comparative study between administration through multiple subcutaneous injections and continuous subcutaneous infusion.\" Diabetologia 36(Suppl 1) (1993): A138[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[12] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[13] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 145994, "ingredient1": "Bepridil", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).", "source": "DDInter", "management_text": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146157/", "reference_text": "[1] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[5] Katz MD, Erstad BL \"Octreotide, a new somatostatin analogue.\" Clin Pharm 8 (1989): 255-73[6] Ho PJ, Boyajy LD, Greenstein E, Barkan AL \"Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.\" Dig Dis Sci 38 (1993): 309-15[7] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Gonadorelin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145995, "ingredient1": "Carteolol", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).", "source": "DDInter", "management_text": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146158/", "reference_text": "[1] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[5] Katz MD, Erstad BL \"Octreotide, a new somatostatin analogue.\" Clin Pharm 8 (1989): 255-73[6] Ho PJ, Boyajy LD, Greenstein E, Barkan AL \"Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.\" Dig Dis Sci 38 (1993): 309-15[7] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "updated_at": 1767369485}, {"id": 145996, "ingredient1": "Copper oxodotreotide Cu-64", "ingredient2": "Octreotide", "severity": "Major", "effect": "INTERVAL: Coadministration of copper Cu 64 dotatate with non-radioactive somatostatin analogs may diminish the diagnostic effects of copper Cu 64 dotatate positron emission tomography (PET) imaging. Somatostatin analogs competitively bind to the same somatostatin receptor as copper Cu 64 dotatate, which may prevent the uptake of copper Cu 64 dotatate into tissues and affect the diagnostic imaging results.", "source": "DDInter", "management_text": "PET imaging with copper Cu 64 dotatate should be performed prior to dosing with somatostatin analogs. For patients receiving short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging. For patients receiving long-acting somatostatin analogs, a washout period of 28 days is recommended prior to imaging.", "mechanism_text": "Distribution", "recommendation": "PET imaging with copper Cu 64 dotatate should be performed prior to dosing with somatostatin analogs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146159/", "reference_text": "[1] \"Product Information. Detectnet (copper cu 64 dotatate).\" Currax Pharmaceuticals LLC, Morristown, NJ.", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145997, "ingredient1": "Digitoxin", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).", "source": "DDInter", "management_text": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146160/", "reference_text": "[1] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[5] Katz MD, Erstad BL \"Octreotide, a new somatostatin analogue.\" Clin Pharm 8 (1989): 255-73[6] Ho PJ, Boyajy LD, Greenstein E, Barkan AL \"Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.\" Dig Dis Sci 38 (1993): 309-15[7] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 145998, "ingredient1": "Entrectinib", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.", "source": "DDInter", "management_text": "Caution is advised when entrectinib is used with CYP450 3A4 inhibitors. Pharmacologic response to entrectinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the entrectinib dosage adjusted as necessary in accordance with the product labeling. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when entrectinib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146161/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[4] Dimartini A \"Isoniazid, tricyclics and the ''cheese reaction''.\" Int Clin Psychopharmacol 10 (1995): 197-8[5] \"Product Information. INH (isoniazid).\" Ciba Pharmaceuticals, Summit, NJ.[6] Smith CK, Durack DT \"Isoniazid and reaction to cheese.\" Ann Intern Med 88 (1978): 520-1[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Self TH, Chrisman CR, Baciewicz AM, Bronze MS \"Isoniazid drug and food interactions.\" Am J Med Sci 317 (1999): 304-11[9] Uragoda CG, Kottegoda SR \"Adverse reactions to isoniazid on ingestion of fish with a high histamine content.\" Tubercle 58 (1977): 83-9", "alternatives_a": "Nafarelin, Cetrorelix, Estradiol, Ganirelix, Gonadorelin", "alternatives_b": "Imatinib, Dabrafenib, Dacomitinib, Pacritinib, Fedratinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 145999, "ingredient1": "Ergometrine", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146162/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Norethisterone, Nafarelin, Cetrorelix, Estradiol, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Misoprostol, Dinoprostone, Oxytocin", "updated_at": 1767369485}, {"id": 146000, "ingredient1": "Ergotamine", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/146163/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Norethisterone, Nafarelin, Cetrorelix, Estradiol, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, More", "updated_at": 1767369485}]